



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/00, 1/44, C12N 9/18, G01N 33/53		A2	(11) International Publication Number: WO 99/01567
			(43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/US98/13776		(US). COOK, William, J. [-/US]; 1322 Badham Drive, Birmingham, AL 35216 (US).	
(22) International Filing Date: 1 July 1998 (01.07.98)		(74) Agent: SERTICH, Gary, J.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).	
(30) Priority Data: 60/051,437 1 July 1997 (01.07.97) US		(81) Designated States: CA, JP, KR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/051,437 (CIP) Filed on 1 July 1997 (01.07.97)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicants (for all designated States except US): THE UNIVERSITY OF UTAH [US/US]; 229 Wintrow, Salt Lake City, UT 84132 (US). EMORY UNIVERSITY [-/US]; 1510 Clifton Road, Atlanta, GA 30322 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): HILL, Christopher, P. [-/US]; 465 3rd Avenue, Salt Lake City, UT 84103 (US). WILKINSON, Keith, D. [-/US]; 2633 Apache Lane, Lilburn, GA 30247 (US). JOHNSTON, Steven, C. [-/US]; 1554 East Bryan, Salt Lake City, UT 84105 (US). LARSEN, Christopher, N. [-/US]; 30 Blain Street, Allston, MA 02134			
(54) Title: METHODS AND COMPOSITIONS FOR A DEUBIQUITINATING ENZYME AND VARIANTS THEREOF			
(57) Abstract The present invention relates to methods for the identification of candidate inhibitor substances that inhibit deubiquitinating activity based on the x-ray crystallographic structure of the active site of the enzyme. Changes in the properties of the enzyme are useful in identifying such substances. Also disclosed are variants of the enzyme that are useful in deubiquitinating proteins and small peptides.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION

METHODS AND COMPOSITIONS FOR A DEUBIQUITINATING ENZYME AND VARIANTS THEREOF

5

BACKGROUND OF THE INVENTION

1. Field of the Invention

10 The present invention is generally directed to crystal protein structures, and more specifically to Ubiquitin C-terminal hydrolase, which catalyzes the removal of adducts from the C-terminus of ubiquitin.

2. Description of Related Art

15 Ubiquitin is a small (8.6 kDa) highly conserved protein that is best known for its role in targeting proteins for degradation by the 26S protease. Recent reviews include (Ciechanover and Schwartz, 1994; Hershko and Ciechanover, 1992; Jentsch, 1992; Wilkinson *et al.*, 1995). Ubiquitin has been implicated in numerous cellular processes, including: cell cycle control, oncoprotein degradation, receptor function, apoptosis, regulation of transcription, stress responses, maintenance of chromatin
20 structure, DNA repair, signaling pathways, antigen presentation, and the degradation of abnormal proteins. Monomeric ubiquitin is activated by E1 (ubiquitin activating enzyme), which forms a thiolester bond with the ubiquitin C-terminus. Families of E2 (ubiquitin conjugating) and E3 (ubiquitin ligase) enzymes then catalyze ligation of the ubiquitin C-terminus to lysine side chains of acceptor proteins. Acceptor proteins can
25 be modified with a single ubiquitin attached to one or more different lysine side chains. Alternatively, acceptor proteins can be polyubiquitinated, with a lysine side chain of the first ubiquitin conjugated to the C-terminus of the next, to form long chains attached to the target protein. Efficient targeting for degradation by the 26S protease appears to require polyubiquitination (Chau *et al.*, 1989; Gregori *et al.*,
30 1990). In addition to targeting proteins for degradation by the 26S protease, other roles of ubiquitination include modification of chromatin structure (Bradbury, 1992)

lysosomal targeting (Hicke and Riezman, 1996) and regulation of a kinase activity (Chen *et al.*, 1996).

5 In addition to isopeptide linkages to the lysine side chains of acceptor proteins, the ubiquitin C-terminus is also found attached to α -amino groups in peptide bonds, since all known ubiquitin genes encode fusion proteins in which ubiquitin is followed by a C-terminal extension (Özkaynak *et al.*, 1987). Proteolytic processing at the ubiquitin C-terminus is catalyzed by deubiquitinating enzymes (DUB). Such processing is likely to be required for several different functions, including: liberation
10 of monomeric ubiquitin from the polyprotein precursors, release of polyubiquitin chains from the remnants of 26S protease substrates, disassembly of polyubiquitin chains to allow recycling of monomeric ubiquitin, reversal of regulatory ubiquitination, editing of inappropriately ubiquitinated proteins, and regeneration of active ubiquitin from adducts with small cellular nucleophiles (such as glutathione)
15 that may be produced by side reactions. Additionally, several ubiquitin-like proteins that occur as fusions or conjugates have been identified, at least some of which appear to undergo a similar processing (Haas *et al.*, 1996; Matunis *et al.*, 1996; Narasimhan *et al.*, 1996; Olvera and Wool, 1993).

20 In light of the many different substrates, and the extensive biological consequences of ubiquitination, it is not surprising that numerous deubiquitinating enzymes have been identified. These enzymes fall into two distinct families of cysteine proteases, UBPs (ubiquitin-specific proteases) (Baker *et al.*, 1992; Tobias and Varshavsky, 1992) and UCHs (ubiquitin C-terminal hydrolases) (Pickart and
25 Rose, 1985). Both classes of enzymes hydrolyze the peptide bond (either α - or ϵ -linked) at the C-terminus of ubiquitin. The UBP enzymes, 16 of which have been identified in yeast, were named for their ability to cleave large model fusion proteins at the C-terminus of ubiquitin. They vary in molecular weight from 50 kDa to 300 kDa, and exhibit a broad range of substrate specificity. Roles assigned for UBPs
30 include cleavage of ubiquitin from the remnants of degraded protein (Papa and Hochstrasser, 1993) and disassembly of polyubiquitin chains to yield functional

monomers (Wilkinson *et al.*, 1995). They appear to function in cell fate determination (Huang *et al.*, 1995), transcriptional silencing (Henchoz *et al.*, 1996; Moazed and Johnson, 1996), and the response to cytokines (Zhu *et al.*, 1996).

5 The well characterized UCH enzymes are generally smaller than the UBPs, (25-28 kDa), although two larger sequences have been deposited in the GenBank database. Disruption or deletion of the one UCH gene identified in yeast confers no discernible phenotype, suggesting that the substrate specificity of UCH enzymes may overlap with the UBP enzymes (Baker *et al.*, 1992; Miller *et al.*, 1989). Biochemical
10 studies have demonstrated that the human enzymes, UCH-L1 and UCH-L3, and the UCHs from *S. cerevisiae* and *D. melanogaster* hydrolyze ϵ -linked amide bonds at the C-terminus of ubiquitin (Cohen) (Roff *et al.*, 1996; Wilkinson, 1997), although most studies have focused on the hydrolysis of α -linked peptide bonds and small thiolester, ester, and amide linked adducts (Pickart and Rose, 1986; Wilkinson *et al.*, 1986). In
15 general, most of these small adducts are good substrates, except for peptide extensions with proline immediately following the scissile bond. UCH-L3 cleaves peptide extensions of up to 20 residues from ubiquitin with high efficiency and low sequence preference, while larger folded extensions are not cleaved (Wilkinson, 1997). Similar results have been reported for the yeast UCH (Liu *et al.*, 1989; Miller *et al.*, 1989).
20 These data suggest that the UCH enzymes may function to regenerate active ubiquitin from adducts with small nucleophiles (Pickart and Rose, 1985). The observed tissue specificity of UCH enzymes may reflect a distinct sets of substrate(s) (Wilkinson *et al.*, 1992). UCH-L1 is identical to PGP9.5, the neuronal ubiquitin C-terminal hydrolase that constitutes several percent of the total soluble protein in mammalian
25 brain (Wilkinson *et al.*, 1989). UCH-L2 appears to be constitutively expressed in many tissues, while UCH-L3 is expressed in hematopoietic cells.

 An alignment of five UCH sequences shows that only 12% of the residues are invariant (FIG. 1). Site directed mutagenesis of invariant residues on UCH-L1
30 implicates Cys-95 (UCH-L3 numbering) as the active site nucleophile, and His-169 as

the general base in catalysis, with an important role also played by Asp-184 (Larsen *et al.*, 1996). The UCH enzymes do not appear to share significant sequence similarity with any other protein.

5 In order to understand better the catalytic mechanism and substrate specificity of UCH enzymes, the inventors have determined the crystal structure of recombinant human UCH-L3 at a resolution of 1.8 Å. This structure has some similarities with the papain family of cysteine proteases, including an active site catalytic triad and oxyanion hole. A major topological difference from papain includes a 20-residue
10 disordered loop that spans the active site. Based upon the structure, the present invention sets forth a binding orientation for ubiquitin substrates on UCH enzymes. Moreover, the invention shows that the UCH active site is normally closed and opens upon binding to substrate, and that the disordered loop may function to define the substrate specificity of UCH enzymes.

15 SUMMARY OF THE INVENTION

In one aspect, the present invention provides an isolated and purified amino acid sequence that encodes a deubiquitinating enzyme polypeptide UCH-L3.
20 Preferably, a UCH-L3 peptide of the invention is a synthetic or recombinant polypeptide. More preferably, a polynucleotide of the present invention encodes a polypeptide comprising the structure of FIG. 1.

In certain embodiments, an amino acid sequence of the present invention
25 encodes a variant UCH-L3 molecule that possesses structural differences from the native UCH-L3 protein. Such structural differences include greater stability; *i.e.* ability to resist the effects of oxidation, heat, and so forth. Moreover, such structural differences may include UCH-L3 variants that are capable of cleaving larger proteins from the ubiquitin molecule than may be accomplished by the native UCH-L3 protein.

A further advantage of the present invention includes the production of inhibitors of UCH-L3 proteins that specifically interact at the active site to reduce or eliminate UCH-L3 activity.

5 In yet another embodiment, the present invention contemplates a process of preparing an UCH-L3 or variant UCH-L3 comprising transfecting a cell with polynucleotide that encodes an UCH-L3 or variant UCH-L3 polypeptide to produce a transformed host cell; and maintaining the transformed host cell under biological conditions sufficient for expression of the polypeptide. The transformed host cell can
10 be a eukaryotic cell. Alternatively, the host cell is a prokaryotic cell.

 In still another embodiment, the present invention provides an antibody immunoreactive with an UCH-L3 or variant UCH-L3. Preferably, an antibody of the invention is a monoclonal antibody.

15 In another aspect, the present invention contemplates a process of producing an antibody immunoreactive with an UCH-L3 or variant UCH-L3 comprising the steps of (a) transfecting a recombinant host cell with a polynucleotide that encodes an UCH-L3 or variant UCH-L3; (b) culturing the host cell under conditions sufficient for
20 expression of the polypeptide; (c) recovering the polypeptide; and (d) preparing the antibody to the polypeptide.

 In yet another aspect, the present invention contemplates a process of screening substances for their ability to interact with UCH-L3 or variant UCH-L3 comprising the steps of providing an UCH-L3 or variant UCH-L3, and testing the
25 ability of selected substances to interact with the UCH-L3 or variant UCH-L3.

 In a preferred embodiment, providing an UCH-L3 or variant UCH-L3 is transfecting a host cell with a polynucleotide that encodes an UCH-L3 or variant
30 UCH-L3 to form a transformed cell and maintaining the transformed cell under biological conditions sufficient for expression of the UCH-L3 or variant UCH-L3.

BRIEF DESCRIPTION OF THE DRAWINGS

5 The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

10 **FIG. 1** Sequence alignment of UCH enzymes. Every tenth UCH-L3 residue is delineated with a space. Active site residues (Gln-89, Cys-95, His-169, and Asp-184 of UCH-L3) are indicated in red. Other invariant residues are indicated in orange. Secondary structural elements seen in the UCH-L3 crystal structure are indicated above the sequence, (FIG. 3). Residues that are disordered in the UCH-L3 crystal structure are indicated with broken lines. SwissProt Database entries shown
15 are: UCH-L3, (Human; SW:P15374); UCH-L1, (Human; SW:P09936); UBL-DROME (*D. melanogaster*; SW:P35122); SCHPO, (*S. pombe*; SW:Q10171); YUH1, (*S. cerevisiae*; SW:P35127).

20 **FIG. 2** Electron Density Map. Electron density map (blue) is shown contoured at 1.0 RMSD with the refined coordinates. Map calculation used $\lambda 1$ (0.9796 Å) structure factor amplitudes in the resolution range 10-2.35 Å. The MAD phases were refined by solvent flattening and histogram shifting. The position of the selenium atom of Met-87 is apparent from the pseudo isomorphous ($\lambda 3$ - $\lambda 1$) difference map (red), which is contoured at 30 RMSD. This figure was made with the program
25 O (Jones *et al*, 1991)

FIG. 3 Ribbon diagram of UCH-L3. Side chains of the active site residues, Gln-89, Cys-85, His-169, and Asp-184, are shown in red and labeled Q, C, H, and D. Amino and Carboxyl termini are denoted with N and C. Residues 146 and
30 167, which mark the ends of the large disordered loop, are indicated. Secondary structures were defined by the program PROMOTIF (Hutchinson and Thornton,

1996). Strands are colored green and helices blue. Helix 4, which contains the active site nucleophile, Cys-95, is colored cyan. Strand 1 (29-34), strand 2 (49-57), strand 3 (168-176), strand 4 (179-183), strand 5 (191-195), strand 6 (223-229). Helix 1 (residues 13-22), helix 2 (39-42), helix 3 (60-76), helix 4 (92-110), helix 5 (118-125), helix 6 (131-140), helix 7 (201-215). Helix 4 has two kinks at residues 95 and 105 that separate the large central α -helical segment from the two short 3_{10} segments at the ends of this helix. All other helices are alpha. FIG. 3 and FIG. 5A were made with the programs MOLSCRIPT (Kraulis, 1991) and RASTER 3D (Bacon and Anderson, 1988).

FIG. 4 Comparison of UCH-L3 and Papain-like active sites. A) Active site residues of UCH-L3. Gln-89, Cys-95, His-169, and Asp-184, are shown in thick lines. A representative collection of 8 papain-like enzyme active sites are shown in thin lines following least squares overlap on the active site residue C α atoms. The papain-like structures shown have PBD identifiers 9pap, 4pad, 1pop, 2act, 1aec, 1huc, 1csb, 1gec. Other papain-like structures used in structural comparisons in this paper are: 1the, 1cpj, 1pad, 2pad, 5pad, 6pad, 1stf, 1pip, 1ppp, 1pe6, 1ppd, 1ppn, 1ppo. Refer to the PBD for primary references to these structures, which are not included here because of space limits.

FIG. 5 Comparison of UCH-L3 with Cathepsin B. A) UCH-L3 (upper) and cathepsin B (lower) shown in a similar orientation as FIG. 3. Equivalent residues were defined by LSQMAN (Kleywegt and Jones, 1994). Pairs of C α atoms were included in the overlap in their separation is less than 3.0 Å and if they form a stretch of at least 5 contiguous residues. Equivalent residues, as defined by LSQMAN, are shown in the cyan ribbon representation, and listed here: residues 32-37 of UCH-L3::residues 152-157 of cathepsin B, 48-60::166-178, 84-90::18-24, 92-106::27-40, 167-174::197-204, 182-186::217-221. B) Topology diagram of secondary structure for β -sheet and helix 4 of UCH-L3 (upper) and structurally equivalent segments of cathepsin B (lower). Secondary structural elements are colored according to their order of occurrence along the amino acid sequence; (red, orange, yellow, green, cyan,

blue, magenta). The main topological difference is for the helix, which in papain-like enzymes is the first of these secondary structural elements in the sequence, while for UCH-L3 helix 4 is found between strands 2 and 3. The long disordered loop of UCH-L3 is indicated with a dotted line.

5

FIG. 6 Active site clefts of papain-like enzymes and UCH-L3. Orientation is the same as for FIG. 3. A) Glycyl Endopeptidase complex with the inhibitor Benzyloxycarbonyl-L-V-G-Methylene, which occupies the S4, S3, S2 and S1 sites (O'Hara *et al.*, 1995). B) Cathepsin B with the inhibitor CA030, which occupies the
10 S2, S1, S1' and S2' sites (Turk *et al.*, 1995). Protein surfaces are colored gray/green according to curvature. Bound inhibitors are red. Active site Cys residue is yellow, other active site residues magenta. C) UCH-L3 molecular surface colored for the invariant residue of FIG. 1. Active site residues are shown in magenta, basic residues blue, acidic residue red, polar residues cyan, and hydrophobic residues green. This
15 figure was prepared with the program GRASP (Nicholls *et al.*, 1991).

FIG. 7 Proposed orientation of UCH-L3/Ubiquitin binding. This view is approximately perpendicular (from the left) of FIG. 3. Crystal structure of UCH-L3 is shown with β -strands green, helix-4 cyan, and other structure yellow. The glycyl endopeptidase and cathepsin B S and S' site inhibitors of FIG. 6A and FIG. 6B are
20 shown in red and magenta respectively after least squares overlap of the papain-like enzyme complexes on the UCH-L3 crystal structure. The structure of ubiquitin (Vijay-Kumar *et al.*, 1987), shown in gray, has been positioned with the basic face adjacent to UCH-L3, the C-terminal carboxylate adjacent to UCH-L3 Cys-95, and
25 with the flexible C-terminal residues following the path of the Glycyl Endopeptidase S site inhibitor.

FIG. 8 The active site cleft of UCH-L3 is blocked. Stereoview of the UCH-L3 active site in approximately the same orientation as FIG. 3. The active site
30 residues Gln-89, Cys-95, His-169, and Asp-184, are labeled with Q, C, H, and D, respectively. UCH-L3 residues Leu-9, Glu-10, Ala-11, and Ser-92 are labeled.

UCH-L3 is colored cyan, with the two segments proposed to move upon binding substrate colored green (residues 9-12; 90-94). The S4-S1 site inhibitor of Glycyl Endopeptidase (FIG. 6A) is shown in red after superposition on the UCH active site residue C α atoms.

5

FIG. 9 Possible orientations of the UCH-L3 disordered loop. The crystal structure of UCH-L3 is shown in the same color representation and orientation as FIG. 7. The docked ubiquitin molecule has been moved slightly away from the UCH-L3 for clarity. Residues that follow ubiquitin in an α -linked substrate adduct have been included in dark gray color. Three possible classes of conformation are shown in magenta, blue, and red, for the disordered loop (residues 147-166) with respect to the substrate.

FIG. 10 Relative rates of hydrolysis of ubiquitin derivatives by UCH isozymes. The rates of hydrolysis were measured by HPLC according to Wilkinson et al. (1986). The brackets [] surround the leaving group. The rates shown are obtained with 15 μ M substrates (~ 20 times K_m) and are given as the ratio of rates for the indicated substrate vs. that for ubiquitin ethyl ester. The error bars represent the standard error of the mean (See Table 1 for absolute rates). Note the log scale.

20

FIG. 11 UbCEP52 is a substrate for UCH-L3. Each lane contains 10 μ g of substrate and 1 μ g of enzyme. The time of digestion is given in minutes. A: SDS-PAGE of the reaction time course, protein detected by Coomassie Blue staining. B: Immunoblot of a duplicate gel, probed with rabbit antisera to human CEP52. The unmarked band is a minor contaminant.

25

FIG. 12 Nucleic acid inhibits the processing of UbCEP52 by UCH-L3. Nucleic acid was added at a concentration of 0.05 mg/mL, and incubated for ten minutes with the substrate before enzyme was added to start the reaction. Addition of dsDNA to UbOEt had no effect on the rate of ester hydrolysis (triangles). The rate of hydrolysis of UbCEP52 is only a few-fold slower (+). Addition of RNase A slightly

30

increased the rate of hydrolysis of UbCEP52 (x). Single stranded DNA had little effect (solid circles), while either *E. coli* RNA (solid squares), a plasmid DNA (open circles), or a double-stranded 42 bp DNA (open squares) significantly inhibited.

5 **FIG. 13 Co-translational processing of the proubiquitin (left panel) and UbCEP80 (right panel) gene products by UCH-L1 and UCH-L3.** The bacterial host BL21(DE3) was co-transformed with a plasmid encoding the substrates and the Amp^r gene product and a second vector encoding the indicated enzyme and Kan^r gene product. Protein production was induced with IPTG for three hours and whole cell
10 lysates were subjected to SDS-PAGE and immunoblotting with anti-ubiquitin (left panel) or anti-CEP80 (right panel) antibodies.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

15 The present inventors have determined the UCH-L3 crystal structure in atomic detail, which provides the basis for altering the active site of the protein. UCH-L3 belongs to a family of UCH (ubiquitin C-terminal hydrolase) enzymes that all catalyze the removal of adducts from the C-terminus of the small protein ubiquitin. Because the similarity in amino acid sequences indicates that all of the UCH enzymes will
20 have the same three dimensional structure, and because UCH-L3 is the first UCH for which a structure is known, the present invention is applicable to all UCH enzymes.

 UCH-L3 has a core catalytic structure that strongly resembles cathepsin B, a papain-like protease. The active site groove is occluded by two loops, and it is
25 postulated that a substrate-induced conformational change is required to clear the cleft and allow access to the active-site cysteine. Thus, only ubiquitin derivatives are substrates because only they can form the extensive interactions with the S' site required to trigger the necessary conformational change generating the active conformation of the enzyme.

30

Specificity for P' residues must be determined by the residues lining the corresponding S' sites on the UCH enzymes. The sequence of these proteins varies widely in several areas, including a region just N-terminal to the active site histidine. This sequence is disordered in the UCH-L3 structure, but may be positioned to form a significant contact region with the P' residues of substrates. Thus, it is likely that this hypervariable region is important in determining substrate selectivity and the somewhat shorter loop near the active site cysteine in UCH-L1 restricts the possible substrates by conferring a narrower or more restricted active site cleft.

UCH enzymes have potential in the commercial production of peptides (and possibly proteins), that are initially expressed as ubiquitin fusions from which the ubiquitin is later cleaved by UCH activity. UCH-L3 is already used in this way for the production of peptides. *See*, for example, U.S. Patent No. 5,620,923. The utility of this process could be enhanced by the availability of a UCH enzyme that possess greater thermal and/or chemical stability.

Knowledge of the UCH-L3 structure can be used to design variants with enhanced properties such as increased stability. This work can be performed by inspection of the UCH-L3 structure on a graphics workstation, by computer manipulation of UCH-L3 coordinates, and calculations such as energy minimization. Variants whose potential properties are initially predicted in light of the UCH-L3 structure can be produced by the usual techniques of molecular biology.

Enhanced stability might result from increasing the number of salt bridge or hydrogen bonding interactions, improving the packing of hydrophobic groups, or by adding disulfide bonds. Chemical stability might be improved by replacement of chemically labile groups with more stable amino acid residues. For example, buried methionine residues might be replaced with the more inert leucine amino acid residue. Cysteine residues might also be replaced, for example with alanine or serine side chains.

The present invention provides teaching to replace an active site residue, such as cysteine-95, with another amino acid residue to produce a more stable enzyme that uses a serine protease mechanism rather than the cysteine protease mechanism of wild type UCH enzymes. For example, the present invention provides guidance to make other changes in the enzyme structure, such changing aspartic acid to asparagine, to alter the specificity or stability of the enzyme. All such approaches to produce a more stable enzyme will be assisted by knowledge of the UCH-L3 structure.

Because ubiquitin chemistry is of fundamental importance to cellular metabolism, it may be possible to design therapeutic agents that function through modification of UCH activities. For example, a specific UCH inhibitor may increase (or reduce) the rate at which a protein(s) is degraded by the 26S protease. Because some proteins that function in proliferation are normally turned over by ubiquitin-mediated degradation, UCH inhibitors may have utility in the treatment of cancers. Another possible utility is in the treatment of wasting diseases which are thought to result from excessive ubiquitin-mediated proteolysis. UCH inhibitors may also find utility in the treatment of neurodegenerative diseases, since the UCH-L1 isozyme is highly abundant in neuronal tissue, and these diseases are characterized by deposits that are rich in ubiquitin conjugates (*i.e.* UCH substrates).

Ubiquitin C-terminal hydrolases catalyze the removal of adducts from the C-terminus of ubiquitin. The present inventors have determined the crystal structure of the recombinant human ubiquitin C-terminal hydrolase, UCH-L3, by X-ray crystallography at 1.8 Å resolution. The structure is comprised of a central antiparallel β -sheet flanked on both sides by α -helices. The β -sheet and one of the helices resemble the well known papain-like cysteine proteases, with the greatest similarity to cathepsin B. This similarity includes the UCH-L3 active site catalytic triad of Cys-95, His-169 and Asp-184, and the oxyanion hole residue Gln-89. Papain and UCH-L3 differ, however, in strand and helix connectivity, which in the UCH-L3 structure includes a disordered 20-residue loop (res 147-166) that is positioned over the active site and may function in the definition of substrate specificity. Based upon

analogy with inhibitor complexes of the papain-like enzymes, the inventors set forth the following mechanism to describe the binding of ubiquitin to UCH-L3. The UCH-L3 active site cleft appears to be masked in the unliganded structure by two different segments of the enzyme (res 9-12 and 90-94), thus implying a conformational change upon substrate binding and suggesting a mechanism to limit non-specific hydrolysis.

Crystallization

The recombinant human UCH-L3 used in these studies was purified as described (Larsen *et al.*, 1996). The protein solution used in crystallization trials was 12 mg/mL UCH-L3 in 50 mM Tris HCl, pH 7.6, 15 mM BME, 1 mM EDTA. This solution was stored in aliquots at -70°C. Crystallization was performed at 4°C in sitting drops. The reservoir solution was 26% (w/w) PEG 4000, 200 mM sodium acetate, 100 mM Pipes pH 6.7, and 10 mM DTT. The drop solution was 3 µL of protein solution mixed with 3 µL of reservoir solution. These conditions produced crystalline aggregates after 4-5 days.

Single crystals were obtained by microseeding. One of the initial aggregates was ground up with a needle, and the needle streaked through a drop that was identical to the conditions described above, but which had equilibrated for 3-5 days. Small single crystals appeared after several days.

Large crystals were obtained by macroseeding. Using a rayon loop, a small single crystal was transferred into reservoir solution, allowed to wash for several minutes, and then transferred into another drop that has been equilibrated for 3-5 days. The same reservoir and drop condition used to obtain the initial aggregates were also used for the subsequent micro and macroseeding. The crystals attain their maximum size in 5-10 days following macroseeding. Typical crystal dimensions are 0.3 mm × 0.3 mm × 0.6 mm.

For generation of selenomethionine-substituted UCH-L3 (SeUCH-L3), the *gal⁻,met⁻* auxotroph B834(DE3) of the BL21 strain (Studier and Moffatt, 1986) harboring pRSL3 (Larsen *et al.*, 1996) was grown on LB agar as colonies. A single colony was inoculated into 50 mL LB media and grown overnight, followed by
5 dilution into 6 liters of modified M9 media. Solutions O, P, S, and V (Weber *et al.*, 1992), uracil (Final concentration of 1 mM), and selenomethionine (final concentration of 50 µg/l) were sterile filtered and added to M9 media.

At an OD_{600nm} of 0.6, the cells were induced with 0.5 mM IPTG for three
10 hours before harvesting by centrifugation. Purification of SeUCH-L3 was the same as for wild type. Ion electrospray mass spectrometry showed an incorporation of >98% Se at each Met codon. SeUCH-L3 and wild type UCH-L3 have comparable specific activities. SeUCH-L3 crystals were grown under the same conditions as native protein, although in this case the seeding steps proved unnecessary and growth time
15 from initial set up was 5-10 days.

Data Collection and Processing

The native and SeUCH-L3 crystals are isomorphous; space group P2₁2₁2₁, cell dimensions: a=48.6 Å, b=60.8 Å, c=81.4 Å. There is one molecule in the asymmetric
20 unit, and the Matthews's parameter, V_m, is 2.37 Å³Da⁻¹, which corresponds to a solvent content of 48% (Matthews, 1968).

All data were collected at 100K. Prior to cryocooling the crystals were transferred to the reservoir solution, and then to a series of solutions that were
25 identical except for 2% increments in glycerol concentration up to a final concentration of 18% glycerol. The cryoprotected crystals were suspended in a rayon loop and cooled by plunging into liquid nitrogen.

Multiwavelength data were collected from a single SeUCH-L3 crystal on a
30 MAR imaging plate detector at beamline X12C of the National Synchrotron Light

Source, Brookhaven National Laboratory. The three wavelengths collected were selected from the fluorescence spectrum; λ_1 (0.9796 Å) was chosen as the inflection, or rise, corresponding to the minimum value of f' ; λ_2 (0.9793 Å) was taken as the peak, corresponding to the maximum in f' ; λ_3 (0.9300 Å) was chosen for the remote wavelength, corresponding to the maximum in f' . Data from each wavelength were indexed and integrated independently, and data from all three wavelengths were scaled together from 6.0 Å to 2.2 Å. The resulting scale factors were then applied separately to each individual wavelength for data from 30 Å to 2.35 Å. Data from a native crystal were collected to 1.8 Å resolution on a MAR imaging plate detector at beamline 7-1 of the Stanford Synchrotron Radiation Laboratory, Palo Alto. All data were processed with the programs DENZO and SCALEPAK (Otwinowski, 1993). See Table 1 for data statistics.

Table 1. Data Processing Statistics

	Native	λ_1	λ_2	λ_3
	SSRL ^a	NSLS ^a	NSLS ^a	NSLS ^a
Wavelength (Å)	1.080	0.9796	0.9793	0.930
Resolution limit (Å)	1.80	2.35	2.35	2.35
High resol. shell (Å)	(1.83-1.80)	(2.43-2.35)	(2.43-2.35)	(2.43-2.35)
#Unique reflections	23334	11282	11217	11108
Completeness (%)	98 (93)	96 (86)	90 (84)	89 (91)
$\langle I/\sigma_I \rangle$	20 (5)	15 (5)	15 (5)	15 (6)
Redundancy ^b	4.5 (3)	2 (1)	2 (1)	2 (1.5)
R sym (%) ^c	4.0 (19)	4.9 (13.2)	4.4 (12.1)	4.8 (13.7)
Mosaicity (°)	1.18	0.42	0.42	0.42

^a Data were collected on MAR imaging plate detectors on beamline 7-1 at the Stanford Synchrotron Radiation Laboratory (SSRL) or beamline X12C of the National Synchrotron Light Source (NSLS).

^b Redundancy is defined as the ratio of observed/unique structure factor amplitudes.

^c $R \text{ sym} = 100 * \sum_{hkl} \sum_i |I_i - \langle I \rangle| / \sum \langle I \rangle$

Data were processed with DENZO and SCALEPACK (Otwinowski, 1993).

Structure Determination and Refinement

Crystallographic computing was performed using programs from the CCP4 suite (CCP4, 1994), unless otherwise stated. Of the seven methionine residues in UCH-L3, all except the amino terminal Met are ordered. The six selenium sites were identified from difference Patterson and Fourier functions using the program XtalView (McRee, 1992). Selenium parameters were refined in MLPHARE (Otwinowski, 1991), treating $\lambda 1$ as the native data of a conventional multiple isomorphous phase determination (Ramakrishnan and Biou, 1997). The mean figure of merit calculated by MLPHARE was 0.42.

Phases computed with MLPHARE were refined by solvent flattening and histogram shifting with the program DM (Cowtan, 1994) to a mean figure of merit of 0.77. The resulting electron density map was readily interpretable for the majority of the UCH-L3 sequence, see FIG. 2. Rounds of refinement with XPLOR (Brünger, 1992b) were interspersed with mode building (Jones *et al.*, 1991). $\lambda 1$ amplitudes from 10.0 Å to 2.35 Å resolution were used in the refinement, with phase restraints also applied. At this stage the Rvalue against 10.0 Å to 2.35 Å data was 24.3% and the free Rvalue was 30.4% (Brünger, 1992a). No sigma cuts were applied to refinement or Rvalue calculations.

Refinement was continued against 6.0 Å to 1.8 Å data collected from a native crystal (see Table 2). Because of a slight deviation from true isomorphism between the native and SeUCH-L3 crystals, phase restraints were not employed for the high resolution refinement. The final model includes 121 water molecules and 205 of the total 230 UCH-L3 residues. The current Rvalue is 23.0% and the free Rvalue is 28.6%. The first four residues at the amino-terminus are disordered, as are residues 147-166 and 218. The model has good stereochemistry as judged by PROCHECK (Laskowski *et al.*, 1993).

UCH-L3 COORDINATES

REMARK FILENAME="l34_reb_8_bref.pdb"

REMARK TOPH19.pep -MACRO for protein sequence

5 REMARK DATE:14-Mar-97 22:45:32 created by user: stemmler

	ATOM 1	CB	ARG	5	34.943	15.749	56.409	1.00	29.03	AAAA
	ATOM 2	CG	ARG	5	34.137	16.647	57.309	1.00	30.95	AAAA
	ATOM 3	CD	ARG	5	34.789	16.934	58.656	1.00	32.26	AAAA
10	ATOM 4	NE	ARG	5	34.211	18.164	59.198	1.00	36.00	AAAA
	ATOM 5	HE	ARG	5	33.836	18.803	58.557	1.00	0.00	AAAA
	ATOM 6	CZ	ARG	5	34.155	18.493	60.486	1.00	36.77	AAAA
	ATOM 7	NH1	ARG	5	33.606	19.646	60.843	1.00	38.66	AAAA
	ATOM 8	HH11	ARG	5	33.219	20.248	60.144	1.00	0.00	AAAA
15	ATOM 9	HH12	ARG	5	33.563	19.905	61.809	1.00	0.00	AAAA
	ATOM 10	NH2	ARG	5	34.687	17.707	61.408	1.00	36.16	AAAA
	ATOM 11	HH21	ARG	5	35.156	16.864	61.142	1.00	0.00	AAAA
	ATOM 12	HH22	ARG	5	34.619	17.958	62.372	1.00	0.00	AAAA
	ATOM 13	C	ARG	5	34.702	17.197	54.397	1.00	26.94	AAAA
20	ATOM 14	O	ARG	5	33.828	18.051	54.424	1.00	24.12	AAAA
	ATOM 15	HT1	ARG	5	36.170	14.703	54.248	1.00	0.00	AAAA
	ATOM 16	HT2	ARG	5	34.879	14.767	53.128	1.00	0.00	AAAA
	ATOM 17	N	ARG	5	35.131	14.709	54.140	1.00	34.97	AAAA
	ATOM 18	HT3	ARG	5	34.838	13.776	54.488	1.00	0.00	AAAA
25	ATOM 19	CA	ARG	5	34.460	15.792	54.952	1.00	30.10	AAAA
	ATOM 20	N	TRP	6	35.923	17.431	53.940	1.00	25.41	AAAA
	ATOM 21	H	TRP	6	36.595	16.737	53.823	1.00	0.00	AAAA
	ATOM 22	CA	TRP	6	36.374	18.767	53.614	1.00	22.76	AAAA
	ATOM 23	CB	TRP	6	37.836	18.901	53.993	1.00	20.39	AAAA
30	ATOM 24	CG	TRP	6	38.117	18.460	55.390	1.00	22.77	AAAA
	ATOM 25	CD2	TRP	6	37.623	19.059	56.594	1.00	20.61	AAAA
	ATOM 26	CE2	TRP	6	38.108	18.291	57.671	1.00	21.75	AAAA
	ATOM 27	CE3	TRP	6	36.823	20.177	56.860	1.00	18.56	AAAA
	ATOM 28	CD1	TRP	6	38.875	17.392	55.778	1.00	23.73	AAAA
35	ATOM 29	NE1	TRP	6	38.872	17.283	57.144	1.00	23.09	AAAA
	ATOM 30	HE1	TRP	6	39.332	16.602	57.685	1.00	0.00	AAAA
	ATOM 31	CZ2	TRP	6	37.816	18.594	59.002	1.00	20.20	AAAA
	ATOM 32	CZ3	TRP	6	36.537	20.483	58.184	1.00	21.88	AAAA
	ATOM 33	CH2	TRP	6	37.032	19.690	59.238	1.00	20.85	AAAA
40	ATOM 34	C	TRP	6	36.187	19.085	52.141	1.00	22.14	AAAA
	ATOM 35	O	TRP	6	36.015	18.194	51.321	1.00	24.44	AAAA
	ATOM 36	N	LEU	7	36.200	20.366	51.815	1.00	20.82	AAAA

-18-

	ATOM 37	H	LEU	7	36.125	21.021	52.539	1.00	0.00	AAAA
	ATOM 38	CA	LEU	7	36.317	20.802	50.423	1.00	24.47	AAAA
	ATOM 39	CB	LEU	7	36.404	22.327	50.367	1.00	24.34	AAAA
	ATOM 40	CG	LEU	7	36.146	23.017	49.040	1.00	22.59	AAAA
5	ATOM 41	CD1	LEU	7	34.687	22.829	48.654	1.00	26.54	AAAA
	ATOM 42	CD2	LEU	7	36.497	24.483	49.174	1.00	21.09	AAAA
	ATOM 43	C	LEU	7	37.567	20.197	49.771	1.00	23.51	AAAA
	ATOM 44	O	LEU	7	38.653	20.247	50.341	1.00	25.30	AAAA
	ATOM 45	N	PRO	8	37.403	19.505	48.638	1.00	26.01	AAAA
10	ATOM 46	CD	PRO	8	36.137	19.093	48.006	1.00	27.47	AAAA
	ATOM 47	CA	PRO	8	38.559	18.953	47.929	1.00	25.82	AAAA
	ATOM 48	CB	PRO	8	37.935	18.297	46.701	1.00	27.75	AAAA
	ATOM 49	CG	PRO	8	36.553	17.925	47.172	1.00	27.83	AAAA
	ATOM 50	C	PRO	8	39.570	20.034	47.550	1.00	24.44	AAAA
15	ATOM 51	O	PRO	8	39.217	21.195	47.386	1.00	22.60	AAAA
	ATOM 52	N	LEU	9	40.829	19.647	47.415	1.00	27.15	AAAA
	ATOM 53	H	LEU	9	41.016	18.683	47.463	1.00	0.00	AAAA
	ATOM 54	CA	LEU	9	41.900	20.614	47.200	1.00	26.84	AAAA
	ATOM 55	CB	LEU	9	43.179	20.145	47.910	1.00	26.91	AAAA
20	ATOM 56	CG	LEU	9	42.992	19.872	49.410	1.00	26.00	AAAA
	ATOM 57	CD1	LEU	9	44.337	19.580	50.023	1.00	27.63	AAAA
	ATOM 58	CD2	LEU	9	42.319	21.062	50.114	1.00	21.92	AAAA
	ATOM 59	C	LEU	9	42.145	20.885	45.712	1.00	26.78	AAAA
	ATOM 60	O	LEU	9	43.133	20.437	45.119	1.00	26.81	AAAA
25	ATOM 61	N	GLU	10	41.168	21.542	45.102	1.00	26.31	AAAA
	ATOM 62	H	GLU	10	40.351	21.729	45.616	1.00	0.00	AAAA
	ATOM 63	CA	GLU	10	41.244	21.971	43.716	1.00	27.90	AAAA
	ATOM 64	CB	GLU	10	40.755	20.874	42.772	1.00	33.87	AAAA
	ATOM 65	CG	GLU	10	39.629	20.026	43.317	1.00	45.72	AAAA
30	ATOM 66	CD	GLU	10	39.141	18.967	42.323	1.00	53.31	AAAA
	ATOM 67	OE1	GLU	10	38.277	19.304	41.469	1.00	52.71	AAAA
	ATOM 68	OE2	GLU	10	39.590	17.796	42.437	1.00	55.78	AAAA
	ATOM 69	C	GLU	10	40.369	23.186	43.571	1.00	25.52	AAAA
	ATOM 70	O	GLU	10	39.368	23.305	44.268	1.00	25.82	AAAA
35	ATOM 71	N	ALA	11	40.835	24.158	42.798	1.00	27.87	AAAA
	ATOM 72	H	ALA	11	41.697	23.992	42.356	1.00	0.00	AAAA
	ATOM 73	CA	ALA	11	40.094	25.395	42.580	1.00	26.92	AAAA
	ATOM 74	CB	ALA	11	41.001	26.443	42.011	1.00	26.26	AAAA
	ATOM 75	C	ALA	11	38.935	25.121	41.620	1.00	30.85	AAAA
40	ATOM 76	O	ALA	11	39.117	25.060	40.401	1.00	35.58	AAAA
	ATOM 77	N	ASN	12	37.764	24.878	42.193	1.00	29.56	AAAA
	ATOM 78	H	ASN	12	37.726	24.985	43.160	1.00	0.00	AAAA
	ATOM 79	CA	ASN	12	36.591	24.423	41.462	1.00	28.53	AAAA

-19-

	ATOM 80	CB	ASN	12	36.368	22.936	41.738	1.00	29.60	AAAA
	ATOM 81	CG	ASN	12	35.298	22.334	40.870	1.00	30.93	AAAA
	ATOM 82	OD1	ASN	12	34.252	22.940	40.629	1.00	33.85	AAAA
	ATOM 83	ND2	ASN	12	35.509	21.098	40.467	1.00	34.38	AAAA
5	ATOM 84	HD21	ASN	12	36.288	20.611	40.798	1.00	0.00	AAAA
	ATOM 85	HD22	ASN	12	34.848	20.762	39.828	1.00	0.00	AAAA
	ATOM 86	C	ASN	12	35.358	25.225	41.891	1.00	24.71	AAAA
	ATOM 87	O	ASN	12	34.693	24.887	42.867	1.00	25.47	AAAA
	ATOM 88	N	PRO	13	35.065	26.321	41.181	1.00	23.24	AAAA
10	ATOM 89	CD	PRO	13	35.778	26.765	39.971	1.00	22.18	AAAA
	ATOM 90	CA	PRO	13	33.963	27.223	41.515	1.00	23.35	AAAA
	ATOM 91	CB	PRO	13	33.883	28.143	40.303	1.00	24.69	AAAA
	ATOM 92	CG	PRO	13	35.244	28.138	39.750	1.00	23.36	AAAA
	ATOM 93	C	PRO	13	32.633	26.507	41.770	1.00	23.21	AAAA
15	ATOM 94	O	PRO	13	31.939	26.820	42.720	1.00	23.70	AAAA
	ATOM 95	N	GLU	14	32.310	25.502	40.966	1.00	26.47	AAAA
	ATOM 96	H	GLU	14	32.975	25.148	40.341	1.00	0.00	AAAA
	ATOM 97	CA	GLU	14	30.975	24.917	41.027	1.00	31.39	AAAA
	ATOM 98	CB	GLU	14	30.666	24.117	39.757	1.00	38.34	AAAA
20	ATOM 99	CG	GLU	14	29.181	23.754	39.611	1.00	51.49	AAAA
	ATOM 100	CD	GLU	14	28.796	23.371	38.181	1.00	60.13	AAAA
	ATOM 101	OE1	GLU	14	28.176	24.206	37.473	1.00	62.58	AAAA
	ATOM 102	OE2	GLU	14	29.120	22.230	37.766	1.00	63.49	AAAA
	ATOM 103	C	GLU	14	30.751	24.051	42.267	1.00	28.36	AAAA
25	ATOM 104	O	GLU	14	29.693	24.131	42.895	1.00	26.17	AAAA
	ATOM 105	N	VAL	15	31.749	23.241	42.618	1.00	25.73	AAAA
	ATOM 106	H	VAL	15	32.517	23.168	42.008	1.00	0.00	AAAA
	ATOM 107	CA	VAL	15	31.733	22.474	43.869	1.00	24.08	AAAA
	ATOM 108	CB	VAL	15	32.956	21.511	43.945	1.00	23.74	AAAA
30	ATOM 109	CG1	VAL	15	33.007	20.829	45.290	1.00	25.22	AAAA
	ATOM 110	CG2	VAL	15	32.860	20.440	42.849	1.00	19.71	AAAA
	ATOM 111	C	VAL	15	31.712	23.397	45.109	1.00	22.96	AAAA
	ATOM 112	O	VAL	15	30.904	23.217	46.023	1.00	22.19	AAAA
	ATOM 113	N	THR	16	32.537	24.440	45.089	1.00	22.52	AAAA
35	ATOM 114	H	THR	16	33.201	24.524	44.368	1.00	0.00	AAAA
	ATOM 115	CA	THR	16	32.530	25.436	46.156	1.00	20.27	AAAA
	ATOM 116	CB	THR	16	33.633	26.458	45.926	1.00	18.24	AAAA
	ATOM 117	OG1	THR	16	34.835	25.756	45.605	1.00	18.68	AAAA
	ATOM 118	HG1	THR	16	35.579	26.372	45.533	1.00	0.00	AAAA
40	ATOM 119	CG2	THR	16	33.858	27.292	47.169	1.00	17.57	AAAA
	ATOM 120	C	THR	16	31.192	26.164	46.315	1.00	22.22	AAAA
	ATOM 121	O	THR	16	30.700	26.352	47.440	1.00	19.76	AAAA
	ATOM 122	N	ASN	17	30.589	26.550	45.192	1.00	22.44	AAAA

-20-

	ATOM 123	H	ASN	17	31.067	26.433	44.350	1.00	0.00	AAAA
	ATOM 124	CA	ASN	17	29.268	27.190	45.197	1.00	22.07	AAAA
	ATOM 125	CB	ASN	17	28.932	27.721	43.807	1.00	22.34	AAAA
	ATOM 126	CG	ASN	17	29.788	28.905	43.424	1.00	23.06	AAAA
5	ATOM 127	OD1	ASN	17	30.205	29.679	44.282	1.00	21.72	AAAA
	ATOM 128	ND2	ASN	17	30.007	29.089	42.129	1.00	20.19	AAAA
	ATOM 129	HD21	ASN	17	29.565	28.488	41.489	1.00	0.00	AAAA
	ATOM 130	HD22	ASN	17	30.606	29.826	41.897	1.00	0.00	AAAA
	ATOM 131	C	ASN	17	28.165	26.234	45.669	1.00	20.44	AAAA
10	ATOM 132	O	ASN	17	27.300	26.625	46.449	1.00	20.46	AAAA
	ATOM 133	N	GLN	18	28.276	24.961	45.316	1.00	20.08	AAAA
	ATOM 134	H	GLN	18	28.974	24.713	44.675	1.00	0.00	AAAA
	ATOM 135	CA	GLN	18	27.358	23.958	45.853	1.00	24.90	AAAA
	ATOM 136	CB	GLN	18	27.549	22.612	45.148	1.00	30.06	AAAA
15	ATOM 137	CG	GLN	18	26.740	22.490	43.862	1.00	42.05	AAAA
	ATOM 138	CD	GLN	18	25.343	23.105	43.988	1.00	51.77	AAAA
	ATOM 139	OE1	GLN	18	24.448	22.521	44.607	1.00	55.04	AAAA
	ATOM 140	NE2	GLN	18	25.173	24.317	43.456	1.00	52.02	AAAA
	ATOM 141	HE21	GLN	18	25.902	24.740	42.952	1.00	0.00	AAAA
20	ATOM 142	HE22	GLN	18	24.293	24.702	43.641	1.00	0.00	AAAA
	ATOM 143	C	GLN	18	27.471	23.778	47.367	1.00	26.45	AAAA
	ATOM 144	O	GLN	18	26.453	23.712	48.068	1.00	21.63	AAAA
	ATOM 145	N	PHE	19	28.705	23.783	47.875	1.00	26.95	AAAA
	ATOM 146	H	PHE	19	29.452	23.787	47.242	1.00	0.00	AAAA
25	ATOM 147	CA	PHE	19	28.967	23.707	49.317	1.00	24.56	AAAA
	ATOM 148	CB	PHE	19	30.471	23.527	49.544	1.00	28.12	AAAA
	ATOM 149	CG	PHE	19	30.836	23.135	50.950	1.00	30.72	AAAA
	ATOM 150	CD1	PHE	19	30.010	22.278	51.692	1.00	30.11	AAAA
	ATOM 151	CD2	PHE	19	32.035	23.577	51.516	1.00	29.96	AAAA
30	ATOM 152	CE1	PHE	19	30.383	21.862	52.980	1.00	31.40	AAAA
	ATOM 153	CE2	PHE	19	32.415	23.167	52.805	1.00	29.30	AAAA
	ATOM 154	CZ	PHE	19	31.591	22.307	53.533	1.00	28.78	AAAA
	ATOM 155	C	PHE	19	28.450	24.948	50.088	1.00	22.86	AAAA
	ATOM 156	O	PHE	19	27.789	24.822	51.121	1.00	20.58	AAAA
35	ATOM 157	N	LEU	20	28.672	26.130	49.525	1.00	19.47	AAAA
	ATOM 158	H	LEU	20	29.271	26.150	48.752	1.00	0.00	AAAA
	ATOM 159	CA	LEU	20	28.088	27.368	50.037	1.00	19.77	AAAA
	ATOM 160	CB	LEU	20	28.421	28.518	49.088	1.00	18.13	AAAA
	ATOM 161	CG	LEU	20	29.828	29.107	49.129	1.00	19.84	AAAA
40	ATOM 162	CD1	LEU	20	29.857	30.462	48.468	1.00	15.91	AAAA
	ATOM 163	CD2	LEU	20	30.234	29.246	50.567	1.00	23.06	AAAA
	ATOM 164	C	LEU	20	26.560	27.271	50.197	1.00	22.72	AAAA
	ATOM 165	O	LEU	20	25.986	27.680	51.211	1.00	21.79	AAAA

-21-

	ATOM 166	N	LYS	21	25.907	26.748	49.171	1.00	22.10	AAAA
	ATOM 167	H	LYS	21	26.421	26.490	48.376	1.00	0.00	AAAA
	ATOM 168	CA	LYS	21	24.474	26.520	49.220	1.00	23.06	AAAA
	ATOM 169	CB	LYS	21	24.026	25.887	47.900	1.00	25.93	AAAA
5	ATOM 170	CG	LYS	21	22.528	25.662	47.768	1.00	35.03	AAAA
	ATOM 171	CD	LYS	21	22.270	24.673	46.651	1.00	43.04	AAAA
	ATOM 172	CE	LYS	21	20.819	24.706	46.198	1.00	49.98	AAAA
	ATOM 173	NZ	LYS	21	20.563	23.681	45.137	1.00	53.62	AAAA
	ATOM 174	HZ1	LYS	21	20.728	22.728	45.519	1.00	0.00	AAAA
10	ATOM 175	HZ2	LYS	21	21.199	23.859	44.333	1.00	0.00	AAAA
	ATOM 176	HZ3	LYS	21	19.576	23.773	44.822	1.00	0.00	AAAA
	ATOM 177	C	LYS	21	24.124	25.607	50.397	1.00	19.59	AAAA
	ATOM 178	O	LYS	21	23.266	25.906	51.220	1.00	24.24	AAAA
	ATOM 179	N	GLN	22	24.836	24.508	50.499	1.00	20.54	AAAA
15	ATOM 180	H	GLN	22	25.555	24.352	49.846	1.00	0.00	AAAA
	ATOM 181	CA	GLN	22	24.549	23.510	51.504	1.00	22.64	AAAA
	ATOM 182	CB	GLN	22	25.314	22.252	51.121	1.00	24.37	AAAA
	ATOM 183	CG	GLN	22	25.554	21.226	52.180	1.00	35.79	AAAA
	ATOM 184	CD	GLN	22	26.685	20.299	51.773	1.00	42.90	AAAA
20	ATOM 185	OE1	GLN	22	27.008	20.178	50.584	1.00	45.37	AAAA
	ATOM 186	NE2	GLN	22	27.353	19.719	52.751	1.00	44.56	AAAA
	ATOM 187	HE21	GLN	22	27.195	19.868	53.698	1.00	0.00	AAAA
	ATOM 188	HE22	GLN	22	28.038	19.097	52.405	1.00	0.00	AAAA
	ATOM 189	C	GLN	22	24.873	24.011	52.924	1.00	25.82	AAAA
25	ATOM 190	O	GLN	22	24.161	23.680	53.878	1.00	25.10	AAAA
	ATOM 191	N	LEU	23	25.756	25.004	53.011	1.00	24.28	AAAA
	ATOM 192	H	LEU	23	26.233	25.265	52.199	1.00	0.00	AAAA
	ATOM 193	CA	LEU	23	26.068	25.649	54.289	1.00	22.60	AAAA
	ATOM 194	CB	LEU	23	27.476	26.249	54.240	1.00	23.15	AAAA
30	ATOM 195	CG	LEU	23	28.621	25.216	54.126	1.00	27.13	AAAA
	ATOM 196	CD1	LEU	23	29.966	25.935	53.935	1.00	22.36	AAAA
	ATOM 197	CD2	LEU	23	28.650	24.292	55.360	1.00	22.91	AAAA
	ATOM 198	C	LEU	23	25.046	26.722	54.690	1.00	21.30	AAAA
	ATOM 199	O	LEU	23	25.134	27.307	55.770	1.00	19.91	AAAA
35	ATOM 200	N	GLY	24	24.102	27.009	53.792	1.00	22.47	AAAA
	ATOM 201	H	GLY	24	24.162	26.600	52.902	1.00	0.00	AAAA
	ATOM 202	CA	GLY	24	22.979	27.880	54.123	1.00	18.64	AAAA
	ATOM 203	C	GLY	24	23.062	29.291	53.583	1.00	20.19	AAAA
	ATOM 204	O	GLY	24	22.359	30.187	54.058	1.00	21.11	AAAA
40	ATOM 205	N	LEU	25	23.917	29.497	52.582	1.00	21.94	AAAA
	ATOM 206	H	LEU	25	24.454	28.744	52.264	1.00	0.00	AAAA
	ATOM 207	CA	LEU	25	24.070	30.802	51.936	1.00	22.38	AAAA
	ATOM 208	CB	LEU	25	25.525	31.053	51.514	1.00	21.52	AAAA

-22-

	ATOM 209	CG	LEU	25	26.611	31.599	52.432	1.00	24.11	AAAA
	ATOM 210	CD1	LEU	25	26.183	32.924	52.976	1.00	26.31	AAAA
	ATOM 211	CD2	LEU	25	26.911	30.589	53.536	1.00	25.31	AAAA
	ATOM 212	C	LEU	25	23.218	30.870	50.670	1.00	23.83	AAAA
5	ATOM 213	O	LEU	25	23.382	30.069	49.744	1.00	22.04	AAAA
	ATOM 214	N	HIS	26	22.437	31.935	50.568	1.00	27.33	AAAA
	ATOM 215	H	HIS	26	22.373	32.444	51.402	1.00	0.00	AAAA
	ATOM 216	CA	HIS	26	21.827	32.302	49.297	1.00	30.72	AAAA
	ATOM 217	CB	HIS	26	20.858	33.461	49.519	1.00	35.03	AAAA
10	ATOM 218	CG	HIS	26	19.725	33.126	50.440	1.00	39.71	AAAA
	ATOM 219	CD2	HIS	26	19.605	33.253	51.781	1.00	38.99	AAAA
	ATOM 220	ND1	HIS	26	18.546	32.562	49.999	1.00	40.72	AAAA
	ATOM 221	HD1	HIS	26	18.332	32.241	49.089	1.00	0.00	AAAA
	ATOM 222	CE1	HIS	26	17.743	32.369	51.032	1.00	39.92	AAAA
15	ATOM 223	NE2	HIS	26	18.359	32.785	52.123	1.00	39.81	AAAA
	ATOM 224	HE2	HIS	26	18.134	32.577	53.054	1.00	0.00	AAAA
	ATOM 225	C	HIS	26	22.910	32.705	48.286	1.00	30.28	AAAA
	ATOM 226	O	HIS	26	23.899	33.337	48.655	1.00	32.24	AAAA
	ATOM 227	N	PRO	27	22.681	32.456	46.989	1.00	28.45	AAAA
20	ATOM 228	CD	PRO	27	21.500	31.803	46.395	1.00	30.37	AAAA
	ATOM 229	CA	PRO	27	23.753	32.629	46.003	1.00	24.28	AAAA
	ATOM 230	CB	PRO	27	23.367	31.657	44.904	1.00	27.20	AAAA
	ATOM 231	CG	PRO	27	21.850	31.731	44.917	1.00	31.25	AAAA
	ATOM 232	C	PRO	27	23.856	34.044	45.465	1.00	23.59	AAAA
25	ATOM 233	O	PRO	27	23.941	34.235	44.267	1.00	28.42	AAAA
	ATOM 234	N	ASN	28	23.971	35.021	46.349	1.00	21.98	AAAA
	ATOM 235	H	ASN	28	24.029	34.719	47.277	1.00	0.00	AAAA
	ATOM 236	CA	ASN	28	24.197	36.393	45.911	1.00	25.40	AAAA
	ATOM 237	CB	ASN	28	23.630	37.402	46.913	1.00	29.65	AAAA
30	ATOM 238	CG	ASN	28	23.848	36.989	48.341	1.00	36.22	AAAA
	ATOM 239	OD1	ASN	28	24.378	37.743	49.162	1.00	39.03	AAAA
	ATOM 240	ND2	ASN	28	23.289	35.853	48.689	1.00	39.95	AAAA
	ATOM 241	HD21	ASN	28	23.560	35.562	49.587	1.00	0.00	AAAA
	ATOM 242	HD22	ASN	28	22.654	35.468	48.059	1.00	0.00	AAAA
35	ATOM 243	C	ASN	28	25.676	36.670	45.714	1.00	24.12	AAAA
	ATOM 244	O	ASN	28	26.063	37.766	45.316	1.00	25.78	AAAA
	ATOM 245	N	TRP	29	26.490	35.759	46.237	1.00	22.87	AAAA
	ATOM 246	H	TRP	29	26.120	35.099	46.851	1.00	0.00	AAAA
	ATOM 247	CA	TRP	29	27.926	35.739	45.966	1.00	21.65	AAAA
40	ATOM 248	CB	TRP	29	28.737	36.004	47.245	1.00	19.38	AAAA
	ATOM 249	CG	TRP	29	28.640	37.388	47.766	1.00	18.45	AAAA
	ATOM 250	CD2	TRP	29	29.441	38.519	47.389	1.00	18.42	AAAA
	ATOM 251	CE2	TRP	29	28.946	39.636	48.101	1.00	19.19	AAAA

	ATOM	252	CE3	TRP	29	30.518	38.706	46.510	1.00	19.40	AAAA
	ATOM	253	CD1	TRP	29	27.736	37.846	48.672	1.00	19.49	AAAA
	ATOM	254	NE1	TRP	29	27.909	39.191	48.881	1.00	19.40	AAAA
	ATOM	255	HE1	TRP	29	27.325	39.692	49.489	1.00	0.00	AAAA
5	ATOM	256	CZ2	TRP	29	29.487	40.924	47.961	1.00	19.87	AAAA
	ATOM	257	CZ3	TRP	29	31.057	39.993	46.367	1.00	18.65	AAAA
	ATOM	258	CH2	TRP	29	30.539	41.079	47.090	1.00	18.95	AAAA
	ATOM	259	C	TRP	29	28.233	34.352	45.446	1.00	19.35	AAAA
	ATOM	260	O	TRP	29	27.682	33.369	45.953	1.00	21.87	AAAA
10	ATOM	261	N	GLN	30	29.000	34.275	44.357	1.00	19.97	AAAA
	ATOM	262	H	GLN	30	29.276	35.096	43.900	1.00	0.00	AAAA
	ATOM	263	CA	GLN	30	29.401	32.984	43.783	1.00	19.00	AAAA
	ATOM	264	CB	GLN	30	28.543	32.671	42.552	1.00	20.67	AAAA
	ATOM	265	CG	GLN	30	27.042	32.621	42.844	1.00	21.49	AAAA
15	ATOM	266	CD	GLN	30	26.632	31.302	43.408	1.00	20.18	AAAA
	ATOM	267	OE1	GLN	30	26.459	30.349	42.671	1.00	23.21	AAAA
	ATOM	268	NE2	GLN	30	26.636	31.188	44.725	1.00	22.75	AAAA
	ATOM	269	HE21	GLN	30	26.874	31.932	45.294	1.00	0.00	AAAA
	ATOM	270	HE22	GLN	30	26.395	30.274	44.998	1.00	0.00	AAAA
20	ATOM	271	C	GLN	30	30.876	32.995	43.383	1.00	18.13	AAAA
	ATOM	272	O	GLN	30	31.378	34.008	42.896	1.00	19.67	AAAA
	ATOM	273	N	PHE	31	31.575	31.892	43.615	1.00	18.15	AAAA
	ATOM	274	H	PHE	31	31.160	31.192	44.148	1.00	0.00	AAAA
	ATOM	275	CA	PHE	31	32.952	31.764	43.136	1.00	18.12	AAAA
25	ATOM	276	CB	PHE	31	33.651	30.576	43.791	1.00	18.21	AAAA
	ATOM	277	CG	PHE	31	34.089	30.841	45.211	1.00	21.78	AAAA
	ATOM	278	CD1	PHE	31	33.322	30.396	46.288	1.00	18.71	AAAA
	ATOM	279	CD2	PHE	31	35.263	31.563	45.476	1.00	20.73	AAAA
	ATOM	280	CE1	PHE	31	33.719	30.657	47.608	1.00	18.40	AAAA
30	ATOM	281	CE2	PHE	31	35.663	31.826	46.789	1.00	17.15	AAAA
	ATOM	282	CZ	PHE	31	34.893	31.374	47.856	1.00	16.61	AAAA
	ATOM	283	C	PHE	31	33.023	31.606	41.631	1.00	20.44	AAAA
	ATOM	284	O	PHE	31	32.214	30.891	41.025	1.00	21.52	AAAA
	ATOM	285	N	VAL	32	34.029	32.232	41.034	1.00	21.92	AAAA
35	ATOM	286	H	VAL	32	34.545	32.853	41.588	1.00	0.00	AAAA
	ATOM	287	CA	VAL	32	34.349	32.045	39.616	1.00	20.67	AAAA
	ATOM	288	CB	VAL	32	34.004	33.332	38.780	1.00	20.87	AAAA
	ATOM	289	CG1	VAL	32	32.508	33.586	38.787	1.00	23.52	AAAA
	ATOM	290	CG2	VAL	32	34.702	34.563	39.345	1.00	18.97	AAAA
40	ATOM	291	C	VAL	32	35.847	31.736	39.494	1.00	21.19	AAAA
	ATOM	292	O	VAL	32	36.619	32.038	40.405	1.00	19.52	AAAA
	ATOM	293	N	ASP	33	36.251	31.088	38.407	1.00	20.92	AAAA
	ATOM	294	H	ASP	33	35.575	30.751	37.793	1.00	0.00	AAAA

5	ATOM 295	CA	ASP	33	37.677	30.936	38.103	1.00	24.10	AAAA
	ATOM 296	CB	ASP	33	37.877	30.087	36.867	1.00	23.40	AAAA
	ATOM 297	CG	ASP	33	37.547	28.662	37.101	1.00	28.62	AAAA
	ATOM 298	OD1	ASP	33	38.155	28.078	38.023	1.00	31.38	AAAA
	ATOM 299	OD2	ASP	33	36.637	28.146	36.415	1.00	31.16	AAAA
10	ATOM 300	C	ASP	33	38.324	32.278	37.849	1.00	24.54	AAAA
	ATOM 301	O	ASP	33	37.694	33.163	37.268	1.00	25.36	AAAA
	ATOM 302	N	VAL	34	39.547	32.465	38.333	1.00	23.21	AAAA
	ATOM 303	H	VAL	34	39.885	31.900	39.060	1.00	0.00	AAAA
	ATOM 304	CA	VAL	34	40.379	33.527	37.787	1.00	26.15	AAAA
15	ATOM 305	CB	VAL	34	41.176	34.265	38.881	1.00	25.11	AAAA
	ATOM 306	CG1	VAL	34	42.030	35.353	38.243	1.00	24.72	AAAA
	ATOM 307	CG2	VAL	34	40.216	34.871	39.916	1.00	23.17	AAAA
	ATOM 308	C	VAL	34	41.324	32.869	36.769	1.00	26.65	AAAA
	ATOM 309	O	VAL	34	41.990	31.884	37.080	1.00	27.57	AAAA
20	ATOM 310	N	TYR	35	41.149	33.214	35.500	1.00	26.68	AAAA
	ATOM 311	H	TYR	35	40.563	33.967	35.283	1.00	0.00	AAAA
	ATOM 312	CA	TYR	35	41.782	32.450	34.430	1.00	26.52	AAAA
	ATOM 313	CB	TYR	35	41.012	32.649	33.116	1.00	25.88	AAAA
	ATOM 314	CG	TYR	35	39.736	31.831	33.066	1.00	22.69	AAAA
25	ATOM 315	CD1	TYR	35	38.494	32.409	33.344	1.00	22.08	AAAA
	ATOM 316	CE1	TYR	35	37.348	31.628	33.440	1.00	18.63	AAAA
	ATOM 317	CD2	TYR	35	39.791	30.455	32.872	1.00	24.37	AAAA
	ATOM 318	CE2	TYR	35	38.657	29.672	32.964	1.00	23.29	AAAA
	ATOM 319	CZ	TYR	35	37.442	30.264	33.251	1.00	21.25	AAAA
30	ATOM 320	OH	TYR	35	36.321	29.472	33.331	1.00	22.79	AAAA
	ATOM 321	HH	TYR	35	35.794	29.791	34.083	1.00	0.00	AAAA
	ATOM 322	C	TYR	35	43.262	32.795	34.266	1.00	28.14	AAAA
	ATOM 323	O	TYR	35	44.064	31.950	33.869	1.00	31.16	AAAA
	ATOM 324	N	GLY	36	43.615	34.023	34.626	1.00	30.78	AAAA
35	ATOM 325	H	GLY	36	42.903	34.661	34.827	1.00	0.00	AAAA
	ATOM 326	CA	GLY	36	45.013	34.404	34.757	1.00	35.11	AAAA
	ATOM 327	C	GLY	36	45.130	35.712	35.520	1.00	37.27	AAAA
	ATOM 328	O	GLY	36	44.114	36.294	35.889	1.00	38.81	AAAA
	ATOM 329	N	MET	37	46.356	36.177	35.756	1.00	41.81	AAAA
40	ATOM 330	H	MET	37	47.091	35.568	35.539	1.00	0.00	AAAA
	ATOM 331	CA	MET	37	46.590	37.477	36.400	1.00	44.35	AAAA
	ATOM 332	CB	MET	37	47.883	37.457	37.231	1.00	48.91	AAAA
	ATOM 333	CG	MET	37	48.285	36.101	37.820	1.00	53.53	AAAA
	ATOM 334	SD	MET	37	47.107	35.436	39.011	1.00	65.33	AAAA
	ATOM 335	CE	MET	37	48.083	34.161	39.821	1.00	58.45	AAAA
	ATOM 336	C	MET	37	46.678	38.598	35.356	1.00	45.24	AAAA
	ATOM 337	O	MET	37	46.695	39.778	35.694	1.00	48.93	AAAA

	ATOM 338	N	ASP	38	46.841	38.214	34.095	1.00	44.40	AAAA
	ATOM 339	H	ASP	38	47.007	37.262	33.943	1.00	0.00	AAAA
	ATOM 340	CA	ASP	38	46.750	39.127	32.958	1.00	44.85	AAAA
	ATOM 341	CB	ASP	38	46.718	38.296	31.668	1.00	54.39	AAAA
5	ATOM 342	CG	ASP	38	47.302	39.024	30.461	1.00	61.36	AAAA
	ATOM 343	OD1	ASP	38	47.368	40.273	30.451	1.00	65.74	AAAA
	ATOM 344	OD2	ASP	38	47.647	38.328	29.478	1.00	67.49	AAAA
	ATOM 345	C	ASP	38	45.477	39.980	33.038	1.00	42.01	AAAA
	ATOM 346	O	ASP	38	44.382	39.453	33.209	1.00	38.13	AAAA
10	ATOM 347	N	PRO	39	45.592	41.284	32.746	1.00	42.09	AAAA
	ATOM 348	CD	PRO	39	46.871	42.020	32.774	1.00	43.41	AAAA
	ATOM 349	CA	PRO	39	44.441	42.193	32.631	1.00	40.63	AAAA
	ATOM 350	CB	PRO	39	45.046	43.461	32.042	1.00	40.54	AAAA
	ATOM 351	CG	PRO	39	46.464	43.449	32.509	1.00	42.45	AAAA
15	ATOM 352	C	PRO	39	43.315	41.673	31.744	1.00	40.33	AAAA
	ATOM 353	O	PRO	39	42.146	41.990	31.959	1.00	40.35	AAAA
	ATOM 354	N	GLU	40	43.683	40.979	30.675	1.00	39.70	AAAA
	ATOM 355	H	GLU	40	44.637	40.883	30.494	1.00	0.00	AAAA
	ATOM 356	CA	GLU	40	42.695	40.457	29.736	1.00	39.58	AAAA
20	ATOM 357	CB	GLU	40	43.391	39.907	28.487	1.00	38.40	AAAA
	ATOM 358	CG	GLU	40	43.806	41.003	27.512	1.00	39.64	AAAA
	ATOM 359	CD	GLU	40	44.733	40.531	26.388	1.00	39.81	AAAA
	ATOM 360	OE1	GLU	40	45.443	39.501	26.546	1.00	35.20	AAAA
	ATOM 361	OE2	GLU	40	44.802	41.261	25.372	1.00	37.81	AAAA
25	ATOM 362	C	GLU	40	41.823	39.381	30.377	1.00	38.35	AAAA
	ATOM 363	O	GLU	40	40.616	39.318	30.134	1.00	39.28	AAAA
	ATOM 364	N	LEU	41	42.426	38.578	31.248	1.00	36.49	AAAA
	ATOM 365	H	LEU	41	43.381	38.714	31.409	1.00	0.00	AAAA
	ATOM 366	CA	LEU	41	41.691	37.538	31.966	1.00	35.44	AAAA
30	ATOM 367	CB	LEU	41	42.567	36.300	32.135	1.00	34.47	AAAA
	ATOM 368	CG	LEU	41	42.961	35.650	30.805	1.00	33.48	AAAA
	ATOM 369	CD1	LEU	41	44.058	34.633	31.026	1.00	34.40	AAAA
	ATOM 370	CD2	LEU	41	41.754	35.002	30.181	1.00	26.42	AAAA
	ATOM 371	C	LEU	41	41.161	38.015	33.321	1.00	34.73	AAAA
35	ATOM 372	O	LEU	41	40.068	37.623	33.735	1.00	35.09	AAAA
	ATOM 373	N	LEU	42	41.834	38.995	33.918	1.00	33.06	AAAA
	ATOM 374	H	LEU	42	42.629	39.346	33.483	1.00	0.00	AAAA
	ATOM 375	CA	LEU	42	41.370	39.565	35.177	1.00	31.32	AAAA
	ATOM 376	CB	LEU	42	42.426	40.495	35.778	1.00	31.53	AAAA
40	ATOM 377	CG	LEU	42	43.141	40.129	37.083	1.00	34.19	AAAA
	ATOM 378	CD1	LEU	42	43.441	41.416	37.830	1.00	37.43	AAAA
	ATOM 379	CD2	LEU	42	42.304	39.211	37.950	1.00	33.17	AAAA
	ATOM 380	C	LEU	42	40.074	40.344	34.983	1.00	31.86	AAAA

-26-

	ATOM	381	O	LEU	42	39.146	40.232	35.782	1.00	31.41	AAAA
	ATOM	382	N	SER	43	39.993	41.114	33.905	1.00	32.09	AAAA
	ATOM	383	H	SER	43	40.722	41.122	33.244	1.00	0.00	AAAA
	ATOM	384	CA	SER	43	38.809	41.942	33.660	1.00	30.91	AAAA
5	ATOM	385	CB	SER	43	39.067	42.895	32.488	1.00	30.06	AAAA
	ATOM	386	OG	SER	43	39.651	42.207	31.402	1.00	33.39	AAAA
	ATOM	387	HG	SER	43	40.500	42.602	31.162	1.00	0.00	AAAA
	ATOM	388	C	SER	43	37.540	41.111	33.401	1.00	27.31	AAAA
	ATOM	389	O	SER	43	36.430	41.614	33.510	1.00	27.97	AAAA
10	ATOM	390	N	MET	44	37.709	39.819	33.160	1.00	24.99	AAAA
	ATOM	391	H	MET	44	38.618	39.473	33.038	1.00	0.00	AAAA
	ATOM	392	CA	MET	44	36.570	38.918	33.035	1.00	27.37	AAAA
	ATOM	393	CB	MET	44	37.007	37.600	32.420	1.00	29.97	AAAA
	ATOM	394	CG	MET	44	37.265	37.623	30.948	1.00	30.45	AAAA
15	ATOM	395	SD	MET	44	38.047	36.072	30.555	1.00	40.12	AAAA
	ATOM	396	CE	MET	44	36.647	34.951	30.644	1.00	38.79	AAAA
	ATOM	397	C	MET	44	35.838	38.595	34.351	1.00	30.11	AAAA
	ATOM	398	O	MET	44	34.770	37.981	34.337	1.00	31.53	AAAA
	ATOM	399	N	VAL	45	36.484	38.830	35.484	1.00	29.44	AAAA
20	ATOM	400	H	VAL	45	37.345	39.290	35.448	1.00	0.00	AAAA
	ATOM	401	CA	VAL	45	35.893	38.445	36.763	1.00	26.30	AAAA
	ATOM	402	CB	VAL	45	36.965	38.411	37.875	1.00	24.98	AAAA
	ATOM	403	CG1	VAL	45	36.338	38.051	39.227	1.00	21.57	AAAA
	ATOM	404	CG2	VAL	45	38.043	37.412	37.503	1.00	23.63	AAAA
25	ATOM	405	C	VAL	45	34.747	39.381	37.173	1.00	26.01	AAAA
	ATOM	406	O	VAL	45	34.901	40.603	37.199	1.00	25.56	AAAA
	ATOM	407	N	PRO	46	33.566	38.820	37.457	1.00	26.96	AAAA
	ATOM	408	CD	PRO	46	33.174	37.412	37.264	1.00	28.85	AAAA
	ATOM	409	CA	PRO	46	32.446	39.616	37.959	1.00	26.67	AAAA
30	ATOM	410	CB	PRO	46	31.356	38.578	38.209	1.00	26.01	AAAA
	ATOM	411	CG	PRO	46	31.679	37.474	37.282	1.00	24.45	AAAA
	ATOM	412	C	PRO	46	32.822	40.338	39.234	1.00	26.63	AAAA
	ATOM	413	O	PRO	46	33.536	39.788	40.054	1.00	29.14	AAAA
	ATOM	414	N	ARG	47	32.427	41.600	39.348	1.00	28.89	AAAA
35	ATOM	415	H	ARG	47	31.947	41.987	38.584	1.00	0.00	AAAA
	ATOM	416	CA	ARG	47	32.660	42.390	40.558	1.00	31.96	AAAA
	ATOM	417	CB	ARG	47	33.439	43.660	40.232	1.00	38.74	AAAA
	ATOM	418	CG	ARG	47	34.628	43.440	39.357	1.00	45.55	AAAA
	ATOM	419	CD	ARG	47	35.882	43.853	40.069	1.00	53.22	AAAA
40	ATOM	420	NE	ARG	47	37.031	43.644	39.196	1.00	57.19	AAAA
	ATOM	421	HE	ARG	47	36.970	42.863	38.611	1.00	0.00	AAAA
	ATOM	422	CZ	ARG	47	38.126	44.395	39.204	1.00	59.13	AAAA
	ATOM	423	NH1	ARG	47	39.033	44.235	38.246	1.00	58.34	AAAA

-27-

	ATOM 424	HH11 ARG	47	38.884	43.574	37.513	1.00	0.00	AAAA
	ATOM 425	HH12 ARG	47	39.848	44.815	38.243	1.00	0.00	AAAA
	ATOM 426	NH2 ARG	47	38.341	45.252	40.202	1.00	57.19	AAAA
	ATOM 427	HH21 ARG	47	39.161	45.822	40.207	1.00	0.00	AAAA
5	ATOM 428	HH22 ARG	47	37.667	45.360	40.937	1.00	0.00	AAAA
	ATOM 429	C ARG	47	31.334	42.788	41.207	1.00	31.57	AAAA
	ATOM 430	O ARG	47	30.279	42.698	40.578	1.00	35.91	AAAA
	ATOM 431	N PRO	48	31.375	43.285	42.450	1.00	28.07	AAAA
	ATOM 432	CD PRO	48	30.207	43.903	43.087	1.00	29.27	AAAA
10	ATOM 433	CA PRO	48	32.511	43.267	43.374	1.00	27.18	AAAA
	ATOM 434	CB PRO	48	31.948	43.916	44.635	1.00	25.16	AAAA
	ATOM 435	CG PRO	48	30.837	44.729	44.159	1.00	30.03	AAAA
	ATOM 436	C PRO	48	33.010	41.854	43.664	1.00	26.56	AAAA
	ATOM 437	O PRO	48	32.286	40.875	43.454	1.00	24.00	AAAA
15	ATOM 438	N VAL	49	34.301	41.761	43.982	1.00	25.54	AAAA
	ATOM 439	H VAL	49	34.852	42.554	43.813	1.00	0.00	AAAA
	ATOM 440	CA VAL	49	34.911	40.547	44.520	1.00	21.73	AAAA
	ATOM 441	CB VAL	49	36.246	40.261	43.799	1.00	22.26	AAAA
	ATOM 442	CG1 VAL	49	36.948	39.064	44.423	1.00	20.99	AAAA
20	ATOM 443	CG2 VAL	49	35.991	40.004	42.332	1.00	21.69	AAAA
	ATOM 444	C VAL	49	35.182	40.791	46.004	1.00	17.83	AAAA
	ATOM 445	O VAL	49	35.671	41.851	46.363	1.00	19.33	AAAA
	ATOM 446	N CYS	50	34.736	39.895	46.880	1.00	19.34	AAAA
	ATOM 447	H CYS	50	34.184	39.155	46.538	1.00	0.00	AAAA
25	ATOM 448	CA CYS	50	35.030	40.082	48.305	1.00	19.43	AAAA
	ATOM 449	CB CYS	50	33.751	40.098	49.147	1.00	18.28	AAAA
	ATOM 450	SG CYS	50	32.923	38.524	49.247	1.00	22.22	AAAA
	ATOM 451	C CYS	50	36.016	39.068	48.892	1.00	18.64	AAAA
	ATOM 452	O CYS	50	36.363	39.141	50.067	1.00	21.41	AAAA
30	ATOM 453	N ALA	51	36.527	38.174	48.064	1.00	16.97	AAAA
	ATOM 454	H ALA	51	36.204	38.132	47.146	1.00	0.00	AAAA
	ATOM 455	CA ALA	51	37.527	37.235	48.525	1.00	12.98	AAAA
	ATOM 456	CB ALA	51	36.899	36.197	49.434	1.00	15.92	AAAA
	ATOM 457	C ALA	51	38.156	36.559	47.345	1.00	17.22	AAAA
35	ATOM 458	O ALA	51	37.489	36.264	46.361	1.00	18.29	AAAA
	ATOM 459	N VAL	52	39.454	36.304	47.447	1.00	16.94	AAAA
	ATOM 460	H VAL	52	39.935	36.706	48.201	1.00	0.00	AAAA
	ATOM 461	CA VAL	52	40.148	35.446	46.485	1.00	16.89	AAAA
	ATOM 462	CB VAL	52	41.325	36.226	45.769	1.00	14.71	AAAA
40	ATOM 463	CG1 VAL	52	42.104	35.295	44.864	1.00	14.13	AAAA
	ATOM 464	CG2 VAL	52	40.784	37.417	44.983	1.00	15.31	AAAA
	ATOM 465	C VAL	52	40.711	34.245	47.249	1.00	15.15	AAAA
	ATOM 466	O VAL	52	41.310	34.403	48.326	1.00	18.19	AAAA

-28-

5	ATOM 467	N	LEU	53	40.428	33.050	46.765	1.00	12.59	AAAA
	ATOM 468	H	LEU	53	39.784	32.985	46.031	1.00	0.00	AAAA
	ATOM 469	CA	LEU	53	41.081	31.873	47.287	1.00	14.74	AAAA
	ATOM 470	CB	LEU	53	40.067	30.754	47.519	1.00	16.32	AAAA
	ATOM 471	CG	LEU	53	39.487	30.583	48.937	1.00	18.05	AAAA
	ATOM 472	CD1	LEU	53	38.986	31.897	49.449	1.00	16.19	AAAA
	ATOM 473	CD2	LEU	53	38.370	29.542	48.921	1.00	15.85	AAAA
	ATOM 474	C	LEU	53	42.186	31.408	46.327	1.00	20.78	AAAA
10	ATOM 475	O	LEU	53	41.992	31.395	45.109	1.00	15.78	AAAA
	ATOM 476	N	LEU	54	43.389	31.205	46.873	1.00	19.44	AAAA
	ATOM 477	H	LEU	54	43.473	31.356	47.838	1.00	0.00	AAAA
	ATOM 478	CA	LEU	54	44.527	30.741	46.081	1.00	19.71	AAAA
	ATOM 479	CB	LEU	54	45.728	31.698	46.209	1.00	19.22	AAAA
	ATOM 480	CG	LEU	54	47.039	31.318	45.501	1.00	18.95	AAAA
	ATOM 481	CD1	LEU	54	46.863	31.342	43.981	1.00	15.60	AAAA
	ATOM 482	CD2	LEU	54	48.118	32.309	45.904	1.00	18.59	AAAA
15	ATOM 483	C	LEU	54	44.938	29.353	46.504	1.00	19.65	AAAA
	ATOM 484	O	LEU	54	45.116	29.081	47.709	1.00	16.10	AAAA
	ATOM 485	N	LEU	55	44.939	28.457	45.517	1.00	19.34	AAAA
	ATOM 486	H	LEU	55	44.559	28.742	44.656	1.00	0.00	AAAA
	ATOM 487	CA	LEU	55	45.465	27.098	45.662	1.00	19.42	AAAA
	ATOM 488	CB	LEU	55	44.586	26.099	44.908	1.00	18.64	AAAA
	ATOM 489	CG	LEU	55	44.979	24.625	45.027	1.00	20.11	AAAA
	ATOM 490	CD1	LEU	55	44.716	24.084	46.435	1.00	22.00	AAAA
25	ATOM 491	CD2	LEU	55	44.183	23.827	44.019	1.00	22.10	AAAA
	ATOM 492	C	LEU	55	46.882	27.044	45.105	1.00	22.01	AAAA
	ATOM 493	O	LEU	55	47.107	27.348	43.930	1.00	19.66	AAAA
	ATOM 494	N	PHE	56	47.836	26.685	45.959	1.00	21.06	AAAA
	ATOM 495	H	PHE	56	47.572	26.417	46.861	1.00	0.00	AAAA
	ATOM 496	CA	PHE	56	49.249	26.696	45.580	1.00	20.59	AAAA
	ATOM 497	CB	PHE	56	49.883	28.048	45.948	1.00	16.88	AAAA
	ATOM 498	CG	PHE	56	50.061	28.261	47.418	1.00	23.60	AAAA
35	ATOM 499	CD1	PHE	56	51.221	27.831	48.063	1.00	25.11	AAAA
	ATOM 500	CD2	PHE	56	49.073	28.886	48.172	1.00	23.92	AAAA
	ATOM 501	CE1	PHE	56	51.384	28.015	49.433	1.00	27.68	AAAA
	ATOM 502	CE2	PHE	56	49.235	29.078	49.549	1.00	23.11	AAAA
	ATOM 503	CZ	PHE	56	50.383	28.642	50.176	1.00	26.70	AAAA
	ATOM 504	C	PHE	56	49.963	25.540	46.266	1.00	22.28	AAAA
	ATOM 505	O	PHE	56	49.394	24.890	47.158	1.00	21.61	AAAA
	ATOM 506	N	PRO	57	51.193	25.208	45.819	1.00	27.77	AAAA
40	ATOM 507	CD	PRO	57	51.930	25.733	44.651	1.00	25.94	AAAA
	ATOM 508	CA	PRO	57	51.891	24.060	46.423	1.00	26.56	AAAA
	ATOM 509	CB	PRO	57	52.538	23.377	45.216	1.00	27.54	AAAA

	ATOM 510	CG	PRO	57	52.668	24.507	44.160	1.00	29.50	AAAA
	ATOM 511	C	PRO	57	52.906	24.439	47.523	1.00	23.83	AAAA
	ATOM 512	O	PRO	57	53.565	25.481	47.460	1.00	23.72	AAAA
	ATOM 513	N	ILE	58	52.874	23.689	48.615	1.00	27.04	AAAA
5	ATOM 514	H	ILE	58	52.184	23.055	48.691	1.00	0.00	AAAA
	ATOM 515	CA	ILE	58	53.800	23.906	49.728	1.00	31.09	AAAA
	ATOM 516	CB	ILE	58	53.241	23.338	51.064	1.00	32.61	AAAA
	ATOM 517	CG2	ILE	58	54.204	23.642	52.226	1.00	31.31	AAAA
	ATOM 518	CG1	ILE	58	51.875	23.949	51.363	1.00	30.84	AAAA
10	ATOM 519	CD	ILE	58	51.174	23.250	52.487	1.00	29.57	AAAA
	ATOM 520	C	ILE	58	55.142	23.234	49.427	1.00	31.74	AAAA
	ATOM 521	O	ILE	58	55.278	22.009	49.512	1.00	33.47	AAAA
	ATOM 522	N	THR	59	56.072	24.022	48.910	1.00	33.63	AAAA
	ATOM 523	H	THR	59	55.804	24.955	48.785	1.00	0.00	AAAA
15	ATOM 524	CA	THR	59	57.390	23.511	48.556	1.00	32.86	AAAA
	ATOM 525	CB	THR	59	57.838	24.082	47.205	1.00	34.38	AAAA
	ATOM 526	OG1	THR	59	57.864	25.513	47.284	1.00	30.05	AAAA
	ATOM 527	HG1	THR	59	57.104	25.829	46.781	1.00	0.00	AAAA
	ATOM 528	CG2	THR	59	56.877	23.658	46.091	1.00	34.44	AAAA
20	ATOM 529	C	THR	59	58.417	23.901	49.616	1.00	34.06	AAAA
	ATOM 530	O	THR	59	58.157	24.786	50.429	1.00	30.95	AAAA
	ATOM 531	N	GLU	60	59.593	23.271	49.578	1.00	36.00	AAAA
	ATOM 532	H	GLU	60	59.653	22.488	48.995	1.00	0.00	AAAA
	ATOM 533	CA	GLU	60	60.720	23.670	50.426	1.00	36.26	AAAA
25	ATOM 534	CB	GLU	60	61.980	22.903	50.033	1.00	42.18	AAAA
	ATOM 535	CG	GLU	60	62.050	21.471	50.549	1.00	53.87	AAAA
	ATOM 536	CD	GLU	60	63.296	20.736	50.068	1.00	59.16	AAAA
	ATOM 537	OE1	GLU	60	64.348	20.813	50.747	1.00	63.06	AAAA
	ATOM 538	OE2	GLU	60	63.225	20.091	48.996	1.00	63.28	AAAA
30	ATOM 539	C	GLU	60	60.982	25.153	50.256	1.00	35.56	AAAA
	ATOM 540	O	GLU	60	61.101	25.890	51.228	1.00	37.03	AAAA
	ATOM 541	N	LYS	61	60.986	25.582	48.999	1.00	35.28	AAAA
	ATOM 542	H	LYS	61	60.883	24.902	48.307	1.00	0.00	AAAA
	ATOM 543	CA	LYS	61	61.178	26.974	48.607	1.00	35.78	AAAA
35	ATOM 544	CB	LYS	61	61.079	27.060	47.088	1.00	38.62	AAAA
	ATOM 545	CG	LYS	61	61.833	28.185	46.448	1.00	43.95	AAAA
	ATOM 546	CD	LYS	61	62.080	27.843	44.990	1.00	46.20	AAAA
	ATOM 547	CE	LYS	61	63.096	28.769	44.355	1.00	48.83	AAAA
	ATOM 548	NZ	LYS	61	63.535	28.244	43.029	1.00	51.71	AAAA
40	ATOM 549	HZ1	LYS	61	62.705	28.054	42.432	1.00	0.00	AAAA
	ATOM 550	HZ2	LYS	61	64.068	27.364	43.181	1.00	0.00	AAAA
	ATOM 551	HZ3	LYS	61	64.154	28.942	42.568	1.00	0.00	AAAA
	ATOM 552	C	LYS	61	60.115	27.877	49.246	1.00	36.67	AAAA

	ATOM	553	O	LYS	61	60.425	28.913	49.836	1.00	36.93	AAAA
	ATOM	554	N	TYR	62	58.859	27.447	49.168	1.00	35.28	AAAA
	ATOM	555	H	TYR	62	58.677	26.650	48.629	1.00	0.00	AAAA
	ATOM	556	CA	TYR	62	57.764	28.114	49.866	1.00	31.76	AAAA
5	ATOM	557	CB	TYR	62	56.460	27.342	49.626	1.00	31.61	AAAA
	ATOM	558	CG	TYR	62	55.310	27.834	50.461	1.00	26.21	AAAA
	ATOM	559	CD1	TYR	62	54.761	29.088	50.222	1.00	30.35	AAAA
	ATOM	560	CE1	TYR	62	53.856	29.659	51.106	1.00	29.55	AAAA
	ATOM	561	CD2	TYR	62	54.905	27.144	51.600	1.00	25.46	AAAA
10	ATOM	562	CE2	TYR	62	54.001	27.710	52.501	1.00	25.74	AAAA
	ATOM	563	CZ	TYR	62	53.488	28.967	52.243	1.00	26.36	AAAA
	ATOM	564	OH	TYR	62	52.641	29.589	53.116	1.00	26.54	AAAA
	ATOM	565	HH	TYR	62	52.044	30.083	52.548	1.00	0.00	AAAA
	ATOM	566	C	TYR	62	58.059	28.190	51.372	1.00	30.10	AAAA
15	ATOM	567	O	TYR	62	58.032	29.266	51.976	1.00	31.64	AAAA
	ATOM	568	N	GLU	63	58.434	27.054	51.946	1.00	31.85	AAAA
	ATOM	569	H	GLU	63	58.606	26.285	51.371	1.00	0.00	AAAA
	ATOM	570	CA	GLU	63	58.638	26.941	53.387	1.00	34.36	AAAA
	ATOM	571	CB	GLU	63	58.892	25.488	53.770	1.00	35.57	AAAA
20	ATOM	572	CG	GLU	63	57.659	24.624	53.771	1.00	36.98	AAAA
	ATOM	573	CD	GLU	63	56.658	25.070	54.806	1.00	38.63	AAAA
	ATOM	574	OE1	GLU	63	55.884	26.008	54.529	1.00	38.48	AAAA
	ATOM	575	OE2	GLU	63	56.652	24.479	55.900	1.00	41.70	AAAA
	ATOM	576	C	GLU	63	59.759	27.814	53.960	1.00	35.89	AAAA
25	ATOM	577	O	GLU	63	59.650	28.290	55.099	1.00	35.16	AAAA
	ATOM	578	N	VAL	64	60.835	28.035	53.207	1.00	34.07	AAAA
	ATOM	579	H	VAL	64	60.904	27.569	52.341	1.00	0.00	AAAA
	ATOM	580	CA	VAL	64	61.879	28.901	53.744	1.00	32.48	AAAA
	ATOM	581	CB	VAL	64	63.282	28.790	52.994	1.00	34.25	AAAA
30	ATOM	582	CG1	VAL	64	63.535	27.365	52.550	1.00	30.44	AAAA
	ATOM	583	CG2	VAL	64	63.400	29.793	51.831	1.00	32.48	AAAA
	ATOM	584	C	VAL	64	61.373	30.339	53.768	1.00	30.07	AAAA
	ATOM	585	O	VAL	64	61.497	31.023	54.794	1.00	30.66	AAAA
	ATOM	586	N	PHE	65	60.649	30.739	52.728	1.00	25.14	AAAA
35	ATOM	587	H	PHE	65	60.486	30.125	51.980	1.00	0.00	AAAA
	ATOM	588	CA	PHE	65	60.092	32.077	52.726	1.00	27.03	AAAA
	ATOM	589	CB	PHE	65	59.362	32.379	51.424	1.00	28.76	AAAA
	ATOM	590	CG	PHE	65	58.726	33.738	51.403	1.00	30.67	AAAA
	ATOM	591	CD1	PHE	65	59.449	34.847	50.985	1.00	31.43	AAAA
40	ATOM	592	CD2	PHE	65	57.462	33.930	51.945	1.00	31.83	AAAA
	ATOM	593	CE1	PHE	65	58.933	36.127	51.122	1.00	33.66	AAAA
	ATOM	594	CE2	PHE	65	56.940	35.203	52.090	1.00	31.50	AAAA
	ATOM	595	CZ	PHE	65	57.677	36.306	51.681	1.00	34.79	AAAA

-31-

	ATOM 596	C	PHE	65	59.127	32.255	53.898	1.00	27.51	AAAA
	ATOM 597	O	PHE	65	59.178	33.253	54.602	1.00	28.94	AAAA
	ATOM 598	N	ARG	66	58.233	31.294	54.087	1.00	29.57	AAAA
	ATOM 599	H	ARG	66	58.211	30.557	53.439	1.00	0.00	AAAA
5	ATOM 600	CA	ARG	66	57.277	31.358	55.189	1.00	28.53	AAAA
	ATOM 601	CB	ARG	66	56.409	30.103	55.210	1.00	28.27	AAAA
	ATOM 602	CG	ARG	66	55.210	30.274	56.099	1.00	30.07	AAAA
	ATOM 603	CD	ARG	66	54.586	28.967	56.414	1.00	34.44	AAAA
	ATOM 604	NE	ARG	66	55.118	28.447	57.657	1.00	43.87	AAAA
10	ATOM 605	HE	ARG	66	55.420	29.082	58.336	1.00	0.00	AAAA
	ATOM 606	CZ	ARG	66	55.251	27.159	57.915	1.00	47.87	AAAA
	ATOM 607	NH1	ARG	66	55.743	26.760	59.077	1.00	56.13	AAAA
	ATOM 608	HH11	ARG	66	55.911	27.432	59.798	1.00	0.00	AAAA
	ATOM 609	HH12	ARG	66	55.849	25.785	59.271	1.00	0.00	AAAA
15	ATOM 610	NH2	ARG	66	54.831	26.267	57.034	1.00	54.07	AAAA
	ATOM 611	HH21	ARG	66	54.902	25.291	57.249	1.00	0.00	AAAA
	ATOM 612	HH22	ARG	66	54.365	26.557	56.200	1.00	0.00	AAAA
	ATOM 613	C	ARG	66	57.923	31.562	56.574	1.00	28.57	AAAA
	ATOM 614	O	ARG	66	57.495	32.431	57.349	1.00	26.47	AAAA
20	ATOM 615	N	THR	67	58.993	30.817	56.856	1.00	28.49	AAAA
	ATOM 616	H	THR	67	59.242	30.128	56.207	1.00	0.00	AAAA
	ATOM 617	CA	THR	67	59.711	30.970	58.127	1.00	26.81	AAAA
	ATOM 618	CB	THR	67	60.732	29.895	58.333	1.00	27.83	AAAA
	ATOM 619	OG1	THR	67	60.144	28.631	58.024	1.00	37.76	AAAA
25	ATOM 620	HG1	THR	67	60.091	28.441	57.077	1.00	0.00	AAAA
	ATOM 621	CG2	THR	67	61.157	29.879	59.784	1.00	34.84	AAAA
	ATOM 622	C	THR	67	60.425	32.297	58.270	1.00	24.31	AAAA
	ATOM 623	O	THR	67	60.343	32.931	59.316	1.00	25.88	AAAA
	ATOM 624	N	GLU	68	61.016	32.776	57.180	1.00	24.39	AAAA
30	ATOM 625	H	GLU	68	61.054	32.210	56.386	1.00	0.00	AAAA
	ATOM 626	CA	GLU	68	61.576	34.117	57.165	1.00	26.47	AAAA
	ATOM 627	CB	GLU	68	62.239	34.391	55.817	1.00	25.86	AAAA
	ATOM 628	CG	GLU	68	63.442	33.483	55.597	1.00	34.86	AAAA
	ATOM 629	CD	GLU	68	64.410	33.971	54.528	1.00	32.64	AAAA
35	ATOM 630	OE1	GLU	68	64.606	35.207	54.393	1.00	33.07	AAAA
	ATOM 631	OE2	GLU	68	65.006	33.097	53.862	1.00	30.30	AAAA
	ATOM 632	C	GLU	68	60.509	35.174	57.451	1.00	28.99	AAAA
	ATOM 633	O	GLU	68	60.692	36.049	58.309	1.00	27.30	AAAA
	ATOM 634	N	GLU	69	59.368	35.048	56.771	1.00	28.12	AAAA
40	ATOM 635	H	GLU	69	59.312	34.308	56.134	1.00	0.00	AAAA
	ATOM 636	CA	GLU	69	58.241	35.966	56.952	1.00	24.58	AAAA
	ATOM 637	CB	GLU	69	57.096	35.565	56.017	1.00	23.71	AAAA
	ATOM 638	CG	GLU	69	55.847	36.368	56.196	1.00	22.11	AAAA

-32-

	ATOM 639	CD	GLU	69	54.705	35.813	55.380	1.00	25.45	AAAA
	ATOM 640	OE1	GLU	69	54.228	34.710	55.713	1.00	23.09	AAAA
	ATOM 641	OE2	GLU	69	54.296	36.476	54.404	1.00	26.44	AAAA
	ATOM 642	C	GLU	69	57.754	35.984	58.404	1.00	21.08	AAAA
5	ATOM 643	O	GLU	69	57.476	37.041	58.959	1.00	20.51	AAAA
	ATOM 644	N	GLU	70	57.714	34.814	59.028	1.00	19.93	AAAA
	ATOM 645	H	GLU	70	57.946	34.008	58.528	1.00	0.00	AAAA
	ATOM 646	CA	GLU	70	57.309	34.721	60.419	1.00	24.42	AAAA
	ATOM 647	CB	GLU	70	57.136	33.256	60.815	1.00	24.09	AAAA
10	ATOM 648	CG	GLU	70	56.382	33.079	62.114	1.00	25.29	AAAA
	ATOM 649	CD	GLU	70	56.333	31.650	62.584	1.00	24.10	AAAA
	ATOM 650	OE1	GLU	70	56.101	30.753	61.745	1.00	25.29	AAAA
	ATOM 651	OE2	GLU	70	56.489	31.431	63.806	1.00	26.77	AAAA
	ATOM 652	C	GLU	70	58.325	35.387	61.354	1.00	26.36	AAAA
15	ATOM 653	O	GLU	70	57.959	36.181	62.222	1.00	27.60	AAAA
	ATOM 654	N	GLU	71	59.605	35.153	61.091	1.00	28.74	AAAA
	ATOM 655	H	GLU	71	59.819	34.531	60.361	1.00	0.00	AAAA
	ATOM 656	CA	GLU	71	60.684	35.764	61.873	1.00	31.06	AAAA
	ATOM 657	CB	GLU	71	62.027	35.154	61.463	1.00	34.77	AAAA
20	ATOM 658	CG	GLU	71	62.138	33.657	61.762	1.00	45.41	AAAA
	ATOM 659	CD	GLU	71	63.521	33.074	61.448	1.00	56.76	AAAA
	ATOM 660	OE1	GLU	71	64.276	33.686	60.642	1.00	58.43	AAAA
	ATOM 661	OE2	GLU	71	63.846	31.993	62.008	1.00	59.87	AAAA
	ATOM 662	C	GLU	71	60.724	37.289	61.717	1.00	27.50	AAAA
25	ATOM 663	O	GLU	71	60.776	38.029	62.706	1.00	26.56	AAAA
	ATOM 664	N	LYS	72	60.557	37.752	60.485	1.00	24.83	AAAA
	ATOM 665	H	LYS	72	60.474	37.104	59.763	1.00	0.00	AAAA
	ATOM 666	CA	LYS	72	60.517	39.184	60.216	1.00	27.68	AAAA
	ATOM 667	CB	LYS	72	60.501	39.444	58.704	1.00	29.44	AAAA
30	ATOM 668	CG	LYS	72	60.634	40.917	58.346	1.00	35.91	AAAA
	ATOM 669	CD	LYS	72	60.541	41.141	56.849	1.00	45.30	AAAA
	ATOM 670	CE	LYS	72	59.768	42.427	56.528	1.00	50.61	AAAA
	ATOM 671	NZ	LYS	72	58.357	42.379	57.040	1.00	52.85	AAAA
	ATOM 672	HZ1	LYS	72	58.363	42.253	58.072	1.00	0.00	AAAA
35	ATOM 673	HZ2	LYS	72	57.867	41.574	56.600	1.00	0.00	AAAA
	ATOM 674	HZ3	LYS	72	57.864	43.263	56.803	1.00	0.00	AAAA
	ATOM 675	C	LYS	72	59.336	39.904	60.898	1.00	28.50	AAAA
	ATOM 676	O	LYS	72	59.505	40.990	61.453	1.00	26.07	AAAA
	ATOM 677	N	ILE	73	58.163	39.269	60.925	1.00	27.98	AAAA
40	ATOM 678	H	ILE	73	58.085	38.402	60.469	1.00	0.00	AAAA
	ATOM 679	CA	ILE	73	57.014	39.870	61.586	1.00	30.16	AAAA
	ATOM 680	CB	ILE	73	55.678	39.221	61.117	1.00	32.09	AAAA
	ATOM 681	CG2	ILE	73	54.518	39.615	62.075	1.00	28.61	AAAA

-33-

	ATOM 682	CG1	ILE	73	55.362	39.681	59.683	1.00	30.18	AAAA
	ATOM 683	CD	ILE	73	54.303	38.839	58.964	1.00	28.53	AAAA
	ATOM 684	C	ILE	73	57.117	39.813	63.117	1.00	32.56	AAAA
	ATOM 685	O	ILE	73	56.658	40.716	63.817	1.00	31.86	AAAA
5	ATOM 686	N	LYS	74	57.758	38.778	63.637	1.00	34.68	AAAA
	ATOM 687	H	LYS	74	58.046	38.050	63.047	1.00	0.00	AAAA
	ATOM 688	CA	LYS	74	57.996	38.703	65.070	1.00	38.56	AAAA
	ATOM 689	CB	LYS	74	58.455	37.292	65.439	1.00	41.67	AAAA
	ATOM 690	CG	LYS	74	57.374	36.221	65.241	1.00	44.95	AAAA
10	ATOM 691	CD	LYS	74	57.997	34.832	65.096	1.00	49.48	AAAA
	ATOM 692	CE	LYS	74	57.330	33.811	66.003	1.00	50.67	AAAA
	ATOM 693	NZ	LYS	74	55.898	33.585	65.661	1.00	53.91	AAAA
	ATOM 694	HZ1	LYS	74	55.817	32.986	64.817	1.00	0.00	AAAA
	ATOM 695	HZ2	LYS	74	55.437	34.499	65.477	1.00	0.00	AAAA
15	ATOM 696	HZ3	LYS	74	55.431	33.117	66.465	1.00	0.00	AAAA
	ATOM 697	C	LYS	74	59.014	39.764	65.542	1.00	40.96	AAAA
	ATOM 698	O	LYS	74	58.880	40.327	66.627	1.00	41.57	AAAA
	ATOM 699	N	SER	75	59.955	40.122	64.675	1.00	41.35	AAAA
	ATOM 700	H	SER	75	60.035	39.595	63.850	1.00	0.00	AAAA
20	ATOM 701	CA	SER	75	60.878	41.219	64.969	1.00	43.19	AAAA
	ATOM 702	CB	SER	75	62.102	41.163	64.046	1.00	44.46	AAAA
	ATOM 703	OG	SER	75	62.467	42.453	63.571	1.00	46.60	AAAA
	ATOM 704	HG	SER	75	62.724	43.054	64.265	1.00	0.00	AAAA
	ATOM 705	C	SER	75	60.217	42.587	64.828	1.00	44.73	AAAA
25	ATOM 706	O	SER	75	60.382	43.463	65.685	1.00	48.52	AAAA
	ATOM 707	N	GLN	76	59.518	42.785	63.715	1.00	41.15	AAAA
	ATOM 708	H	GLN	76	59.362	42.019	63.126	1.00	0.00	AAAA
	ATOM 709	CA	GLN	76	59.108	44.117	63.303	1.00	38.47	AAAA
	ATOM 710	CB	GLN	76	59.590	44.350	61.875	1.00	41.98	AAAA
30	ATOM 711	CG	GLN	76	58.516	44.515	60.824	1.00	43.50	AAAA
	ATOM 712	CD	GLN	76	59.007	45.325	59.660	1.00	44.41	AAAA
	ATOM 713	OE1	GLN	76	60.119	45.841	59.675	1.00	43.52	AAAA
	ATOM 714	NE2	GLN	76	58.182	45.449	58.644	1.00	48.56	AAAA
	ATOM 715	HE21	GLN	76	57.294	45.040	58.703	1.00	0.00	AAAA
35	ATOM 716	HE22	GLN	76	58.569	45.963	57.911	1.00	0.00	AAAA
	ATOM 717	C	GLN	76	57.606	44.411	63.444	1.00	35.54	AAAA
	ATOM 718	O	GLN	76	57.170	45.564	63.305	1.00	33.94	AAAA
	ATOM 719	N	GLY	77	56.852	43.400	63.867	1.00	31.89	AAAA
	ATOM 720	H	GLY	77	57.272	42.529	63.999	1.00	0.00	AAAA
40	ATOM 721	CA	GLY	77	55.429	43.573	64.095	1.00	29.13	AAAA
	ATOM 722	C	GLY	77	54.617	43.816	62.833	1.00	26.74	AAAA
	ATOM 723	O	GLY	77	55.167	44.016	61.743	1.00	25.60	AAAA
	ATOM 724	N	GLN	78	53.297	43.804	62.985	1.00	24.43	AAAA

	ATOM 725	H	GLN	78	52.921	43.551	63.845	1.00	0.00	AAAA
	ATOM 726	CA	GLN	78	52.385	44.167	61.900	1.00	22.99	AAAA
	ATOM 727	CB	GLN	78	52.217	42.990	60.942	1.00	23.16	AAAA
	ATOM 728	CG	GLN	78	51.534	41.796	61.602	1.00	23.53	AAAA
5	ATOM 729	CD	GLN	78	51.099	40.730	60.627	1.00	17.76	AAAA
	ATOM 730	OE1	GLN	78	51.185	40.900	59.408	1.00	16.41	AAAA
	ATOM 731	NE2	GLN	78	50.685	39.597	61.160	1.00	15.76	AAAA
	ATOM 732	HE21	GLN	78	50.651	39.510	62.138	1.00	0.00	AAAA
	ATOM 733	HE22	GLN	78	50.447	38.904	60.516	1.00	0.00	AAAA
10	ATOM 734	C	GLN	78	51.032	44.498	62.540	1.00	25.68	AAAA
	ATOM 735	O	GLN	78	50.757	44.098	63.676	1.00	26.20	AAAA
	ATOM 736	N	ASP	79	50.185	45.223	61.826	1.00	23.31	AAAA
	ATOM 737	H	ASP	79	50.483	45.471	60.932	1.00	0.00	AAAA
	ATOM 738	CA	ASP	79	48.838	45.466	62.326	1.00	25.37	AAAA
15	ATOM 739	CB	ASP	79	48.386	46.880	61.962	1.00	24.45	AAAA
	ATOM 740	CG	ASP	79	49.211	47.959	62.672	1.00	28.21	AAAA
	ATOM 741	OD1	ASP	79	50.071	47.598	63.516	1.00	26.57	AAAA
	ATOM 742	OD2	ASP	79	49.018	49.158	62.360	1.00	28.96	AAAA
	ATOM 743	C	ASP	79	47.824	44.428	61.824	1.00	27.86	AAAA
20	ATOM 744	O	ASP	79	47.821	44.089	60.638	1.00	26.79	AAAA
	ATOM 745	N	VAL	80	47.133	43.784	62.770	1.00	27.61	AAAA
	ATOM 746	H	VAL	80	47.439	43.860	63.690	1.00	0.00	AAAA
	ATOM 747	CA	VAL	80	45.971	42.948	62.457	1.00	25.15	AAAA
	ATOM 748	CB	VAL	80	46.207	41.477	62.840	1.00	23.30	AAAA
25	ATOM 749	CG1	VAL	80	45.007	40.651	62.450	1.00	25.36	AAAA
	ATOM 750	CG2	VAL	80	47.438	40.941	62.141	1.00	22.16	AAAA
	ATOM 751	C	VAL	80	44.739	43.452	63.201	1.00	24.57	AAAA
	ATOM 752	O	VAL	80	44.644	43.295	64.413	1.00	22.28	AAAA
	ATOM 753	N	THR	81	43.813	44.073	62.474	1.00	24.26	AAAA
30	ATOM 754	H	THR	81	44.032	44.168	61.520	1.00	0.00	AAAA
	ATOM 755	CA	THR	81	42.571	44.571	63.078	1.00	27.38	AAAA
	ATOM 756	CB	THR	81	41.646	45.222	62.002	1.00	28.45	AAAA
	ATOM 757	OG1	THR	81	40.486	45.773	62.625	1.00	39.19	AAAA
	ATOM 758	HG1	THR	81	40.319	46.609	62.180	1.00	0.00	AAAA
35	ATOM 759	CG2	THR	81	41.194	44.214	60.995	1.00	31.37	AAAA
	ATOM 760	C	THR	81	41.806	43.489	63.857	1.00	27.08	AAAA
	ATOM 761	O	THR	81	41.840	42.302	63.503	1.00	25.09	AAAA
	ATOM 762	N	SER	82	41.203	43.873	64.978	1.00	26.66	AAAA
	ATOM 763	H	SER	82	41.296	44.807	65.280	1.00	0.00	AAAA
40	ATOM 764	CA	SER	82	40.425	42.912	65.764	1.00	27.37	AAAA
	ATOM 765	CB	SER	82	39.992	43.506	67.113	1.00	27.54	AAAA
	ATOM 766	OG	SER	82	39.073	44.565	66.929	1.00	32.64	AAAA
	ATOM 767	HG	SER	82	38.160	44.228	66.813	1.00	0.00	AAAA

	ATOM 768	C	SER	82	39.192	42.404	65.014	1.00	23.10	AAAA
	ATOM 769	O	SER	82	38.628	41.385	65.374	1.00	24.03	AAAA
	ATOM 770	N	SER	83	38.790	43.105	63.962	1.00	25.20	AAAA
	ATOM 771	H	SER	83	39.201	43.984	63.811	1.00	0.00	AAAA
5	ATOM 772	CA	SER	83	37.682	42.640	63.126	1.00	27.82	AAAA
	ATOM 773	CB	SER	83	37.339	43.671	62.046	1.00	31.00	AAAA
	ATOM 774	OG	SER	83	37.002	44.929	62.602	1.00	44.02	AAAA
	ATOM 775	HG	SER	83	37.201	45.629	61.989	1.00	0.00	AAAA
	ATOM 776	C	SER	83	38.014	41.315	62.432	1.00	27.88	AAAA
10	ATOM 777	O	SER	83	37.114	40.593	61.985	1.00	29.20	AAAA
	ATOM 778	N	VAL	84	39.303	41.087	62.191	1.00	23.83	AAAA
	ATOM 779	H	VAL	84	39.969	41.681	62.581	1.00	0.00	AAAA
	ATOM 780	CA	VAL	84	39.723	39.940	61.402	1.00	20.73	AAAA
	ATOM 781	CB	VAL	84	41.231	39.971	61.120	1.00	20.85	AAAA
15	ATOM 782	CG1	VAL	84	41.681	38.634	60.533	1.00	21.87	AAAA
	ATOM 783	CG2	VAL	84	41.536	41.072	60.152	1.00	20.91	AAAA
	ATOM 784	C	VAL	84	39.383	38.619	62.064	1.00	19.51	AAAA
	ATOM 785	O	VAL	84	39.745	38.379	63.206	1.00	20.68	AAAA
	ATOM 786	N	TYR	85	38.640	37.780	61.352	1.00	19.17	AAAA
20	ATOM 787	H	TYR	85	38.292	38.118	60.502	1.00	0.00	AAAA
	ATOM 788	CA	TYR	85	38.314	36.450	61.837	1.00	18.54	AAAA
	ATOM 789	CB	TYR	85	36.921	36.008	61.331	1.00	18.00	AAAA
	ATOM 790	CG	TYR	85	36.466	34.641	61.825	1.00	15.07	AAAA
	ATOM 791	CD1	TYR	85	35.489	34.517	62.828	1.00	18.67	AAAA
25	ATOM 792	CE1	TYR	85	35.074	33.258	63.284	1.00	13.74	AAAA
	ATOM 793	CD2	TYR	85	37.012	33.469	61.299	1.00	14.59	AAAA
	ATOM 794	CE2	TYR	85	36.619	32.219	61.754	1.00	14.12	AAAA
	ATOM 795	CZ	TYR	85	35.637	32.122	62.741	1.00	15.13	AAAA
	ATOM 796	OH	TYR	85	35.201	30.885	63.110	1.00	15.74	AAAA
30	ATOM 797	HH	TYR	85	34.434	30.990	63.679	1.00	0.00	AAAA
	ATOM 798	C	TYR	85	39.388	35.494	61.339	1.00	18.88	AAAA
	ATOM 799	O	TYR	85	39.503	35.234	60.137	1.00	17.70	AAAA
	ATOM 800	N	PHE	86	40.173	34.976	62.269	1.00	17.16	AAAA
	ATOM 801	H	PHE	86	40.037	35.264	63.201	1.00	0.00	AAAA
35	ATOM 802	CA	PHE	86	41.227	34.031	61.938	1.00	17.14	AAAA
	ATOM 803	CB	PHE	86	42.609	34.633	62.294	1.00	18.81	AAAA
	ATOM 804	CG	PHE	86	43.792	33.771	61.884	1.00	17.09	AAAA
	ATOM 805	CD1	PHE	86	43.981	33.389	60.551	1.00	12.60	AAAA
	ATOM 806	CD2	PHE	86	44.690	33.306	62.854	1.00	16.07	AAAA
40	ATOM 807	CE1	PHE	86	45.016	32.547	60.198	1.00	14.83	AAAA
	ATOM 808	CE2	PHE	86	45.725	32.467	62.520	1.00	14.81	AAAA
	ATOM 809	CZ	PHE	86	45.892	32.070	61.188	1.00	17.97	AAAA
	ATOM 810	C	PHE	86	41.002	32.701	62.650	1.00	15.56	AAAA

-36-

	ATOM 811	O	PHE	86	40.664	32.654	63.837	1.00	17.84	AAAA
	ATOM 812	N	MET	87	41.296	31.626	61.931	1.00	13.32	AAAA
	ATOM 813	H	MET	87	41.818	31.793	61.129	1.00	0.00	AAAA
	ATOM 814	CA	MET	87	41.169	30.274	62.428	1.00	14.74	AAAA
5	ATOM 815	CB	MET	87	39.993	29.606	61.716	1.00	16.52	AAAA
	ATOM 816	CG	MET	87	39.985	28.110	61.685	1.00	22.12	AAAA
	ATOM 817	SD	MET	87	38.551	27.590	60.704	1.00	27.94	AAAA
	ATOM 818	CE	MET	87	37.291	27.521	61.947	1.00	28.36	AAAA
	ATOM 819	C	MET	87	42.462	29.523	62.118	1.00	18.15	AAAA
10	ATOM 820	O	MET	87	42.961	29.560	60.983	1.00	16.50	AAAA
	ATOM 821	N	LYS	88	42.988	28.824	63.115	1.00	17.57	AAAA
	ATOM 822	H	LYS	88	42.584	28.893	64.004	1.00	0.00	AAAA
	ATOM 823	CA	LYS	88	44.121	27.929	62.896	1.00	18.62	AAAA
	ATOM 824	CB	LYS	88	44.778	27.577	64.237	1.00	19.52	AAAA
15	ATOM 825	CG	LYS	88	45.534	28.739	64.872	1.00	24.91	AAAA
	ATOM 826	CD	LYS	88	46.825	29.043	64.112	1.00	24.92	AAAA
	ATOM 827	CE	LYS	88	47.815	27.882	64.223	1.00	24.92	AAAA
	ATOM 828	NZ	LYS	88	48.821	27.887	63.118	1.00	25.56	AAAA
	ATOM 829	HZ1	LYS	88	49.214	28.843	63.013	1.00	0.00	AAAA
20	ATOM 830	HZ2	LYS	88	48.349	27.612	62.237	1.00	0.00	AAAA
	ATOM 831	HZ3	LYS	88	49.584	27.213	63.330	1.00	0.00	AAAA
	ATOM 832	C	LYS	88	43.749	26.644	62.146	1.00	19.29	AAAA
	ATOM 833	O	LYS	88	42.616	26.158	62.220	1.00	21.43	AAAA
	ATOM 834	N	GLN	89	44.728	26.082	61.450	1.00	16.58	AAAA
25	ATOM 835	H	GLN	89	45.585	26.556	61.420	1.00	0.00	AAAA
	ATOM 836	CA	GLN	89	44.599	24.779	60.819	1.00	17.18	AAAA
	ATOM 837	CB	GLN	89	45.271	24.813	59.456	1.00	18.38	AAAA
	ATOM 838	CG	GLN	89	45.350	23.485	58.760	1.00	18.24	AAAA
	ATOM 839	CD	GLN	89	45.853	23.651	57.355	1.00	24.51	AAAA
30	ATOM 840	OE1	GLN	89	45.367	24.502	56.594	1.00	26.71	AAAA
	ATOM 841	NE2	GLN	89	46.881	22.904	57.017	1.00	25.25	AAAA
	ATOM 842	HE21	GLN	89	47.154	22.895	56.079	1.00	0.00	AAAA
	ATOM 843	HE22	GLN	89	47.349	22.434	57.721	1.00	0.00	AAAA
	ATOM 844	C	GLN	89	45.241	23.691	61.658	1.00	20.11	AAAA
35	ATOM 845	O	GLN	89	46.413	23.781	61.998	1.00	22.59	AAAA
	ATOM 846	N	THR	90	44.517	22.603	61.869	1.00	18.50	AAAA
	ATOM 847	H	THR	90	43.585	22.629	61.598	1.00	0.00	AAAA
	ATOM 848	CA	THR	90	45.072	21.439	62.550	1.00	21.73	AAAA
	ATOM 849	CB	THR	90	44.283	21.115	63.812	1.00	24.69	AAAA
40	ATOM 850	OG1	THR	90	42.924	20.794	63.464	1.00	30.17	AAAA
	ATOM 851	HG1	THR	90	42.428	21.483	62.994	1.00	0.00	AAAA
	ATOM 852	CG2	THR	90	44.301	22.312	64.752	1.00	28.14	AAAA
	ATOM 853	C	THR	90	45.102	20.191	61.676	1.00	24.47	AAAA

-37-

	ATOM 854	O	THR	90	45.846	19.252	61.956	1.00	28.80	AAAA
	ATOM 855	N	ILE	91	44.271	20.171	60.632	1.00	22.87	AAAA
	ATOM 856	H	ILE	91	43.593	20.871	60.590	1.00	0.00	AAAA
	ATOM 857	CA	ILE	91	44.258	19.096	59.633	1.00	22.19	AAAA
5	ATOM 858	CB	ILE	91	42.921	18.326	59.639	1.00	22.46	AAAA
	ATOM 859	CG2	ILE	91	42.989	17.157	58.695	1.00	18.95	AAAA
	ATOM 860	CG1	ILE	91	42.591	17.837	61.050	1.00	24.03	AAAA
	ATOM 861	CD	ILE	91	41.259	17.099	61.123	1.00	24.83	AAAA
	ATOM 862	C	ILE	91	44.422	19.717	58.245	1.00	23.19	AAAA
10	ATOM 863	O	ILE	91	43.626	20.562	57.846	1.00	23.87	AAAA
	ATOM 864	N	SER	92	45.413	19.266	57.487	1.00	23.54	AAAA
	ATOM 865	H	SER	92	45.791	18.403	57.734	1.00	0.00	AAAA
	ATOM 866	CA	SER	92	45.793	19.943	56.248	1.00	23.64	AAAA
	ATOM 867	CB	SER	92	47.119	19.387	55.737	1.00	25.35	AAAA
15	ATOM 868	OG	SER	92	46.993	18.012	55.412	1.00	35.43	AAAA
	ATOM 869	HG	SER	92	46.797	17.917	54.451	1.00	0.00	AAAA
	ATOM 870	C	SER	92	44.735	19.799	55.165	1.00	22.11	AAAA
	ATOM 871	O	SER	92	44.459	20.730	54.423	1.00	22.66	AAAA
	ATOM 872	N	ASN	93	44.099	18.644	55.117	1.00	21.74	AAAA
20	ATOM 873	H	ASN	93	44.414	17.915	55.705	1.00	0.00	AAAA
	ATOM 874	CA	ASN	93	43.007	18.434	54.183	1.00	27.91	AAAA
	ATOM 875	CB	ASN	93	42.571	16.979	54.207	1.00	35.85	AAAA
	ATOM 876	CG	ASN	93	43.673	16.057	53.764	1.00	47.97	AAAA
	ATOM 877	OD1	ASN	93	44.253	16.233	52.684	1.00	52.33	AAAA
25	ATOM 878	ND2	ASN	93	44.076	15.160	54.652	1.00	54.60	AAAA
	ATOM 879	HD21	ASN	93	43.681	15.126	55.548	1.00	0.00	AAAA
	ATOM 880	HD22	ASN	93	44.780	14.587	54.290	1.00	0.00	AAAA
	ATOM 881	C	ASN	93	41.793	19.323	54.428	1.00	25.96	AAAA
	ATOM 882	O	ASN	93	40.897	19.373	53.585	1.00	24.44	AAAA
30	ATOM 883	N	ALA	94	41.760	19.994	55.583	1.00	24.06	AAAA
	ATOM 884	H	ALA	94	42.454	19.832	56.247	1.00	0.00	AAAA
	ATOM 885	CA	ALA	94	40.690	20.934	55.921	1.00	21.31	AAAA
	ATOM 886	CB	ALA	94	40.516	21.022	57.440	1.00	16.74	AAAA
	ATOM 887	C	ALA	94	40.940	22.325	55.354	1.00	19.83	AAAA
35	ATOM 888	O	ALA	94	40.089	23.195	55.464	1.00	18.59	AAAA
	ATOM 889	N	CYS	95	42.103	22.544	54.744	1.00	17.72	AAAA
	ATOM 890	H	CYS	95	42.699	21.784	54.585	1.00	0.00	AAAA
	ATOM 891	CA	CYS	95	42.480	23.899	54.322	1.00	17.66	AAAA
	ATOM 892	CB	CYS	95	43.908	23.905	53.752	1.00	17.95	AAAA
40	ATOM 893	SG	CYS	95	44.087	23.036	52.185	1.00	18.91	AAAA
	ATOM 894	C	CYS	95	41.503	24.581	53.325	1.00	14.55	AAAA
	ATOM 895	O	CYS	95	41.304	25.792	53.388	1.00	12.57	AAAA
	ATOM 896	N	GLY	96	40.878	23.808	52.439	1.00	16.10	AAAA

-38-

	ATOM 897	H	GLY	96	41.029	22.839	52.444	1.00	0.00	AAAA
	ATOM 898	CA	GLY	96	39.900	24.384	51.525	1.00	14.24	AAAA
	ATOM 899	C	GLY	96	38.660	24.858	52.274	1.00	13.81	AAAA
	ATOM 900	O	GLY	96	38.220	25.996	52.109	1.00	12.17	AAAA
5	ATOM 901	N	THR	97	38.141	24.009	53.164	1.00	13.86	AAAA
	ATOM 902	H	THR	97	38.518	23.101	53.219	1.00	0.00	AAAA
	ATOM 903	CA	THR	97	37.033	24.406	54.037	1.00	14.26	AAAA
	ATOM 904	CB	THR	97	36.597	23.257	54.922	1.00	14.44	AAAA
	ATOM 905	OG1	THR	97	36.020	22.234	54.099	1.00	17.53	AAAA
10	ATOM 906	HG1	THR	97	35.307	21.820	54.623	1.00	0.00	AAAA
	ATOM 907	CG2	THR	97	35.580	23.736	55.981	1.00	16.30	AAAA
	ATOM 908	C	THR	97	37.383	25.596	54.927	1.00	14.53	AAAA
	ATOM 909	O	THR	97	36.600	26.539	55.051	1.00	13.21	AAAA
	ATOM 910	N	ILE	98	38.603	25.614	55.455	1.00	14.07	AAAA
15	ATOM 911	H	ILE	98	39.176	24.833	55.314	1.00	0.00	AAAA
	ATOM 912	CA	ILE	98	39.058	26.755	56.242	1.00	13.22	AAAA
	ATOM 913	CB	ILE	98	40.417	26.468	56.920	1.00	12.18	AAAA
	ATOM 914	CG2	ILE	98	40.910	27.704	57.610	1.00	11.29	AAAA
	ATOM 915	CG1	ILE	98	40.260	25.356	57.946	1.00	12.23	AAAA
20	ATOM 916	CD	ILE	98	41.556	24.629	58.268	1.00	15.43	AAAA
	ATOM 917	C	ILE	98	39.156	28.017	55.404	1.00	11.49	AAAA
	ATOM 918	O	ILE	98	38.755	29.093	55.853	1.00	12.87	AAAA
	ATOM 919	N	GLY	99	39.597	27.885	54.157	1.00	11.22	AAAA
	ATOM 920	H	GLY	99	39.875	27.007	53.832	1.00	0.00	AAAA
25	ATOM 921	CA	GLY	99	39.628	29.044	53.281	1.00	9.85	AAAA
	ATOM 922	C	GLY	99	38.244	29.632	53.007	1.00	9.08	AAAA
	ATOM 923	O	GLY	99	38.036	30.835	53.040	1.00	9.42	AAAA
	ATOM 924	N	LEU	100	37.277	28.747	52.841	1.00	12.12	AAAA
	ATOM 925	H	LEU	100	37.522	27.794	52.840	1.00	0.00	AAAA
30	ATOM 926	CA	LEU	100	35.900	29.148	52.602	1.00	15.16	AAAA
	ATOM 927	CB	LEU	100	35.078	27.891	52.267	1.00	18.24	AAAA
	ATOM 928	CG	LEU	100	33.723	28.022	51.575	1.00	24.26	AAAA
	ATOM 929	CD1	LEU	100	33.831	29.058	50.465	1.00	26.09	AAAA
	ATOM 930	CD2	LEU	100	33.289	26.660	51.015	1.00	21.41	AAAA
35	ATOM 931	C	LEU	100	35.347	29.870	53.838	1.00	13.53	AAAA
	ATOM 932	O	LEU	100	34.837	30.980	53.740	1.00	14.20	AAAA
	ATOM 933	N	ILE	101	35.598	29.300	55.013	1.00	13.77	AAAA
	ATOM 934	H	ILE	101	36.051	28.431	55.000	1.00	0.00	AAAA
	ATOM 935	CA	ILE	101	35.205	29.911	56.281	1.00	12.23	AAAA
40	ATOM 936	CB	ILE	101	35.571	28.996	57.462	1.00	13.26	AAAA
	ATOM 937	CG2	ILE	101	35.402	29.734	58.786	1.00	15.98	AAAA
	ATOM 938	CG1	ILE	101	34.697	27.732	57.405	1.00	11.45	AAAA
	ATOM 939	CD	ILE	101	34.958	26.730	58.500	1.00	16.30	AAAA

	ATOM 940	C	ILE	101	35.829	31.283	56.483	1.00	14.03	AAAA
	ATOM 941	O	ILE	101	35.126	32.245	56.782	1.00	12.42	AAAA
	ATOM 942	N	HIS	102	37.120	31.421	56.177	1.00	13.04	AAAA
	ATOM 943	H	HIS	102	37.593	30.615	55.893	1.00	0.00	AAAA
5	ATOM 944	CA	HIS	102	37.769	32.738	56.239	1.00	10.47	AAAA
	ATOM 945	CB	HIS	102	39.265	32.613	55.897	1.00	13.05	AAAA
	ATOM 946	CG	HIS	102	40.107	32.125	57.030	1.00	10.70	AAAA
	ATOM 947	CD2	HIS	102	40.153	32.499	58.332	1.00	13.91	AAAA
	ATOM 948	ND1	HIS	102	41.088	31.168	56.877	1.00	11.81	AAAA
10	ATOM 949	HD1	HIS	102	41.295	30.682	56.041	1.00	0.00	AAAA
	ATOM 950	CE1	HIS	102	41.708	30.974	58.028	1.00	11.88	AAAA
	ATOM 951	NE2	HIS	102	41.162	31.778	58.927	1.00	15.13	AAAA
	ATOM 952	HE2	HIS	102	41.468	31.860	59.843	1.00	0.00	AAAA
	ATOM 953	C	HIS	102	37.125	33.757	55.291	1.00	11.19	AAAA
15	ATOM 954	O	HIS	102	36.969	34.935	55.640	1.00	12.51	AAAA
	ATOM 955	N	ALA	103	36.844	33.328	54.055	1.00	13.10	AAAA
	ATOM 956	H	ALA	103	37.020	32.394	53.814	1.00	0.00	AAAA
	ATOM 957	CA	ALA	103	36.264	34.227	53.056	1.00	10.96	AAAA
	ATOM 958	CB	ALA	103	36.140	33.504	51.703	1.00	9.09	AAAA
20	ATOM 959	C	ALA	103	34.881	34.712	53.531	1.00	15.64	AAAA
	ATOM 960	O	ALA	103	34.558	35.899	53.440	1.00	18.87	AAAA
	ATOM 961	N	ILE	104	34.073	33.787	54.047	1.00	15.87	AAAA
	ATOM 962	H	ILE	104	34.402	32.864	54.115	1.00	0.00	AAAA
	ATOM 963	CA	ILE	104	32.701	34.118	54.460	1.00	15.42	AAAA
25	ATOM 964	CB	ILE	104	31.813	32.829	54.537	1.00	13.84	AAAA
	ATOM 965	CG2	ILE	104	30.365	33.200	54.915	1.00	18.30	AAAA
	ATOM 966	CG1	ILE	104	31.822	32.081	53.204	1.00	13.16	AAAA
	ATOM 967	CD	ILE	104	31.510	32.966	51.997	1.00	14.57	AAAA
	ATOM 968	C	ILE	104	32.677	34.862	55.822	1.00	15.78	AAAA
30	ATOM 969	O	ILE	104	32.051	35.922	55.942	1.00	16.92	AAAA
	ATOM 970	N	ALA	105	33.411	34.345	56.813	1.00	16.50	AAAA
	ATOM 971	H	ALA	105	33.832	33.486	56.631	1.00	0.00	AAAA
	ATOM 972	CA	ALA	105	33.529	34.998	58.121	1.00	17.00	AAAA
	ATOM 973	CB	ALA	105	34.492	34.239	59.022	1.00	16.84	AAAA
35	ATOM 974	C	ALA	105	33.963	36.448	58.039	1.00	20.96	AAAA
	ATOM 975	O	ALA	105	33.452	37.298	58.776	1.00	23.63	AAAA
	ATOM 976	N	ASN	106	34.869	36.760	57.117	1.00	16.81	AAAA
	ATOM 977	H	ASN	106	35.225	36.046	56.549	1.00	0.00	AAAA
	ATOM 978	CA	ASN	106	35.347	38.132	57.002	1.00	17.98	AAAA
40	ATOM 979	CB	ASN	106	36.825	38.128	56.611	1.00	17.74	AAAA
	ATOM 980	CG	ASN	106	37.707	37.690	57.755	1.00	14.08	AAAA
	ATOM 981	OD1	ASN	106	37.977	38.463	58.655	1.00	17.07	AAAA
	ATOM 982	ND2	ASN	106	38.042	36.415	57.795	1.00	14.28	AAAA

	ATOM 983	HD21 ASN	106	37.713	35.831	57.096	1.00	0.00	AAAA
	ATOM 984	HD22 ASN	106	38.611	36.181	58.571	1.00	0.00	AAAA
	ATOM 985	C ASN	106	34.522	39.008	56.048	1.00	19.28	AAAA
	ATOM 986	O ASN	106	34.898	40.129	55.748	1.00	17.22	AAAA
5	ATOM 987	N ASN	107	33.389	38.478	55.584	1.00	21.43	AAAA
	ATOM 988	H ASN	107	33.219	37.539	55.782	1.00	0.00	AAAA
	ATOM 989	CA ASN	107	32.445	39.213	54.739	1.00	21.54	AAAA
	ATOM 990	CB ASN	107	32.611	38.786	53.296	1.00	18.81	AAAA
	ATOM 991	CG ASN	107	33.897	39.275	52.710	1.00	21.63	AAAA
10	ATOM 992	OD1 ASN	107	34.079	40.472	52.495	1.00	22.45	AAAA
	ATOM 993	ND2 ASN	107	34.833	38.368	52.514	1.00	17.35	AAAA
	ATOM 994	HD21 ASN	107	34.605	37.441	52.622	1.00	0.00	AAAA
	ATOM 995	HD22 ASN	107	35.709	38.734	52.238	1.00	0.00	AAAA
	ATOM 996	C ASN	107	31.006	38.927	55.177	1.00	25.95	AAAA
15	ATOM 997	O ASN	107	30.073	39.091	54.399	1.00	26.08	AAAA
	ATOM 998	N LYS	108	30.856	38.514	56.435	1.00	27.04	AAAA
	ATOM 999	H LYS	108	31.660	38.510	56.994	1.00	0.00	AAAA
	ATOM 1000	CA LYS	108	29.611	37.983	56.984	1.00	30.55	AAAA
	ATOM 1001	CB LYS	108	29.821	37.766	58.483	1.00	31.98	AAAA
20	ATOM 1002	CG LYS	108	28.880	36.783	59.136	1.00	39.13	AAAA
	ATOM 1003	CD LYS	108	29.420	36.324	60.493	1.00	44.06	AAAA
	ATOM 1004	CE LYS	108	29.708	37.491	61.442	1.00	45.91	AAAA
	ATOM 1005	NZ LYS	108	29.833	37.023	62.849	1.00	46.37	AAAA
	ATOM 1006	HZ1 LYS	108	30.640	36.383	62.912	1.00	0.00	AAAA
25	ATOM 1007	HZ2 LYS	108	28.963	36.525	63.134	1.00	0.00	AAAA
	ATOM 1008	HZ3 LYS	108	29.992	37.838	63.478	1.00	0.00	AAAA
	ATOM 1009	C LYS	108	28.400	38.907	56.732	1.00	30.21	AAAA
	ATOM 1010	O LYS	108	27.330	38.462	56.309	1.00	28.80	AAAA
	ATOM 1011	N ASP	109	28.647	40.206	56.792	1.00	31.65	AAAA
30	ATOM 1012	H ASP	109	29.573	40.464	56.950	1.00	0.00	AAAA
	ATOM 1013	CA ASP	109	27.601	41.191	56.575	1.00	34.09	AAAA
	ATOM 1014	CB ASP	109	27.982	42.501	57.274	1.00	38.39	AAAA
	ATOM 1015	CG ASP	109	28.062	42.354	58.800	1.00	43.78	AAAA
	ATOM 1016	OD1 ASP	109	28.880	43.070	59.420	1.00	45.93	AAAA
35	ATOM 1017	OD2 ASP	109	27.300	41.549	59.384	1.00	47.42	AAAA
	ATOM 1018	C ASP	109	27.247	41.456	55.109	1.00	33.23	AAAA
	ATOM 1019	O ASP	109	26.350	42.237	54.827	1.00	37.51	AAAA
	ATOM 1020	N LYS	110	27.966	40.836	54.176	1.00	30.81	AAAA
	ATOM 1021	H LYS	110	28.781	40.371	54.456	1.00	0.00	AAAA
40	ATOM 1022	CA LYS	110	27.619	40.913	52.747	1.00	26.81	AAAA
	ATOM 1023	CB LYS	110	28.877	40.922	51.873	1.00	26.19	AAAA
	ATOM 1024	CG LYS	110	29.898	41.966	52.267	1.00	31.88	AAAA
	ATOM 1025	CD LYS	110	31.034	42.039	51.252	1.00	35.86	AAAA

-41-

	ATOM	1026	CE	LYS	110	32.009	43.165	51.577	1.00	35.07	AAAA
	ATOM	1027	NZ	LYS	110	32.734	42.922	52.858	1.00	40.57	AAAA
	ATOM	1028	HZ1	LYS	110	33.276	42.042	52.794	1.00	0.00	AAAA
	ATOM	1029	HZ2	LYS	110	32.047	42.849	53.637	1.00	0.00	AAAA
5	ATOM	1030	HZ3	LYS	110	33.388	43.708	53.047	1.00	0.00	AAAA
	ATOM	1031	C	LYS	110	26.772	39.722	52.335	1.00	23.39	AAAA
	ATOM	1032	O	LYS	110	26.329	39.623	51.190	1.00	23.47	AAAA
	ATOM	1033	N	MET	111	26.727	38.729	53.210	1.00	24.31	AAAA
	ATOM	1034	H	MET	111	27.069	38.886	54.106	1.00	0.00	AAAA
10	ATOM	1035	CA	MET	111	26.133	37.439	52.884	1.00	24.62	AAAA
	ATOM	1036	CB	MET	111	26.875	36.314	53.595	1.00	25.74	AAAA
	ATOM	1037	CG	MET	111	28.355	36.281	53.307	1.00	27.29	AAAA
	ATOM	1038	SD	MET	111	28.669	35.921	51.605	1.00	28.33	AAAA
	ATOM	1039	CE	MET	111	29.842	37.263	51.197	1.00	22.52	AAAA
15	ATOM	1040	C	MET	111	24.684	37.388	53.313	1.00	25.26	AAAA
	ATOM	1041	O	MET	111	24.304	37.974	54.325	1.00	24.63	AAAA
	ATOM	1042	N	HIS	112	23.947	36.513	52.656	1.00	25.79	AAAA
	ATOM	1043	H	HIS	112	24.366	36.111	51.894	1.00	0.00	AAAA
	ATOM	1044	CA	HIS	112	22.548	36.291	52.965	1.00	27.47	AAAA
20	ATOM	1045	CB	HIS	112	21.683	36.549	51.723	1.00	35.41	AAAA
	ATOM	1046	CG	HIS	112	20.209	36.375	51.954	1.00	42.70	AAAA
	ATOM	1047	CD2	HIS	112	19.494	36.271	53.103	1.00	43.97	AAAA
	ATOM	1048	ND1	HIS	112	19.300	36.261	50.924	1.00	44.16	AAAA
	ATOM	1049	HD1	HIS	112	19.465	36.489	49.979	1.00	0.00	AAAA
25	ATOM	1050	CE1	HIS	112	18.090	36.100	51.426	1.00	46.54	AAAA
	ATOM	1051	NE2	HIS	112	18.180	36.091	52.742	1.00	46.27	AAAA
	ATOM	1052	HE2	HIS	112	17.442	36.197	53.384	1.00	0.00	AAAA
	ATOM	1053	C	HIS	112	22.391	34.867	53.431	1.00	24.85	AAAA
	ATOM	1054	O	HIS	112	22.325	33.931	52.618	1.00	23.17	AAAA
30	ATOM	1055	N	PHE	113	22.357	34.714	54.748	1.00	24.82	AAAA
	ATOM	1056	H	PHE	113	22.542	35.493	55.300	1.00	0.00	AAAA
	ATOM	1057	CA	PHE	113	22.154	33.414	55.374	1.00	29.11	AAAA
	ATOM	1058	CB	PHE	113	22.758	33.401	56.794	1.00	27.84	AAAA
	ATOM	1059	CG	PHE	113	24.247	33.637	56.832	1.00	24.66	AAAA
35	ATOM	1060	CD1	PHE	113	24.753	34.910	57.086	1.00	23.03	AAAA
	ATOM	1061	CD2	PHE	113	25.141	32.586	56.598	1.00	25.31	AAAA
	ATOM	1062	CE1	PHE	113	26.133	35.146	57.096	1.00	27.19	AAAA
	ATOM	1063	CE2	PHE	113	26.520	32.814	56.608	1.00	24.97	AAAA
	ATOM	1064	CZ	PHE	113	27.014	34.100	56.858	1.00	24.09	AAAA
40	ATOM	1065	C	PHE	113	20.670	33.008	55.449	1.00	31.00	AAAA
	ATOM	1066	O	PHE	113	19.790	33.848	55.686	1.00	33.09	AAAA
	ATOM	1067	N	GLU	114	20.402	31.772	55.043	1.00	29.35	AAAA
	ATOM	1068	H	GLU	114	21.111	31.342	54.547	1.00	0.00	AAAA

	ATOM	1069	CA	GLU	114	19.173	31.085	55.391	1.00	29.30	AAAA
	ATOM	1070	CB	GLU	114	19.167	29.712	54.748	1.00	30.12	AAAA
	ATOM	1071	CG	GLU	114	19.228	29.750	53.232	1.00	32.89	AAAA
	ATOM	1072	CD	GLU	114	19.340	28.379	52.624	1.00	34.82	AAAA
5	ATOM	1073	OE1	GLU	114	19.097	27.384	53.338	1.00	37.36	AAAA
	ATOM	1074	OE2	GLU	114	19.713	28.293	51.437	1.00	43.01	AAAA
	ATOM	1075	C	GLU	114	19.067	30.927	56.903	1.00	32.03	AAAA
	ATOM	1076	O	GLU	114	20.080	30.731	57.575	1.00	30.35	AAAA
	ATOM	1077	N	SER	115	17.836	30.830	57.403	1.00	32.06	AAAA
10	ATOM	1078	H	SER	115	17.081	30.845	56.781	1.00	0.00	AAAA
	ATOM	1079	CA	SER	115	17.596	30.797	58.849	1.00	34.83	AAAA
	ATOM	1080	CB	SER	115	16.098	30.682	59.157	1.00	37.46	AAAA
	ATOM	1081	OG	SER	115	15.337	31.576	58.368	1.00	40.20	AAAA
	ATOM	1082	HG	SER	115	15.254	31.197	57.494	1.00	0.00	AAAA
15	ATOM	1083	C	SER	115	18.324	29.642	59.522	1.00	32.68	AAAA
	ATOM	1084	O	SER	115	18.964	29.820	60.551	1.00	34.71	AAAA
	ATOM	1085	N	GLY	116	18.230	28.461	58.931	1.00	28.08	AAAA
	ATOM	1086	H	GLY	116	17.723	28.386	58.104	1.00	0.00	AAAA
	ATOM	1087	CA	GLY	116	18.890	27.314	59.525	1.00	30.75	AAAA
20	ATOM	1088	C	GLY	116	20.331	27.077	59.087	1.00	29.04	AAAA
	ATOM	1089	O	GLY	116	20.821	25.954	59.221	1.00	27.89	AAAA
	ATOM	1090	N	SER	117	21.011	28.123	58.601	1.00	28.86	AAAA
	ATOM	1091	H	SER	117	20.613	29.011	58.704	1.00	0.00	AAAA
	ATOM	1092	CA	SER	117	22.365	28.000	58.017	1.00	25.44	AAAA
25	ATOM	1093	CB	SER	117	22.867	29.378	57.561	1.00	23.69	AAAA
	ATOM	1094	OG	SER	117	24.260	29.369	57.281	1.00	21.52	AAAA
	ATOM	1095	HG	SER	117	24.415	28.790	56.527	1.00	0.00	AAAA
	ATOM	1096	C	SER	117	23.352	27.412	59.027	1.00	24.07	AAAA
	ATOM	1097	O	SER	117	23.536	27.980	60.107	1.00	23.98	AAAA
30	ATOM	1098	N	THR	118	23.959	26.271	58.701	1.00	22.14	AAAA
	ATOM	1099	H	THR	118	23.711	25.878	57.836	1.00	0.00	AAAA
	ATOM	1100	CA	THR	118	24.950	25.660	59.593	1.00	23.25	AAAA
	ATOM	1101	CB	THR	118	25.389	24.266	59.128	1.00	26.09	AAAA
	ATOM	1102	OG1	THR	118	25.837	24.326	57.771	1.00	26.52	AAAA
35	ATOM	1103	HG1	THR	118	25.089	24.335	57.150	1.00	0.00	AAAA
	ATOM	1104	CG2	THR	118	24.255	23.298	59.235	1.00	28.30	AAAA
	ATOM	1105	C	THR	118	26.219	26.506	59.721	1.00	25.21	AAAA
	ATOM	1106	O	THR	118	26.783	26.627	60.806	1.00	23.40	AAAA
	ATOM	1107	N	LEU	119	26.662	27.117	58.623	1.00	24.77	AAAA
40	ATOM	1108	H	LEU	119	26.247	26.892	57.763	1.00	0.00	AAAA
	ATOM	1109	CA	LEU	119	27.793	28.025	58.711	1.00	21.55	AAAA
	ATOM	1110	CB	LEU	119	28.278	28.446	57.317	1.00	21.35	AAAA
	ATOM	1111	CG	LEU	119	29.527	29.346	57.292	1.00	22.12	AAAA

-43-

	ATOM	1112	CD1	LEU	119	30.675	28.670	58.031	1.00	21.90	AAAA
	ATOM	1113	CD2	LEU	119	29.938	29.618	55.852	1.00	25.56	AAAA
	ATOM	1114	C	LEU	119	27.447	29.257	59.547	1.00	22.56	AAAA
	ATOM	1115	O	LEU	119	28.249	29.680	60.377	1.00	21.20	AAAA
5	ATOM	1116	N	LYS	120	26.240	29.800	59.384	1.00	19.77	AAAA
	ATOM	1117	H	LYS	120	25.624	29.429	58.719	1.00	0.00	AAAA
	ATOM	1118	CA	LYS	120	25.847	30.974	60.164	1.00	20.58	AAAA
	ATOM	1119	CB	LYS	120	24.408	31.368	59.844	1.00	27.26	AAAA
	ATOM	1120	CG	LYS	120	23.917	32.629	60.548	1.00	31.17	AAAA
10	ATOM	1121	CD	LYS	120	22.398	32.703	60.494	1.00	37.84	AAAA
	ATOM	1122	CE	LYS	120	21.870	33.951	61.161	1.00	41.70	AAAA
	ATOM	1123	NZ	LYS	120	22.115	33.910	62.630	1.00	46.53	AAAA
	ATOM	1124	HZ1	LYS	120	23.142	33.971	62.791	1.00	0.00	AAAA
	ATOM	1125	HZ2	LYS	120	21.749	33.022	63.030	1.00	0.00	AAAA
15	ATOM	1126	HZ3	LYS	120	21.652	34.725	63.081	1.00	0.00	AAAA
	ATOM	1127	C	LYS	120	25.978	30.687	61.659	1.00	21.21	AAAA
	ATOM	1128	O	LYS	120	26.554	31.485	62.406	1.00	21.15	AAAA
	ATOM	1129	N	LYS	121	25.509	29.511	62.066	1.00	21.91	AAAA
	ATOM	1130	H	LYS	121	25.104	28.933	61.385	1.00	0.00	AAAA
20	ATOM	1131	CA	LYS	121	25.564	29.109	63.460	1.00	22.16	AAAA
	ATOM	1132	CB	LYS	121	24.764	27.828	63.710	1.00	22.21	AAAA
	ATOM	1133	CG	LYS	121	24.645	27.532	65.204	1.00	26.49	AAAA
	ATOM	1134	CD	LYS	121	24.221	26.114	65.506	1.00	30.08	AAAA
	ATOM	1135	CE	LYS	121	24.099	25.911	67.019	1.00	32.98	AAAA
25	ATOM	1136	NZ	LYS	121	23.937	24.481	67.402	1.00	34.13	AAAA
	ATOM	1137	HZ1	LYS	121	24.516	23.891	66.772	1.00	0.00	AAAA
	ATOM	1138	HZ2	LYS	121	22.943	24.188	67.309	1.00	0.00	AAAA
	ATOM	1139	HZ3	LYS	121	24.240	24.348	68.384	1.00	0.00	AAAA
	ATOM	1140	C	LYS	121	26.994	28.898	63.946	1.00	23.88	AAAA
30	ATOM	1141	O	LYS	121	27.315	29.236	65.088	1.00	24.24	AAAA
	ATOM	1142	N	PHE	122	27.834	28.301	63.104	1.00	21.06	AAAA
	ATOM	1143	H	PHE	122	27.476	27.916	62.273	1.00	0.00	AAAA
	ATOM	1144	CA	PHE	122	29.258	28.160	63.437	1.00	20.87	AAAA
	ATOM	1145	CB	PHE	122	30.001	27.412	62.333	1.00	18.89	AAAA
35	ATOM	1146	CG	PHE	122	31.468	27.264	62.599	1.00	21.64	AAAA
	ATOM	1147	CD1	PHE	122	31.950	26.174	63.324	1.00	21.50	AAAA
	ATOM	1148	CD2	PHE	122	32.369	28.255	62.192	1.00	21.09	AAAA
	ATOM	1149	CE1	PHE	122	33.314	26.065	63.644	1.00	18.48	AAAA
	ATOM	1150	CE2	PHE	122	33.727	28.158	62.515	1.00	19.92	AAAA
40	ATOM	1151	CZ	PHE	122	34.192	27.058	63.239	1.00	18.04	AAAA
	ATOM	1152	C	PHE	122	29.934	29.514	63.670	1.00	20.43	AAAA
	ATOM	1153	O	PHE	122	30.666	29.699	64.647	1.00	22.71	AAAA
	ATOM	1154	N	LEU	123	29.646	30.471	62.800	1.00	16.51	AAAA

-44-

	ATOM	1155	H	LEU	123	29.032	30.251	62.069	1.00	0.00	AAAA
	ATOM	1156	CA	LEU	123	30.224	31.793	62.905	1.00	19.43	AAAA
	ATOM	1157	CB	LEU	123	29.913	32.592	61.645	1.00	16.02	AAAA
	ATOM	1158	CG	LEU	123	30.559	32.020	60.383	1.00	15.88	AAAA
5	ATOM	1159	CD1	LEU	123	30.139	32.849	59.185	1.00	16.91	AAAA
	ATOM	1160	CD2	LEU	123	32.097	32.005	60.562	1.00	17.98	AAAA
	ATOM	1161	C	LEU	123	29.777	32.574	64.137	1.00	23.21	AAAA
	ATOM	1162	O	LEU	123	30.581	33.249	64.777	1.00	22.18	AAAA
	ATOM	1163	N	GLU	124	28.492	32.499	64.469	1.00	24.39	AAAA
10	ATOM	1164	H	GLU	124	27.889	31.989	63.882	1.00	0.00	AAAA
	ATOM	1165	CA	GLU	124	28.003	33.237	65.628	1.00	25.74	AAAA
	ATOM	1166	CB	GLU	124	26.474	33.412	65.587	1.00	29.50	AAAA
	ATOM	1167	CG	GLU	124	25.678	32.166	65.281	1.00	36.33	AAAA
	ATOM	1168	CD	GLU	124	24.262	32.483	64.795	1.00	42.27	AAAA
15	ATOM	1169	OE1	GLU	124	23.941	33.685	64.630	1.00	43.67	AAAA
	ATOM	1170	OE2	GLU	124	23.474	31.531	64.578	1.00	42.51	AAAA
	ATOM	1171	C	GLU	124	28.439	32.576	66.924	1.00	21.63	AAAA
	ATOM	1172	O	GLU	124	28.850	33.260	67.850	1.00	25.47	AAAA
	ATOM	1173	N	GLU	125	28.531	31.256	66.928	1.00	20.31	AAAA
20	ATOM	1174	H	GLU	125	28.213	30.752	66.151	1.00	0.00	AAAA
	ATOM	1175	CA	GLU	125	29.072	30.570	68.091	1.00	24.49	AAAA
	ATOM	1176	CB	GLU	125	28.836	29.061	68.010	1.00	29.56	AAAA
	ATOM	1177	CG	GLU	125	27.352	28.625	68.085	1.00	35.07	AAAA
	ATOM	1178	CD	GLU	125	26.599	29.184	69.303	1.00	40.25	AAAA
25	ATOM	1179	OE1	GLU	125	27.239	29.516	70.334	1.00	38.36	AAAA
	ATOM	1180	OE2	GLU	125	25.353	29.280	69.224	1.00	40.90	AAAA
	ATOM	1181	C	GLU	125	30.558	30.832	68.290	1.00	25.02	AAAA
	ATOM	1182	O	GLU	125	31.037	30.829	69.426	1.00	27.15	AAAA
	ATOM	1183	N	SER	126	31.291	31.034	67.194	1.00	24.83	AAAA
30	ATOM	1184	H	SER	126	30.820	31.102	66.338	1.00	0.00	AAAA
	ATOM	1185	CA	SER	126	32.759	31.135	67.256	1.00	22.04	AAAA
	ATOM	1186	CB	SER	126	33.406	30.320	66.130	1.00	19.89	AAAA
	ATOM	1187	OG	SER	126	33.126	30.932	64.880	1.00	18.20	AAAA
	ATOM	1188	HG	SER	126	32.193	30.782	64.685	1.00	0.00	AAAA
35	ATOM	1189	C	SER	126	33.294	32.562	67.200	1.00	23.67	AAAA
	ATOM	1190	O	SER	126	34.507	32.768	67.080	1.00	25.05	AAAA
	ATOM	1191	N	VAL	127	32.422	33.533	67.456	1.00	22.04	AAAA
	ATOM	1192	H	VAL	127	31.518	33.298	67.748	1.00	0.00	AAAA
	ATOM	1193	CA	VAL	127	32.757	34.942	67.278	1.00	24.22	AAAA
40	ATOM	1194	CB	VAL	127	31.479	35.822	67.390	1.00	25.46	AAAA
	ATOM	1195	CG1	VAL	127	31.117	36.056	68.842	1.00	27.14	AAAA
	ATOM	1196	CG2	VAL	127	31.667	37.136	66.669	1.00	29.08	AAAA
	ATOM	1197	C	VAL	127	33.817	35.436	68.274	1.00	25.27	AAAA

-45-

	ATOM	1198	O	VAL	127	34.596	36.339	67.977	1.00	26.45	AAAA
	ATOM	1199	N	SER	128	33.872	34.807	69.440	1.00	25.75	AAAA
	ATOM	1200	H	SER	128	33.200	34.110	69.594	1.00	0.00	AAAA
	ATOM	1201	CA	SER	128	34.781	35.242	70.497	1.00	26.71	AAAA
5	ATOM	1202	CB	SER	128	33.983	35.692	71.723	1.00	26.97	AAAA
	ATOM	1203	OG	SER	128	33.345	36.937	71.487	1.00	32.77	AAAA
	ATOM	1204	HG	SER	128	33.932	37.594	71.090	1.00	0.00	AAAA
	ATOM	1205	C	SER	128	35.786	34.166	70.909	1.00	27.80	AAAA
	ATOM	1206	O	SER	128	36.560	34.351	71.857	1.00	29.12	AAAA
10	ATOM	1207	N	MET	129	35.807	33.056	70.180	1.00	22.86	AAAA
	ATOM	1208	H	MET	129	35.182	33.002	69.438	1.00	0.00	AAAA
	ATOM	1209	CA	MET	129	36.810	32.030	70.416	1.00	20.85	AAAA
	ATOM	1210	CB	MET	129	36.426	30.738	69.710	1.00	21.01	AAAA
	ATOM	1211	CG	MET	129	35.109	30.156	70.115	1.00	21.58	AAAA
15	ATOM	1212	SD	MET	129	34.770	28.650	69.190	1.00	24.74	AAAA
	ATOM	1213	CE	MET	129	33.164	28.188	69.880	1.00	20.30	AAAA
	ATOM	1214	C	MET	129	38.166	32.500	69.875	1.00	21.66	AAAA
	ATOM	1215	O	MET	129	38.238	33.329	68.961	1.00	19.22	AAAA
	ATOM	1216	N	SER	130	39.232	31.880	70.361	1.00	20.89	AAAA
20	ATOM	1217	H	SER	130	39.092	31.193	71.016	1.00	0.00	AAAA
	ATOM	1218	CA	SER	130	40.568	32.109	69.800	1.00	21.92	AAAA
	ATOM	1219	CB	SER	130	41.633	31.625	70.783	1.00	13.02	AAAA
	ATOM	1220	OG	SER	130	41.639	30.219	70.811	1.00	14.33	AAAA
	ATOM	1221	HG	SER	130	42.205	29.949	71.540	1.00	0.00	AAAA
25	ATOM	1222	C	SER	130	40.726	31.351	68.464	1.00	20.98	AAAA
	ATOM	1223	O	SER	130	40.168	30.269	68.293	1.00	22.57	AAAA
	ATOM	1224	N	PRO	131	41.686	31.774	67.624	1.00	21.58	AAAA
	ATOM	1225	CD	PRO	131	42.485	33.009	67.725	1.00	18.87	AAAA
	ATOM	1226	CA	PRO	131	42.056	30.997	66.431	1.00	19.82	AAAA
30	ATOM	1227	CB	PRO	131	43.341	31.675	65.975	1.00	18.16	AAAA
	ATOM	1228	CG	PRO	131	43.131	33.097	66.364	1.00	18.91	AAAA
	ATOM	1229	C	PRO	131	42.256	29.503	66.685	1.00	18.54	AAAA
	ATOM	1230	O	PRO	131	41.773	28.660	65.939	1.00	19.61	AAAA
	ATOM	1231	N	GLU	132	42.866	29.180	67.811	1.00	17.68	AAAA
35	ATOM	1232	H	GLU	132	43.096	29.935	68.378	1.00	0.00	AAAA
	ATOM	1233	CA	GLU	132	43.061	27.789	68.210	1.00	20.89	AAAA
	ATOM	1234	CB	GLU	132	44.060	27.717	69.377	1.00	21.09	AAAA
	ATOM	1235	CG	GLU	132	45.413	28.416	69.127	1.00	32.04	AAAA
	ATOM	1236	CD	GLU	132	45.333	29.949	69.017	1.00	36.37	AAAA
40	ATOM	1237	OE1	GLU	132	44.489	30.566	69.701	1.00	37.91	AAAA
	ATOM	1238	OE2	GLU	132	46.148	30.546	68.269	1.00	42.82	AAAA
	ATOM	1239	C	GLU	132	41.727	27.114	68.620	1.00	17.56	AAAA
	ATOM	1240	O	GLU	132	41.441	25.973	68.252	1.00	18.36	AAAA

	ATOM	1241	N	GLU	133	40.913	27.830	69.380	1.00	20.52	AAAA
	ATOM	1242	H	GLU	133	41.184	28.735	69.645	1.00	0.00	AAAA
	ATOM	1243	CA	GLU	133	39.625	27.290	69.796	1.00	20.73	AAAA
	ATOM	1244	CB	GLU	133	38.943	28.259	70.762	1.00	23.60	AAAA
5	ATOM	1245	CG	GLU	133	39.479	28.128	72.198	1.00	24.26	AAAA
	ATOM	1246	CD	GLU	133	39.027	29.241	73.118	1.00	25.00	AAAA
	ATOM	1247	OE1	GLU	133	38.859	30.389	72.659	1.00	25.09	AAAA
	ATOM	1248	OE2	GLU	133	38.907	28.977	74.331	1.00	28.62	AAAA
	ATOM	1249	C	GLU	133	38.730	27.019	68.597	1.00	18.69	AAAA
10	ATOM	1250	O	GLU	133	38.093	25.967	68.514	1.00	19.64	AAAA
	ATOM	1251	N	ARG	134	38.800	27.908	67.612	1.00	20.05	AAAA
	ATOM	1252	H	ARG	134	39.396	28.673	67.722	1.00	0.00	AAAA
	ATOM	1253	CA	ARG	134	37.986	27.786	66.391	1.00	18.25	AAAA
	ATOM	1254	CB	ARG	134	38.135	29.038	65.543	1.00	13.07	AAAA
15	ATOM	1255	CG	ARG	134	37.576	30.266	66.200	1.00	12.02	AAAA
	ATOM	1256	CD	ARG	134	37.921	31.498	65.435	1.00	14.57	AAAA
	ATOM	1257	NE	ARG	134	37.128	32.629	65.891	1.00	14.70	AAAA
	ATOM	1258	HE	ARG	134	36.251	32.439	66.282	1.00	0.00	AAAA
	ATOM	1259	CZ	ARG	134	37.518	33.894	65.804	1.00	17.08	AAAA
20	ATOM	1260	NH1	ARG	134	36.702	34.867	66.202	1.00	19.69	AAAA
	ATOM	1261	HH11	ARG	134	37.003	35.819	66.165	1.00	0.00	AAAA
	ATOM	1262	HH12	ARG	134	35.791	34.643	66.549	1.00	0.00	AAAA
	ATOM	1263	NH2	ARG	134	38.697	34.191	65.267	1.00	17.97	AAAA
	ATOM	1264	HH21	ARG	134	39.284	33.466	64.908	1.00	0.00	AAAA
25	ATOM	1265	HH22	ARG	134	38.996	35.145	65.226	1.00	0.00	AAAA
	ATOM	1266	C	ARG	134	38.311	26.543	65.566	1.00	17.76	AAAA
	ATOM	1267	O	ARG	134	37.406	25.854	65.078	1.00	17.79	AAAA
	ATOM	1268	N	ALA	135	39.585	26.156	65.568	1.00	16.35	AAAA
	ATOM	1269	H	ALA	135	40.235	26.734	66.017	1.00	0.00	AAAA
30	ATOM	1270	CA	ALA	135	40.009	24.934	64.905	1.00	16.21	AAAA
	ATOM	1271	CB	ALA	135	41.538	24.867	64.833	1.00	15.84	AAAA
	ATOM	1272	C	ALA	135	39.462	23.712	65.635	1.00	19.65	AAAA
	ATOM	1273	O	ALA	135	39.029	22.744	65.010	1.00	20.84	AAAA
	ATOM	1274	N	ARG	136	39.476	23.762	66.963	1.00	21.92	AAAA
35	ATOM	1275	H	ARG	136	39.873	24.554	67.393	1.00	0.00	AAAA
	ATOM	1276	CA	ARG	136	38.935	22.677	67.785	1.00	22.78	AAAA
	ATOM	1277	CB	ARG	136	39.268	22.948	69.255	1.00	22.88	AAAA
	ATOM	1278	CG	ARG	136	39.719	21.737	70.028	1.00	30.16	AAAA
	ATOM	1279	CD	ARG	136	40.153	22.137	71.432	0.00	26.92	AAAA
40	ATOM	1280	NE	ARG	136	40.848	21.059	72.132	0.00	27.01	AAAA
	ATOM	1281	HE	ARG	136	41.821	20.997	72.030	0.00	0.00	AAAA
	ATOM	1282	CZ	ARG	136	40.251	20.159	72.908	0.00	26.44	AAAA
	ATOM	1283	NH1	ARG	136	40.975	19.250	73.546	0.00	26.25	AAAA

-47-

	ATOM	1284	HH11	ARG	136	41.972	19.258	73.462	1.00	0.00	AAAA
	ATOM	1285	HH12	ARG	136	40.527	18.592	74.150	1.00	0.00	AAAA
	ATOM	1286	NH2	ARG	136	38.930	20.142	73.022	0.00	26.23	AAAA
	ATOM	1287	HH21	ARG	136	38.372	20.799	72.513	1.00	0.00	AAAA
5	ATOM	1288	HH22	ARG	136	38.488	19.468	73.613	1.00	0.00	AAAA
	ATOM	1289	C	ARG	136	37.400	22.548	67.608	1.00	20.95	AAAA
	ATOM	1290	O	ARG	136	36.854	21.445	67.486	1.00	20.97	AAAA
	ATOM	1291	N	TYR	137	36.717	23.684	67.612	1.00	17.84	AAAA
	ATOM	1292	H	TYR	137	37.205	24.511	67.800	1.00	0.00	AAAA
10	ATOM	1293	CA	TYR	137	35.289	23.702	67.369	1.00	17.54	AAAA
	ATOM	1294	CB	TYR	137	34.772	25.129	67.536	1.00	18.25	AAAA
	ATOM	1295	CG	TYR	137	33.262	25.292	67.445	1.00	21.44	AAAA
	ATOM	1296	CD1	TYR	137	32.388	24.288	67.867	1.00	22.83	AAAA
	ATOM	1297	CE1	TYR	137	30.989	24.460	67.767	1.00	24.57	AAAA
15	ATOM	1298	CD2	TYR	137	32.712	26.467	66.931	1.00	24.44	AAAA
	ATOM	1299	CE2	TYR	137	31.336	26.645	66.837	1.00	23.60	AAAA
	ATOM	1300	CZ	TYR	137	30.481	25.645	67.253	1.00	23.28	AAAA
	ATOM	1301	OH	TYR	137	29.124	25.869	67.158	1.00	26.64	AAAA
	ATOM	1302	HH	TYR	137	28.634	25.119	67.487	1.00	0.00	AAAA
20	ATOM	1303	C	TYR	137	34.982	23.136	65.969	1.00	19.09	AAAA
	ATOM	1304	O	TYR	137	34.284	22.126	65.862	1.00	19.43	AAAA
	ATOM	1305	N	LEU	138	35.682	23.621	64.939	1.00	18.53	AAAA
	ATOM	1306	H	LEU	138	36.295	24.357	65.103	1.00	0.00	AAAA
	ATOM	1307	CA	LEU	138	35.518	23.068	63.582	1.00	20.95	AAAA
25	ATOM	1308	CB	LEU	138	36.472	23.730	62.586	1.00	17.16	AAAA
	ATOM	1309	CG	LEU	138	36.270	23.242	61.144	1.00	17.24	AAAA
	ATOM	1310	CD1	LEU	138	34.887	23.658	60.627	1.00	18.51	AAAA
	ATOM	1311	CD2	LEU	138	37.357	23.808	60.262	1.00	18.65	AAAA
	ATOM	1312	C	LEU	138	35.679	21.547	63.480	1.00	23.49	AAAA
30	ATOM	1313	O	LEU	138	34.883	20.888	62.811	1.00	23.89	AAAA
	ATOM	1314	N	GLU	139	36.717	21.001	64.115	1.00	23.27	AAAA
	ATOM	1315	H	GLU	139	37.378	21.603	64.525	1.00	0.00	AAAA
	ATOM	1316	CA	GLU	139	36.884	19.555	64.225	1.00	26.59	AAAA
	ATOM	1317	CB	GLU	139	38.111	19.221	65.081	1.00	31.75	AAAA
35	ATOM	1318	CG	GLU	139	39.429	19.788	64.559	1.00	42.46	AAAA
	ATOM	1319	CD	GLU	139	40.623	19.513	65.491	1.00	47.40	AAAA
	ATOM	1320	OE1	GLU	139	41.176	18.390	65.443	1.00	50.41	AAAA
	ATOM	1321	OE2	GLU	139	41.027	20.429	66.245	1.00	50.25	AAAA
	ATOM	1322	C	GLU	139	35.639	18.897	64.842	1.00	27.54	AAAA
40	ATOM	1323	O	GLU	139	35.147	17.903	64.318	1.00	30.37	AAAA
	ATOM	1324	N	ASN	140	35.090	19.484	65.904	1.00	26.57	AAAA
	ATOM	1325	H	ASN	140	35.529	20.277	66.280	1.00	0.00	AAAA
	ATOM	1326	CA	ASN	140	33.884	18.922	66.545	1.00	30.15	AAAA

-48-

	ATOM	1327	CB	ASN	140	33.647	19.558	67.922	1.00	32.80	AAAA
	ATOM	1328	CG	ASN	140	34.831	19.416	68.854	1.00	35.71	AAAA
	ATOM	1329	OD1	ASN	140	35.740	18.621	68.634	1.00	37.11	AAAA
	ATOM	1330	ND2	ASN	140	34.828	20.210	69.906	1.00	38.04	AAAA
5	ATOM	1331	HD21	ASN	140	34.054	20.795	70.059	1.00	0.00	AAAA
	ATOM	1332	HD22	ASN	140	35.627	20.136	70.454	1.00	0.00	AAAA
	ATOM	1333	C	ASN	140	32.601	19.106	65.720	1.00	30.97	AAAA
	ATOM	1334	O	ASN	140	31.654	18.317	65.819	1.00	33.89	AAAA
	ATOM	1335	N	TYR	141	32.524	20.242	65.041	1.00	29.95	AAAA
10	ATOM	1336	H	TYR	141	33.363	20.717	64.917	1.00	0.00	AAAA
	ATOM	1337	CA	TYR	141	31.299	20.738	64.430	1.00	28.02	AAAA
	ATOM	1338	CB	TYR	141	31.466	22.222	64.099	1.00	25.30	AAAA
	ATOM	1339	CG	TYR	141	30.191	22.921	63.727	1.00	23.02	AAAA
	ATOM	1340	CD1	TYR	141	29.318	23.352	64.711	1.00	24.68	AAAA
15	ATOM	1341	CE1	TYR	141	28.155	24.034	64.396	1.00	23.87	AAAA
	ATOM	1342	CD2	TYR	141	29.878	23.186	62.400	1.00	17.67	AAAA
	ATOM	1343	CE2	TYR	141	28.722	23.874	62.073	1.00	26.80	AAAA
	ATOM	1344	CZ	TYR	141	27.863	24.298	63.083	1.00	25.22	AAAA
	ATOM	1345	OH	TYR	141	26.738	25.024	62.790	1.00	27.16	AAAA
20	ATOM	1346	HH	TYR	141	26.724	25.168	61.847	1.00	0.00	AAAA
	ATOM	1347	C	TYR	141	30.968	19.958	63.162	1.00	29.46	AAAA
	ATOM	1348	O	TYR	141	31.220	20.422	62.047	1.00	28.34	AAAA
	ATOM	1349	N	ASP	142	30.217	18.882	63.349	1.00	30.05	AAAA
	ATOM	1350	H	ASP	142	29.913	18.788	64.276	1.00	0.00	AAAA
25	ATOM	1351	CA	ASP	142	29.980	17.888	62.311	1.00	33.85	AAAA
	ATOM	1352	CB	ASP	142	29.123	16.750	62.880	1.00	42.00	AAAA
	ATOM	1353	CG	ASP	142	29.400	16.473	64.361	1.00	49.95	AAAA
	ATOM	1354	OD1	ASP	142	28.696	17.052	65.230	1.00	48.78	AAAA
	ATOM	1355	OD2	ASP	142	30.288	15.633	64.648	1.00	53.91	AAAA
30	ATOM	1356	C	ASP	142	29.308	18.452	61.047	1.00	32.97	AAAA
	ATOM	1357	O	ASP	142	29.589	18.017	59.926	1.00	31.12	AAAA
	ATOM	1358	N	ALA	143	28.443	19.442	61.243	1.00	30.82	AAAA
	ATOM	1359	H	ALA	143	28.396	19.832	62.132	1.00	0.00	AAAA
	ATOM	1360	CA	ALA	143	27.622	19.997	60.176	1.00	31.33	AAAA
35	ATOM	1361	CB	ALA	143	26.685	21.056	60.747	1.00	30.92	AAAA
	ATOM	1362	C	ALA	143	28.407	20.577	58.989	1.00	32.79	AAAA
	ATOM	1363	O	ALA	143	27.900	20.600	57.869	1.00	37.58	AAAA
	ATOM	1364	N	ILE	144	29.628	21.061	59.215	1.00	29.28	AAAA
	ATOM	1365	H	ILE	144	30.015	21.012	60.119	1.00	0.00	AAAA
40	ATOM	1366	CA	ILE	144	30.416	21.591	58.107	1.00	27.01	AAAA
	ATOM	1367	CB	ILE	144	31.344	22.736	58.568	1.00	27.54	AAAA
	ATOM	1368	CG2	ILE	144	32.231	23.223	57.416	1.00	27.82	AAAA
	ATOM	1369	CG1	ILE	144	30.485	23.919	59.024	1.00	25.26	AAAA

	ATOM	1370	CD	ILE	144	31.254	25.121	59.464	1.00	24.22	AAAA
	ATOM	1371	C	ILE	144	31.177	20.463	57.420	1.00	29.24	AAAA
	ATOM	1372	O	ILE	144	32.313	20.126	57.774	1.00	30.95	AAAA
	ATOM	1373	N	ARG	145	30.454	19.795	56.524	1.00	28.91	AAAA
5	ATOM	1374	H	ARG	145	29.547	20.114	56.340	1.00	0.00	AAAA
	ATOM	1375	CA	ARG	145	30.895	18.579	55.834	1.00	29.33	AAAA
	ATOM	1376	CB	ARG	145	30.311	17.342	56.539	1.00	30.28	AAAA
	ATOM	1377	CG	ARG	145	29.988	16.150	55.646	0.00	29.38	AAAA
	ATOM	1378	CD	ARG	145	31.078	15.091	55.690	0.00	29.04	AAAA
10	ATOM	1379	NE	ARG	145	31.399	14.683	57.056	0.00	28.60	AAAA
	ATOM	1380	HE	ARG	145	31.308	15.336	57.782	0.00	0.00	AAAA
	ATOM	1381	CZ	ARG	145	31.833	13.473	57.396	0.00	28.42	AAAA
	ATOM	1382	NH1	ARG	145	32.122	13.208	58.663	0.00	28.25	AAAA
	ATOM	1383	HH11	ARG	145	32.021	13.923	59.354	1.00	0.00	AAAA
15	ATOM	1384	HH12	ARG	145	32.454	12.300	58.923	1.00	0.00	AAAA
	ATOM	1385	NH2	ARG	145	31.974	12.524	56.479	0.00	28.30	AAAA
	ATOM	1386	HH21	ARG	145	32.314	11.623	56.749	1.00	0.00	AAAA
	ATOM	1387	HH22	ARG	145	31.721	12.696	55.526	1.00	0.00	AAAA
	ATOM	1388	C	ARG	145	30.355	18.676	54.415	1.00	29.88	AAAA
20	ATOM	1389	O	ARG	145	29.256	19.167	54.236	1.00	31.53	AAAA
	ATOM	1390	N	VAL	146	31.187	18.416	53.415	1.00	31.91	AAAA
	ATOM	1391	H	VAL	146	32.098	18.132	53.593	1.00	0.00	AAAA
	ATOM	1392	CA	VAL	146	30.698	18.434	52.042	1.00	37.37	AAAA
	ATOM	1393	CB	VAL	146	31.845	18.531	50.978	1.00	36.83	AAAA
25	ATOM	1394	CG1	VAL	146	32.686	19.774	51.208	1.00	33.88	AAAA
	ATOM	1395	CG2	VAL	146	32.717	17.285	50.996	1.00	36.91	AAAA
	ATOM	1396	C	VAL	146	29.899	17.155	51.815	1.00	44.69	AAAA
	ATOM	1397	OT1	VAL	146	30.301	16.119	52.395	1.00	50.73	AAAA
	ATOM	1398	OT2	VAL	146	28.808	17.228	51.203	1.00	51.33	AAAA
30	ATOM	1399	CB	ASP	167	51.716	18.609	47.898	1.00	49.54	BBBB
	ATOM	1400	CG	ASP	167	53.148	18.936	47.435	1.00	55.49	BBBB
	ATOM	1401	OD1	ASP	167	53.852	17.986	47.033	1.00	58.95	BBBB
	ATOM	1402	OD2	ASP	167	53.560	20.123	47.426	1.00	57.98	BBBB
	ATOM	1403	C	ASP	167	50.546	20.690	48.673	1.00	38.29	BBBB
35	ATOM	1404	O	ASP	167	51.079	21.780	48.786	1.00	37.35	BBBB
	ATOM	1405	HT1	ASP	167	49.531	18.285	49.508	1.00	0.00	BBBB
	ATOM	1406	HT2	ASP	167	50.055	19.203	50.836	1.00	0.00	BBBB
	ATOM	1407	N	ASP	167	50.385	18.623	50.034	1.00	44.61	BBBB
	ATOM	1408	HT3	ASP	167	50.902	17.811	50.403	1.00	0.00	BBBB
40	ATOM	1409	CA	ASP	167	51.272	19.431	49.130	1.00	43.35	BBBB
	ATOM	1410	N	LEU	168	49.330	20.523	48.152	1.00	32.28	BBBB
	ATOM	1411	H	LEU	168	48.993	19.646	47.910	1.00	0.00	BBBB
	ATOM	1412	CA	LEU	168	48.483	21.649	47.735	1.00	30.48	BBBB

-50-

	ATOM	1413	CB	LEU	168	47.434	21.174	46.711	1.00	29.61	BBBB
	ATOM	1414	CG	LEU	168	47.519	21.629	45.234	1.00	34.32	BBBB
	ATOM	1415	CD1	LEU	168	48.957	21.832	44.759	1.00	27.65	BBBB
	ATOM	1416	CD2	LEU	168	46.800	20.592	44.368	1.00	27.35	BBBB
5	ATOM	1417	C	LEU	168	47.786	22.321	48.937	1.00	27.15	BBBB
	ATOM	1418	O	LEU	168	47.365	21.644	49.867	1.00	28.57	BBBB
	ATOM	1419	N	HIS	169	47.712	23.649	48.927	1.00	22.41	BBBB
	ATOM	1420	H	HIS	169	47.989	24.120	48.109	1.00	0.00	BBBB
	ATOM	1421	CA	HIS	169	47.223	24.415	50.068	1.00	16.79	BBBB
10	ATOM	1422	CB	HIS	169	48.425	24.912	50.889	1.00	15.93	BBBB
	ATOM	1423	CG	HIS	169	48.067	25.462	52.235	1.00	13.63	BBBB
	ATOM	1424	CD2	HIS	169	48.301	26.674	52.792	1.00	13.31	BBBB
	ATOM	1425	ND1	HIS	169	47.275	24.780	53.135	1.00	19.04	BBBB
	ATOM	1426	HD1	HIS	169	46.915	23.885	53.069	1.00	0.00	BBBB
15	ATOM	1427	CE1	HIS	169	47.024	25.550	54.177	1.00	15.56	BBBB
	ATOM	1428	NE2	HIS	169	47.641	26.704	53.996	1.00	14.61	BBBB
	ATOM	1429	HE2	HIS	169	47.457	27.477	54.543	1.00	0.00	BBBB
	ATOM	1430	C	HIS	169	46.378	25.605	49.589	1.00	15.63	BBBB
	ATOM	1431	O	HIS	169	46.655	26.195	48.551	1.00	15.56	BBBB
20	ATOM	1432	N	PHE	170	45.336	25.936	50.347	1.00	11.37	BBBB
	ATOM	1433	H	PHE	170	45.080	25.342	51.078	1.00	0.00	BBBB
	ATOM	1434	CA	PHE	170	44.529	27.119	50.091	1.00	13.04	BBBB
	ATOM	1435	CB	PHE	170	43.034	26.820	50.263	1.00	15.00	BBBB
	ATOM	1436	CG	PHE	170	42.363	26.294	49.024	1.00	13.40	BBBB
25	ATOM	1437	CD1	PHE	170	42.008	24.954	48.930	1.00	16.80	BBBB
	ATOM	1438	CD2	PHE	170	41.975	27.160	48.016	1.00	17.90	BBBB
	ATOM	1439	CE1	PHE	170	41.253	24.481	47.862	1.00	15.73	BBBB
	ATOM	1440	CE2	PHE	170	41.216	26.692	46.931	1.00	19.11	BBBB
	ATOM	1441	CZ	PHE	170	40.856	25.352	46.866	1.00	14.95	BBBB
30	ATOM	1442	C	PHE	170	44.870	28.218	51.068	1.00	12.35	BBBB
	ATOM	1443	O	PHE	170	45.009	27.977	52.273	1.00	13.04	BBBB
	ATOM	1444	N	ILE	171	44.908	29.438	50.562	1.00	13.08	BBBB
	ATOM	1445	H	ILE	171	44.992	29.531	49.589	1.00	0.00	BBBB
	ATOM	1446	CA	ILE	171	44.790	30.602	51.423	1.00	17.13	BBBB
35	ATOM	1447	CB	ILE	171	46.115	31.418	51.506	1.00	17.52	BBBB
	ATOM	1448	CG2	ILE	171	47.216	30.540	52.100	1.00	18.45	BBBB
	ATOM	1449	CG1	ILE	171	46.520	31.954	50.133	1.00	19.39	BBBB
	ATOM	1450	CD	ILE	171	47.653	32.960	50.180	1.00	21.31	BBBB
	ATOM	1451	C	ILE	171	43.646	31.499	50.942	1.00	15.82	BBBB
40	ATOM	1452	O	ILE	171	43.136	31.317	49.826	1.00	15.55	BBBB
	ATOM	1453	N	ALA	172	43.153	32.332	51.855	1.00	14.30	BBBB
	ATOM	1454	H	ALA	172	43.513	32.279	52.767	1.00	0.00	BBBB
	ATOM	1455	CA	ALA	172	42.126	33.309	51.554	1.00	11.34	BBBB

	ATOM	1456	CB	ALA	172	40.961	33.159	52.534	1.00	12.21	BBBB
	ATOM	1457	C	ALA	172	42.715	34.705	51.626	1.00	13.20	BBBB
	ATOM	1458	O	ALA	172	43.537	35.009	52.500	1.00	13.74	BBBB
	ATOM	1459	N	LEU	173	42.324	35.544	50.670	1.00	14.10	BBBB
5	ATOM	1460	H	LEU	173	41.732	35.187	49.978	1.00	0.00	BBBB
	ATOM	1461	CA	LEU	173	42.744	36.942	50.630	1.00	13.28	BBBB
	ATOM	1462	CB	LEU	173	43.535	37.208	49.345	1.00	14.89	BBBB
	ATOM	1463	CG	LEU	173	44.958	36.611	49.358	1.00	17.25	BBBB
	ATOM	1464	CD1	LEU	173	45.526	36.424	47.940	1.00	14.54	BBBB
10	ATOM	1465	CD2	LEU	173	45.847	37.539	50.191	1.00	15.04	BBBB
	ATOM	1466	C	LEU	173	41.502	37.827	50.688	1.00	16.11	BBBB
	ATOM	1467	O	LEU	173	40.568	37.637	49.907	1.00	16.45	BBBB
	ATOM	1468	N	VAL	174	41.425	38.646	51.736	1.00	16.31	BBBB
	ATOM	1469	H	VAL	174	42.209	38.693	52.325	1.00	0.00	BBBB
15	ATOM	1470	CA	VAL	174	40.237	39.448	52.028	1.00	17.92	BBBB
	ATOM	1471	CB	VAL	174	39.351	38.822	53.157	1.00	17.86	BBBB
	ATOM	1472	CG1	VAL	174	38.869	37.422	52.764	1.00	15.30	BBBB
	ATOM	1473	CG2	VAL	174	40.130	38.787	54.480	1.00	16.97	BBBB
	ATOM	1474	C	VAL	174	40.588	40.865	52.459	1.00	18.53	BBBB
20	ATOM	1475	O	VAL	174	41.690	41.149	52.931	1.00	17.41	BBBB
	ATOM	1476	N	HIS	175	39.623	41.751	52.294	1.00	18.01	BBBB
	ATOM	1477	H	HIS	175	38.768	41.427	51.928	1.00	0.00	BBBB
	ATOM	1478	CA	HIS	175	39.784	43.137	52.667	1.00	22.89	BBBB
	ATOM	1479	CB	HIS	175	39.178	44.038	51.590	1.00	24.46	BBBB
25	ATOM	1480	CG	HIS	175	38.940	45.443	52.047	1.00	28.42	BBBB
	ATOM	1481	CD2	HIS	175	39.797	46.404	52.459	1.00	29.90	BBBB
	ATOM	1482	ND1	HIS	175	37.680	45.987	52.146	1.00	29.90	BBBB
	ATOM	1483	HD1	HIS	175	36.868	45.469	51.941	1.00	0.00	BBBB
	ATOM	1484	CE1	HIS	175	37.769	47.222	52.596	1.00	30.93	BBBB
30	ATOM	1485	NE2	HIS	175	39.044	47.499	52.797	1.00	31.81	BBBB
	ATOM	1486	HE2	HIS	175	39.397	48.399	52.952	1.00	0.00	BBBB
	ATOM	1487	C	HIS	175	39.090	43.373	53.994	1.00	23.68	BBBB
	ATOM	1488	O	HIS	175	37.890	43.165	54.103	1.00	23.93	BBBB
	ATOM	1489	N	VAL	176	39.852	43.761	55.011	1.00	24.25	BBBB
35	ATOM	1490	H	VAL	176	40.832	43.727	54.897	1.00	0.00	BBBB
	ATOM	1491	CA	VAL	176	39.259	44.145	56.291	1.00	25.87	BBBB
	ATOM	1492	CB	VAL	176	39.486	43.065	57.389	1.00	26.10	BBBB
	ATOM	1493	CG1	VAL	176	38.747	43.442	58.658	1.00	23.79	BBBB
	ATOM	1494	CG2	VAL	176	39.012	41.709	56.905	1.00	23.00	BBBB
40	ATOM	1495	C	VAL	176	39.844	45.471	56.765	1.00	26.17	BBBB
	ATOM	1496	O	VAL	176	41.061	45.661	56.745	1.00	25.83	BBBB
	ATOM	1497	N	ASP	177	38.961	46.423	57.064	1.00	30.10	BBBB
	ATOM	1498	H	ASP	177	38.013	46.197	56.991	1.00	0.00	BBBB

-52-

	ATOM	1499	CA	ASP	177	39.348	47.735	57.593	1.00	31.23	BBBB
	ATOM	1500	CB	ASP	177	39.656	47.634	59.088	1.00	37.10	BBBB
	ATOM	1501	CG	ASP	177	38.434	47.241	59.924	1.00	43.92	BBBB
	ATOM	1502	OD1	ASP	177	38.610	46.901	61.115	1.00	45.60	BBBB
5	ATOM	1503	OD2	ASP	177	37.299	47.249	59.388	1.00	48.64	BBBB
	ATOM	1504	C	ASP	177	40.540	48.339	56.864	1.00	30.72	BBBB
	ATOM	1505	O	ASP	177	41.580	48.596	57.472	1.00	31.89	BBBB
	ATOM	1506	N	GLY	178	40.456	48.339	55.535	1.00	29.77	BBBB
	ATOM	1507	H	GLY	178	39.689	47.869	55.161	1.00	0.00	BBBB
10	ATOM	1508	CA	GLY	178	41.435	49.035	54.715	1.00	30.17	BBBB
	ATOM	1509	C	GLY	178	42.725	48.298	54.407	1.00	28.13	BBBB
	ATOM	1510	O	GLY	178	43.607	48.833	53.738	1.00	28.30	BBBB
	ATOM	1511	N	HIS	179	42.842	47.061	54.877	1.00	27.85	BBBB
	ATOM	1512	H	HIS	179	42.131	46.661	55.410	1.00	0.00	BBBB
15	ATOM	1513	CA	HIS	179	44.031	46.272	54.588	1.00	27.46	BBBB
	ATOM	1514	CB	HIS	179	44.917	46.186	55.822	1.00	31.40	BBBB
	ATOM	1515	CG	HIS	179	45.299	47.526	56.364	1.00	39.75	BBBB
	ATOM	1516	CD2	HIS	179	46.221	48.424	55.942	1.00	39.28	BBBB
	ATOM	1517	ND1	HIS	179	44.541	48.174	57.317	1.00	39.91	BBBB
20	ATOM	1518	HD1	HIS	179	43.819	47.792	57.859	1.00	0.00	BBBB
	ATOM	1519	CE1	HIS	179	44.971	49.417	57.448	1.00	42.46	BBBB
	ATOM	1520	NE2	HIS	179	45.990	49.592	56.624	1.00	43.86	BBBB
	ATOM	1521	HE2	HIS	179	46.444	50.449	56.500	1.00	0.00	BBBB
	ATOM	1522	C	HIS	179	43.726	44.885	54.074	1.00	26.07	BBBB
25	ATOM	1523	O	HIS	179	42.624	44.362	54.290	1.00	24.18	BBBB
	ATOM	1524	N	LEU	180	44.642	44.397	53.238	1.00	23.29	BBBB
	ATOM	1525	H	LEU	180	45.398	44.952	52.987	1.00	0.00	BBBB
	ATOM	1526	CA	LEU	180	44.582	43.062	52.646	1.00	23.82	BBBB
	ATOM	1527	CB	LEU	180	45.308	43.066	51.299	1.00	22.59	BBBB
30	ATOM	1528	CG	LEU	180	45.434	41.775	50.491	1.00	22.52	BBBB
	ATOM	1529	CD1	LEU	180	44.070	41.212	50.147	1.00	22.19	BBBB
	ATOM	1530	CD2	LEU	180	46.206	42.094	49.223	1.00	24.25	BBBB
	ATOM	1531	C	LEU	180	45.208	42.006	53.560	1.00	22.99	BBBB
	ATOM	1532	O	LEU	180	46.402	42.059	53.876	1.00	23.65	BBBB
35	ATOM	1533	N	TYR	181	44.395	41.055	53.994	1.00	20.53	BBBB
	ATOM	1534	H	TYR	181	43.466	41.057	53.679	1.00	0.00	BBBB
	ATOM	1535	CA	TYR	181	44.867	40.015	54.896	1.00	18.31	BBBB
	ATOM	1536	CB	TYR	181	43.975	39.921	56.143	1.00	16.99	BBBB
	ATOM	1537	CG	TYR	181	44.141	41.097	57.092	1.00	19.91	BBBB
40	ATOM	1538	CD1	TYR	181	43.303	42.210	57.001	1.00	21.59	BBBB
	ATOM	1539	CE1	TYR	181	43.493	43.329	57.820	1.00	22.12	BBBB
	ATOM	1540	CD2	TYR	181	45.172	41.126	58.034	1.00	19.21	BBBB
	ATOM	1541	CE2	TYR	181	45.361	42.236	58.863	1.00	20.75	BBBB

	ATOM	1542	CZ	TYR	181	44.515	43.332	58.751	1.00	21.81	BBBB
	ATOM	1543	OH	TYR	181	44.643	44.415	59.594	1.00	21.78	BBBB
	ATOM	1544	HH	TYR	181	44.032	45.113	59.325	1.00	0.00	BBBB
	ATOM	1545	C	TYR	181	44.903	38.688	54.188	1.00	17.40	BBBB
5	ATOM	1546	O	TYR	181	44.002	38.360	53.412	1.00	16.63	BBBB
	ATOM	1547	N	GLU	182	46.057	38.049	54.272	1.00	15.21	BBBB
	ATOM	1548	H	GLU	182	46.791	38.531	54.688	1.00	0.00	BBBB
	ATOM	1549	CA	GLU	182	46.195	36.674	53.845	1.00	13.51	BBBB
	ATOM	1550	CB	GLU	182	47.642	36.373	53.429	1.00	11.85	BBBB
10	ATOM	1551	CG	GLU	182	47.980	34.891	53.391	1.00	11.30	BBBB
	ATOM	1552	CD	GLU	182	49.468	34.613	53.230	1.00	14.98	BBBB
	ATOM	1553	OE1	GLU	182	50.230	35.561	52.970	1.00	15.00	BBBB
	ATOM	1554	OE2	GLU	182	49.865	33.441	53.342	1.00	14.93	BBBB
	ATOM	1555	C	GLU	182	45.847	35.874	55.071	1.00	14.99	BBBB
15	ATOM	1556	O	GLU	182	46.449	36.065	56.140	1.00	15.11	BBBB
	ATOM	1557	N	LEU	183	44.835	35.028	54.934	1.00	12.67	BBBB
	ATOM	1558	H	LEU	183	44.349	35.063	54.090	1.00	0.00	BBBB
	ATOM	1559	CA	LEU	183	44.445	34.127	56.002	1.00	12.90	BBBB
	ATOM	1560	CB	LEU	183	42.942	34.265	56.275	1.00	15.03	BBBB
20	ATOM	1561	CG	LEU	183	42.456	35.701	56.541	1.00	15.56	BBBB
	ATOM	1562	CD1	LEU	183	40.936	35.730	56.613	1.00	15.32	BBBB
	ATOM	1563	CD2	LEU	183	43.039	36.234	57.858	1.00	16.89	BBBB
	ATOM	1564	C	LEU	183	44.829	32.687	55.682	1.00	11.08	BBBB
	ATOM	1565	O	LEU	183	44.329	32.073	54.757	1.00	10.71	BBBB
25	ATOM	1566	N	ASP	184	45.836	32.203	56.387	1.00	13.16	BBBB
	ATOM	1567	H	ASP	184	46.219	32.837	57.037	1.00	0.00	BBBB
	ATOM	1568	CA	ASP	184	46.376	30.859	56.192	1.00	14.34	BBBB
	ATOM	1569	CB	ASP	184	47.759	30.964	55.527	1.00	14.33	BBBB
	ATOM	1570	CG	ASP	184	48.432	29.613	55.334	1.00	15.44	BBBB
30	ATOM	1571	OD1	ASP	184	49.409	29.556	54.558	1.00	16.13	BBBB
	ATOM	1572	OD2	ASP	184	47.999	28.611	55.936	1.00	14.97	BBBB
	ATOM	1573	C	ASP	184	46.511	30.220	57.570	1.00	16.33	BBBB
	ATOM	1574	O	ASP	184	47.346	30.644	58.356	1.00	16.05	BBBB
	ATOM	1575	N	GLY	185	45.728	29.185	57.850	1.00	16.42	BBBB
35	ATOM	1576	H	GLY	185	45.154	28.820	57.141	1.00	0.00	BBBB
	ATOM	1577	CA	GLY	185	45.700	28.623	59.199	1.00	17.67	BBBB
	ATOM	1578	C	GLY	185	46.987	27.929	59.618	1.00	18.28	BBBB
	ATOM	1579	O	GLY	185	47.130	27.512	60.762	1.00	18.70	BBBB
	ATOM	1580	N	ARG	186	47.867	27.685	58.650	1.00	19.25	BBBB
40	ATOM	1581	H	ARG	186	47.535	27.821	57.748	1.00	0.00	BBBB
	ATOM	1582	CA	ARG	186	49.198	27.155	58.937	1.00	19.66	BBBB
	ATOM	1583	CB	ARG	186	49.894	26.714	57.644	1.00	17.80	BBBB
	ATOM	1584	CG	ARG	186	49.340	25.429	57.048	1.00	21.14	BBBB

-54-

	ATOM	1585	CD	ARG	186	50.144	24.967	55.843	1.00	24.27	BBBB
	ATOM	1586	NE	ARG	186	51.324	24.196	56.228	1.00	28.78	BBBB
	ATOM	1587	HE	ARG	186	51.195	23.379	56.760	1.00	0.00	BBBB
	ATOM	1588	CZ	ARG	186	52.575	24.524	55.907	1.00	29.73	BBBB
5	ATOM	1589	NH1	ARG	186	53.569	23.710	56.236	1.00	28.20	BBBB
	ATOM	1590	HH11	ARG	186	54.505	23.980	56.016	1.00	0.00	BBBB
	ATOM	1591	HH12	ARG	186	53.390	22.890	56.781	1.00	0.00	BBBB
	ATOM	1592	NH2	ARG	186	52.836	25.644	55.239	1.00	27.79	BBBB
	ATOM	1593	HH21	ARG	186	52.060	26.225	55.039	1.00	0.00	BBBB
10	ATOM	1594	HH22	ARG	186	53.769	25.882	54.957	1.00	0.00	BBBB
	ATOM	1595	C	ARG	186	50.068	28.189	59.644	1.00	18.52	BBBB
	ATOM	1596	O	ARG	186	51.114	27.871	60.187	1.00	23.14	BBBB
	ATOM	1597	N	LYS	187	49.713	29.450	59.504	1.00	16.47	BBBB
	ATOM	1598	H	LYS	187	48.842	29.675	59.124	1.00	0.00	BBBB
15	ATOM	1599	CA	LYS	187	50.543	30.506	60.036	1.00	17.08	BBBB
	ATOM	1600	CB	LYS	187	50.565	31.671	59.049	1.00	13.37	BBBB
	ATOM	1601	CG	LYS	187	51.244	31.276	57.737	1.00	11.69	BBBB
	ATOM	1602	CD	LYS	187	51.391	32.462	56.792	1.00	12.40	BBBB
	ATOM	1603	CE	LYS	187	52.035	32.009	55.491	1.00	12.88	BBBB
20	ATOM	1604	NZ	LYS	187	52.331	33.162	54.604	1.00	12.97	BBBB
	ATOM	1605	HZ1	LYS	187	52.773	33.902	55.169	1.00	0.00	BBBB
	ATOM	1606	HZ2	LYS	187	51.461	33.563	54.210	1.00	0.00	BBBB
	ATOM	1607	HZ3	LYS	187	52.951	32.823	53.846	1.00	0.00	BBBB
	ATOM	1608	C	LYS	187	50.068	30.931	61.426	1.00	20.11	BBBB
25	ATOM	1609	O	LYS	187	48.968	30.575	61.849	1.00	18.37	BBBB
	ATOM	1610	N	PRO	188	50.942	31.591	62.199	1.00	19.32	BBBB
	ATOM	1611	CD	PRO	188	52.404	31.644	62.017	1.00	19.27	BBBB
	ATOM	1612	CA	PRO	188	50.522	31.951	63.565	1.00	20.87	BBBB
	ATOM	1613	CB	PRO	188	51.831	32.398	64.248	1.00	20.84	BBBB
30	ATOM	1614	CG	PRO	188	52.852	32.527	63.125	1.00	20.92	BBBB
	ATOM	1615	C	PRO	188	49.442	33.047	63.618	1.00	18.51	BBBB
	ATOM	1616	O	PRO	188	48.838	33.303	64.661	1.00	18.14	BBBB
	ATOM	1617	N	PHE	189	49.258	33.744	62.506	1.00	16.00	BBBB
	ATOM	1618	H	PHE	189	49.673	33.425	61.681	1.00	0.00	BBBB
35	ATOM	1619	CA	PHE	189	48.441	34.954	62.474	1.00	14.73	BBBB
	ATOM	1620	CB	PHE	189	49.161	36.151	63.126	1.00	19.72	BBBB
	ATOM	1621	CG	PHE	189	50.668	36.158	62.952	1.00	18.33	BBBB
	ATOM	1622	CD1	PHE	189	51.248	36.237	61.693	1.00	19.90	BBBB
	ATOM	1623	CD2	PHE	189	51.502	36.056	64.061	1.00	24.46	BBBB
40	ATOM	1624	CE1	PHE	189	52.632	36.200	61.537	1.00	18.74	BBBB
	ATOM	1625	CE2	PHE	189	52.891	36.026	63.913	1.00	23.39	BBBB
	ATOM	1626	CZ	PHE	189	53.449	36.090	62.650	1.00	20.37	BBBB
	ATOM	1627	C	PHE	189	48.102	35.292	61.035	1.00	14.51	BBBB

-55-

	ATOM	1628	O	PHE	189	48.654	34.694	60.113	1.00	14.41	BBBB
	ATOM	1629	N	PRO	190	47.090	36.150	60.829	1.00	18.27	BBBB
	ATOM	1630	CD	PRO	190	46.101	36.625	61.817	1.00	16.54	BBBB
	ATOM	1631	CA	PRO	190	46.885	36.773	59.516	1.00	15.88	BBBB
5	ATOM	1632	CB	PRO	190	45.744	37.757	59.764	1.00	14.74	BBBB
	ATOM	1633	CG	PRO	190	45.020	37.200	60.949	1.00	13.70	BBBB
	ATOM	1634	C	PRO	190	48.155	37.495	59.086	1.00	18.93	BBBB
	ATOM	1635	O	PRO	190	48.944	37.917	59.937	1.00	18.46	BBBB
	ATOM	1636	N	ILE	191	48.385	37.566	57.781	1.00	16.14	BBBB
10	ATOM	1637	H	ILE	191	47.811	37.011	57.212	1.00	0.00	BBBB
	ATOM	1638	CA	ILE	191	49.478	38.380	57.235	1.00	18.56	BBBB
	ATOM	1639	CB	ILE	191	50.307	37.590	56.177	1.00	15.52	BBBB
	ATOM	1640	CG2	ILE	191	51.435	38.471	55.632	1.00	15.36	BBBB
	ATOM	1641	CG1	ILE	191	50.814	36.270	56.771	1.00	14.75	BBBB
15	ATOM	1642	CD	ILE	191	51.668	36.421	58.031	1.00	14.66	BBBB
	ATOM	1643	C	ILE	191	48.922	39.646	56.584	1.00	19.70	BBBB
	ATOM	1644	O	ILE	191	48.062	39.578	55.691	1.00	17.72	BBBB
	ATOM	1645	N	ASN	192	49.352	40.799	57.091	1.00	19.71	BBBB
	ATOM	1646	H	ASN	192	49.955	40.764	57.864	1.00	0.00	BBBB
20	ATOM	1647	CA	ASN	192	48.901	42.083	56.564	1.00	22.28	BBBB
	ATOM	1648	CB	ASN	192	49.056	43.189	57.615	1.00	22.85	BBBB
	ATOM	1649	CG	ASN	192	48.416	44.496	57.183	1.00	20.68	BBBB
	ATOM	1650	OD1	ASN	192	48.436	44.855	56.012	1.00	26.53	BBBB
	ATOM	1651	ND2	ASN	192	47.814	45.191	58.122	1.00	19.89	BBBB
25	ATOM	1652	HD21	ASN	192	47.456	46.053	57.850	1.00	0.00	BBBB
	ATOM	1653	HD22	ASN	192	47.775	44.794	59.012	1.00	0.00	BBBB
	ATOM	1654	C	ASN	192	49.725	42.422	55.327	1.00	23.91	BBBB
	ATOM	1655	O	ASN	192	50.945	42.513	55.405	1.00	24.94	BBBB
	ATOM	1656	N	HIS	193	49.070	42.470	54.169	1.00	20.91	BBBB
30	ATOM	1657	H	HIS	193	48.105	42.354	54.248	1.00	0.00	BBBB
	ATOM	1658	CA	HIS	193	49.767	42.707	52.912	1.00	20.25	BBBB
	ATOM	1659	CB	HIS	193	49.263	41.761	51.834	1.00	20.01	BBBB
	ATOM	1660	CG	HIS	193	49.789	40.375	51.968	1.00	17.79	BBBB
	ATOM	1661	CD2	HIS	193	49.220	39.255	52.470	1.00	16.56	BBBB
35	ATOM	1662	ND1	HIS	193	51.053	40.007	51.553	1.00	18.33	BBBB
	ATOM	1663	HD1	HIS	193	51.743	40.596	51.162	1.00	0.00	BBBB
	ATOM	1664	CE1	HIS	193	51.234	38.723	51.776	1.00	20.03	BBBB
	ATOM	1665	NE2	HIS	193	50.135	38.237	52.335	1.00	19.35	BBBB
	ATOM	1666	HE2	HIS	193	49.908	37.313	52.494	1.00	0.00	BBBB
40	ATOM	1667	C	HIS	193	49.639	44.132	52.422	1.00	22.80	BBBB
	ATOM	1668	O	HIS	193	49.923	44.426	51.253	1.00	29.84	BBBB
	ATOM	1669	N	GLY	194	49.166	45.005	53.296	1.00	20.96	BBBB
	ATOM	1670	H	GLY	194	48.902	44.693	54.183	1.00	0.00	BBBB

-56-

	ATOM	1671	CA	GLY	194	49.081	46.400	52.948	1.00	24.33	BBBB
	ATOM	1672	C	GLY	194	47.666	46.870	52.713	1.00	26.93	BBBB
	ATOM	1673	O	GLY	194	46.698	46.192	53.033	1.00	26.69	BBBB
	ATOM	1674	N	GLU	195	47.552	48.092	52.226	1.00	29.16	BBBB
5	ATOM	1675	H	GLU	195	48.399	48.549	52.034	1.00	0.00	BBBB
	ATOM	1676	CA	GLU	195	46.259	48.704	52.028	1.00	33.78	BBBB
	ATOM	1677	CB	GLU	195	46.428	50.216	51.875	1.00	39.83	BBBB
	ATOM	1678	CG	GLU	195	47.130	50.868	53.070	1.00	50.66	BBBB
	ATOM	1679	CD	GLU	195	46.813	52.348	53.202	1.00	57.04	BBBB
10	ATOM	1680	OE1	GLU	195	46.101	52.716	54.167	1.00	59.34	BBBB
	ATOM	1681	OE2	GLU	195	47.273	53.138	52.344	1.00	59.02	BBBB
	ATOM	1682	C	GLU	195	45.509	48.121	50.830	1.00	33.75	BBBB
	ATOM	1683	O	GLU	195	46.112	47.615	49.876	1.00	32.74	BBBB
	ATOM	1684	N	THR	196	44.185	48.102	50.947	1.00	34.10	BBBB
15	ATOM	1685	H	THR	196	43.806	48.428	51.792	1.00	0.00	BBBB
	ATOM	1686	CA	THR	196	43.301	47.694	49.860	1.00	31.68	BBBB
	ATOM	1687	CB	THR	196	43.282	46.156	49.687	1.00	29.60	BBBB
	ATOM	1688	OG1	THR	196	42.575	45.819	48.494	1.00	29.82	BBBB
	ATOM	1689	HG1	THR	196	43.221	45.594	47.824	1.00	0.00	BBBB
20	ATOM	1690	CG2	THR	196	42.599	45.489	50.864	1.00	28.59	BBBB
	ATOM	1691	C	THR	196	41.882	48.182	50.156	1.00	35.53	BBBB
	ATOM	1692	O	THR	196	41.587	48.676	51.258	1.00	37.07	BBBB
	ATOM	1693	N	SER	197	40.978	47.955	49.210	1.00	34.92	BBBB
	ATOM	1694	H	SER	197	41.230	47.386	48.452	1.00	0.00	BBBB
25	ATOM	1695	CA	SER	197	39.614	48.467	49.318	1.00	35.94	BBBB
	ATOM	1696	CB	SER	197	39.469	49.780	48.532	1.00	35.57	BBBB
	ATOM	1697	OG	SER	197	39.576	49.545	47.140	1.00	38.66	BBBB
	ATOM	1698	HG	SER	197	40.504	49.351	46.898	1.00	0.00	BBBB
	ATOM	1699	C	SER	197	38.645	47.453	48.752	1.00	34.85	BBBB
30	ATOM	1700	O	SER	197	39.049	46.547	48.023	1.00	35.33	BBBB
	ATOM	1701	N	ASP	198	37.357	47.688	48.978	1.00	35.50	BBBB
	ATOM	1702	H	ASP	198	37.148	48.444	49.563	1.00	0.00	BBBB
	ATOM	1703	CA	ASP	198	36.314	46.892	48.341	1.00	34.12	BBBB
	ATOM	1704	CB	ASP	198	34.941	47.470	48.669	1.00	38.91	BBBB
35	ATOM	1705	CG	ASP	198	34.511	47.206	50.096	1.00	42.65	BBBB
	ATOM	1706	OD1	ASP	198	35.030	46.260	50.727	1.00	41.80	BBBB
	ATOM	1707	OD2	ASP	198	33.596	47.923	50.565	1.00	48.05	BBBB
	ATOM	1708	C	ASP	198	36.490	46.878	46.821	1.00	32.19	BBBB
	ATOM	1709	O	ASP	198	36.313	45.851	46.159	1.00	30.03	BBBB
40	ATOM	1710	N	GLU	199	36.900	48.018	46.283	1.00	31.22	BBBB
	ATOM	1711	H	GLU	199	37.225	48.737	46.860	1.00	0.00	BBBB
	ATOM	1712	CA	GLU	199	36.906	48.216	44.845	1.00	32.54	BBBB
	ATOM	1713	CB	GLU	199	36.896	49.714	44.535	1.00	35.99	BBBB

-57-

	ATOM	1714	CG	GLU	199	36.693	50.048	43.064	0.00	35.94	BBBB
	ATOM	1715	CD	GLU	199	36.794	51.537	42.786	0.00	36.71	BBBB
	ATOM	1716	OE1	GLU	199	35.736	52.191	42.663	0.00	36.92	BBBB
	ATOM	1717	OE2	GLU	199	37.927	52.049	42.678	0.00	36.88	BBBB
5	ATOM	1718	C	GLU	199	38.102	47.549	44.182	1.00	33.23	BBBB
	ATOM	1719	O	GLU	199	38.022	47.094	43.042	1.00	35.95	BBBB
	ATOM	1720	N	THR	200	39.211	47.466	44.900	1.00	31.19	BBBB
	ATOM	1721	H	THR	200	39.195	47.740	45.842	1.00	0.00	BBBB
	ATOM	1722	CA	THR	200	40.448	47.014	44.286	1.00	29.88	BBBB
10	ATOM	1723	CB	THR	200	41.550	48.032	44.504	1.00	30.21	BBBB
	ATOM	1724	OG1	THR	200	41.741	48.226	45.912	1.00	33.62	BBBB
	ATOM	1725	HG1	THR	200	42.647	47.966	46.081	1.00	0.00	BBBB
	ATOM	1726	CG2	THR	200	41.169	49.349	43.883	1.00	32.46	BBBB
	ATOM	1727	C	THR	200	40.929	45.671	44.820	1.00	29.23	BBBB
15	ATOM	1728	O	THR	200	42.026	45.222	44.478	1.00	29.48	BBBB
	ATOM	1729	N	LEU	201	40.112	45.022	45.645	1.00	26.09	BBBB
	ATOM	1730	H	LEU	201	39.262	45.438	45.894	1.00	0.00	BBBB
	ATOM	1731	CA	LEU	201	40.495	43.741	46.234	1.00	24.40	BBBB
	ATOM	1732	CB	LEU	201	39.347	43.148	47.081	1.00	23.41	BBBB
20	ATOM	1733	CG	LEU	201	39.696	41.793	47.723	1.00	22.38	BBBB
	ATOM	1734	CD1	LEU	201	40.856	41.971	48.697	1.00	19.43	BBBB
	ATOM	1735	CD2	LEU	201	38.518	41.208	48.436	1.00	20.99	BBBB
	ATOM	1736	C	LEU	201	41.004	42.699	45.222	1.00	24.10	BBBB
	ATOM	1737	O	LEU	201	42.039	42.067	45.458	1.00	21.46	BBBB
25	ATOM	1738	N	LEU	202	40.311	42.538	44.092	1.00	23.29	BBBB
	ATOM	1739	H	LEU	202	39.506	43.062	43.967	1.00	0.00	BBBB
	ATOM	1740	CA	LEU	202	40.734	41.578	43.076	1.00	23.58	BBBB
	ATOM	1741	CB	LEU	202	39.769	41.570	41.881	1.00	22.67	BBBB
	ATOM	1742	CG	LEU	202	40.123	40.532	40.796	1.00	23.83	BBBB
30	ATOM	1743	CD1	LEU	202	40.060	39.135	41.378	1.00	23.97	BBBB
	ATOM	1744	CD2	LEU	202	39.184	40.629	39.609	1.00	24.35	BBBB
	ATOM	1745	C	LEU	202	42.167	41.851	42.583	1.00	24.21	BBBB
	ATOM	1746	O	LEU	202	43.008	40.966	42.636	1.00	25.26	BBBB
	ATOM	1747	N	GLU	203	42.466	43.102	42.246	1.00	24.33	BBBB
35	ATOM	1748	H	GLU	203	41.743	43.756	42.344	1.00	0.00	BBBB
	ATOM	1749	CA	GLU	203	43.797	43.484	41.769	1.00	26.76	BBBB
	ATOM	1750	CB	GLU	203	43.822	44.942	41.347	1.00	30.49	BBBB
	ATOM	1751	CG	GLU	203	43.153	45.233	40.052	1.00	44.95	BBBB
	ATOM	1752	CD	GLU	203	41.698	44.838	40.070	1.00	53.45	BBBB
40	ATOM	1753	OE1	GLU	203	40.954	45.332	40.954	1.00	53.33	BBBB
	ATOM	1754	OE2	GLU	203	41.329	43.967	39.245	1.00	59.22	BBBB
	ATOM	1755	C	GLU	203	44.853	43.314	42.844	1.00	25.56	BBBB
	ATOM	1756	O	GLU	203	45.928	42.792	42.585	1.00	26.26	BBBB

-58-

	ATOM	1757	N	ASP	204	44.567	43.846	44.027	1.00	24.51	BBBB
	ATOM	1758	H	ASP	204	43.705	44.302	44.116	1.00	0.00	BBBB
	ATOM	1759	CA	ASP	204	45.501	43.796	45.156	1.00	26.31	BBBB
	ATOM	1760	CB	ASP	204	44.968	44.665	46.303	1.00	24.27	BBBB
5	ATOM	1761	CG	ASP	204	44.849	46.143	45.911	1.00	30.80	BBBB
	ATOM	1762	OD1	ASP	204	45.337	46.520	44.820	1.00	31.50	BBBB
	ATOM	1763	OD2	ASP	204	44.263	46.935	46.682	1.00	30.67	BBBB
	ATOM	1764	C	ASP	204	45.807	42.370	45.646	1.00	25.41	BBBB
	ATOM	1765	O	ASP	204	46.962	42.039	45.946	1.00	25.28	BBBB
10	ATOM	1766	N	ALA	205	44.800	41.501	45.617	1.00	21.59	BBBB
	ATOM	1767	H	ALA	205	43.910	41.827	45.372	1.00	0.00	BBBB
	ATOM	1768	CA	ALA	205	44.993	40.103	45.971	1.00	20.94	BBBB
	ATOM	1769	CB	ALA	205	43.635	39.417	46.210	1.00	19.51	BBBB
	ATOM	1770	C	ALA	205	45.792	39.335	44.919	1.00	23.38	BBBB
15	ATOM	1771	O	ALA	205	46.581	38.449	45.245	1.00	23.30	BBBB
	ATOM	1772	N	ILE	206	45.561	39.641	43.648	1.00	24.50	BBBB
	ATOM	1773	H	ILE	206	44.861	40.303	43.440	1.00	0.00	BBBB
	ATOM	1774	CA	ILE	206	46.316	38.996	42.577	1.00	23.48	BBBB
	ATOM	1775	CB	ILE	206	45.614	39.219	41.198	1.00	25.93	BBBB
20	ATOM	1776	CG2	ILE	206	46.548	38.880	40.046	1.00	28.83	BBBB
	ATOM	1777	CG1	ILE	206	44.306	38.403	41.140	1.00	24.14	BBBB
	ATOM	1778	CD	ILE	206	44.460	36.916	41.168	1.00	22.80	BBBB
	ATOM	1779	C	ILE	206	47.794	39.462	42.556	1.00	21.88	BBBB
	ATOM	1780	O	ILE	206	48.690	38.647	42.356	1.00	22.55	BBBB
25	ATOM	1781	N	GLU	207	48.053	40.704	42.952	1.00	23.56	BBBB
	ATOM	1782	H	GLU	207	47.305	41.330	43.060	1.00	0.00	BBBB
	ATOM	1783	CA	GLU	207	49.433	41.154	43.183	1.00	24.83	BBBB
	ATOM	1784	CB	GLU	207	49.462	42.580	43.716	1.00	28.57	BBBB
	ATOM	1785	CG	GLU	207	48.898	43.637	42.782	1.00	38.93	BBBB
30	ATOM	1786	CD	GLU	207	49.151	43.327	41.327	1.00	46.17	BBBB
	ATOM	1787	OE1	GLU	207	50.338	43.204	40.949	1.00	46.72	BBBB
	ATOM	1788	OE2	GLU	207	48.157	43.174	40.573	1.00	53.27	BBBB
	ATOM	1789	C	GLU	207	50.150	40.256	44.176	1.00	26.10	BBBB
	ATOM	1790	O	GLU	207	51.250	39.775	43.910	1.00	24.31	BBBB
35	ATOM	1791	N	VAL	208	49.502	39.990	45.311	1.00	26.00	BBBB
	ATOM	1792	H	VAL	208	48.670	40.493	45.482	1.00	0.00	BBBB
	ATOM	1793	CA	VAL	208	50.015	39.009	46.273	1.00	24.95	BBBB
	ATOM	1794	CB	VAL	208	49.129	38.946	47.549	1.00	24.26	BBBB
	ATOM	1795	CG1	VAL	208	49.612	37.844	48.496	1.00	23.70	BBBB
40	ATOM	1796	CG2	VAL	208	49.155	40.275	48.244	1.00	21.67	BBBB
	ATOM	1797	C	VAL	208	50.151	37.597	45.674	1.00	26.78	BBBB
	ATOM	1798	O	VAL	208	51.154	36.911	45.916	1.00	29.35	BBBB
	ATOM	1799	N	CYS	209	49.183	37.171	44.863	1.00	22.50	BBBB

-59-

	ATOM	1800	H	CYS	209	48.377	37.730	44.776	1.00	0.00	BBBB
	ATOM	1801	CA	CYS	209	49.296	35.871	44.203	1.00	25.82	BBBB
	ATOM	1802	CB	CYS	209	48.036	35.546	43.395	1.00	26.60	BBBB
	ATOM	1803	SG	CYS	209	46.543	35.387	44.399	1.00	28.29	BBBB
5	ATOM	1804	C	CYS	209	50.518	35.796	43.277	1.00	26.91	BBBB
	ATOM	1805	O	CYS	209	51.212	34.772	43.229	1.00	25.85	BBBB
	ATOM	1806	N	LYS	210	50.766	36.875	42.537	1.00	29.99	BBBB
	ATOM	1807	H	LYS	210	50.179	37.646	42.629	1.00	0.00	BBBB
	ATOM	1808	CA	LYS	210	51.919	36.947	41.631	1.00	34.45	BBBB
10	ATOM	1809	CB	LYS	210	51.820	38.188	40.737	1.00	33.88	BBBB
	ATOM	1810	CG	LYS	210	50.789	38.051	39.625	1.00	39.79	BBBB
	ATOM	1811	CD	LYS	210	50.793	39.254	38.687	1.00	40.27	BBBB
	ATOM	1812	CE	LYS	210	49.886	40.351	39.183	1.00	37.63	BBBB
	ATOM	1813	NZ	LYS	210	50.066	41.602	38.404	1.00	42.21	BBBB
15	ATOM	1814	HZ1	LYS	210	49.737	41.477	37.425	1.00	0.00	BBBB
	ATOM	1815	HZ2	LYS	210	51.073	41.858	38.408	1.00	0.00	BBBB
	ATOM	1816	HZ3	LYS	210	49.517	42.363	38.853	1.00	0.00	BBBB
	ATOM	1817	C	LYS	210	53.255	36.951	42.395	1.00	35.34	BBBB
	ATOM	1818	O	LYS	210	54.226	36.338	41.956	1.00	37.89	BBBB
20	ATOM	1819	N	LYS	211	53.252	37.513	43.601	1.00	33.64	BBBB
	ATOM	1820	H	LYS	211	52.463	38.041	43.867	1.00	0.00	BBBB
	ATOM	1821	CA	LYS	211	54.402	37.428	44.485	1.00	33.59	BBBB
	ATOM	1822	CB	LYS	211	54.171	38.308	45.710	1.00	37.75	BBBB
	ATOM	1823	CG	LYS	211	54.711	39.721	45.563	1.00	43.42	BBBB
25	ATOM	1824	CD	LYS	211	54.109	40.692	46.592	1.00	46.72	BBBB
	ATOM	1825	CE	LYS	211	53.933	40.053	47.968	1.00	51.43	BBBB
	ATOM	1826	NZ	LYS	211	53.323	41.004	48.941	1.00	56.76	BBBB
	ATOM	1827	HZ1	LYS	211	52.474	41.435	48.539	1.00	0.00	BBBB
	ATOM	1828	HZ2	LYS	211	54.006	41.758	49.162	1.00	0.00	BBBB
30	ATOM	1829	HZ3	LYS	211	53.063	40.507	49.815	1.00	0.00	BBBB
	ATOM	1830	C	LYS	211	54.693	35.984	44.917	1.00	34.73	BBBB
	ATOM	1831	O	LYS	211	55.852	35.548	44.921	1.00	35.11	BBBB
	ATOM	1832	N	PHE	212	53.643	35.231	45.243	1.00	29.19	BBBB
	ATOM	1833	H	PHE	212	52.776	35.679	45.325	1.00	0.00	BBBB
35	ATOM	1834	CA	PHE	212	53.775	33.795	45.490	1.00	26.68	BBBB
	ATOM	1835	CB	PHE	212	52.394	33.176	45.751	1.00	25.71	BBBB
	ATOM	1836	CG	PHE	212	51.936	33.288	47.180	1.00	21.00	BBBB
	ATOM	1837	CD1	PHE	212	51.766	34.545	47.774	1.00	19.39	BBBB
	ATOM	1838	CD2	PHE	212	51.759	32.137	47.950	1.00	21.10	BBBB
40	ATOM	1839	CE1	PHE	212	51.434	34.655	49.131	1.00	20.27	BBBB
	ATOM	1840	CE2	PHE	212	51.426	32.226	49.303	1.00	21.64	BBBB
	ATOM	1841	CZ	PHE	212	51.266	33.497	49.896	1.00	19.69	BBBB
	ATOM	1842	C	PHE	212	54.438	33.069	44.308	1.00	27.94	BBBB

-60-

	ATOM	1843	O	PHE	212	55.379	32.289	44.469	1.00	29.82	BBBB
	ATOM	1844	N	MET	213	53.942	33.347	43.114	1.00	28.49	BBBB
	ATOM	1845	H	MET	213	53.195	33.982	43.073	1.00	0.00	BBBB
	ATOM	1846	CA	MET	213	54.439	32.709	41.909	1.00	31.13	BBBB
5	ATOM	1847	CB	MET	213	53.534	33.080	40.748	1.00	31.76	BBBB
	ATOM	1848	CG	MET	213	52.139	32.540	40.911	1.00	32.92	BBBB
	ATOM	1849	SD	MET	213	51.144	32.918	39.495	1.00	39.38	BBBB
	ATOM	1850	CE	MET	213	51.471	31.457	38.429	1.00	35.56	BBBB
	ATOM	1851	C	MET	213	55.888	33.089	41.596	1.00	32.08	BBBB
10	ATOM	1852	O	MET	213	56.729	32.220	41.400	1.00	30.06	BBBB
	ATOM	1853	N	GLU	214	56.192	34.380	41.688	1.00	36.22	BBBB
	ATOM	1854	H	GLU	214	55.459	34.995	41.879	1.00	0.00	BBBB
	ATOM	1855	CA	GLU	214	57.558	34.879	41.512	1.00	42.62	BBBB
	ATOM	1856	CB	GLU	214	57.613	36.380	41.817	1.00	45.96	BBBB
15	ATOM	1857	CG	GLU	214	57.738	37.265	40.579	1.00	54.19	BBBB
	ATOM	1858	CD	GLU	214	56.753	38.427	40.570	1.00	59.49	BBBB
	ATOM	1859	OE1	GLU	214	56.618	39.120	41.609	1.00	62.81	BBBB
	ATOM	1860	OE2	GLU	214	56.119	38.648	39.513	1.00	61.93	BBBB
	ATOM	1861	C	GLU	214	58.572	34.144	42.392	1.00	44.13	BBBB
20	ATOM	1862	O	GLU	214	59.653	33.783	41.938	1.00	46.23	BBBB
	ATOM	1863	N	ARG	215	58.188	33.867	43.633	1.00	44.81	BBBB
	ATOM	1864	H	ARG	215	57.295	34.167	43.910	1.00	0.00	BBBB
	ATOM	1865	CA	ARG	215	59.052	33.164	44.573	1.00	47.12	BBBB
	ATOM	1866	CB	ARG	215	58.419	33.174	45.959	1.00	49.23	BBBB
25	ATOM	1867	CG	ARG	215	58.442	34.512	46.634	1.00	54.62	BBBB
	ATOM	1868	CD	ARG	215	57.749	34.429	47.970	1.00	59.28	BBBB
	ATOM	1869	NE	ARG	215	57.032	35.662	48.269	1.00	63.64	BBBB
	ATOM	1870	HE	ARG	215	57.427	36.515	47.986	1.00	0.00	BBBB
	ATOM	1871	CZ	ARG	215	55.866	35.700	48.902	1.00	66.38	BBBB
30	ATOM	1872	NH1	ARG	215	55.281	36.866	49.147	1.00	69.59	BBBB
	ATOM	1873	HH1	ARG	215	55.682	37.708	48.788	1.00	0.00	BBBB
	ATOM	1874	HH2	ARG	215	54.403	36.895	49.629	1.00	0.00	BBBB
	ATOM	1875	NH2	ARG	215	55.298	34.569	49.314	1.00	66.82	BBBB
	ATOM	1876	HH21	ARG	215	54.426	34.601	49.803	1.00	0.00	BBBB
35	ATOM	1877	HH22	ARG	215	55.711	33.685	49.101	1.00	0.00	BBBB
	ATOM	1878	C	ARG	215	59.321	31.719	44.166	1.00	48.10	BBBB
	ATOM	1879	O	ARG	215	60.245	31.077	44.670	1.00	49.48	BBBB
	ATOM	1880	N	ASP	216	58.422	31.164	43.369	1.00	47.98	BBBB
	ATOM	1881	H	ASP	216	57.679	31.721	43.049	1.00	0.00	BBBB
40	ATOM	1882	CA	ASP	216	58.530	29.771	42.972	1.00	47.13	BBBB
	ATOM	1883	CB	ASP	216	57.473	28.944	43.711	1.00	47.78	BBBB
	ATOM	1884	CG	ASP	216	57.963	27.553	44.093	1.00	50.19	BBBB
	ATOM	1885	OD1	ASP	216	58.843	26.996	43.395	1.00	51.39	BBBB

	ATOM	1886	OD2	ASP	216	57.431	26.985	45.072	1.00	48.92	BBBB
	ATOM	1887	C	ASP	216	58.355	29.651	41.458	1.00	47.63	BBBB
	ATOM	1888	O	ASP	216	57.382	29.067	40.979	1.00	48.75	BBBB
	ATOM	1889	N	PRO	217	59.337	30.147	40.685	1.00	47.00	BBBB
5	ATOM	1890	CD	PRO	217	60.664	30.580	41.150	1.00	46.27	BBBB
	ATOM	1891	CA	PRO	217	59.102	30.558	39.299	1.00	46.24	BBBB
	ATOM	1892	CB	PRO	217	60.344	31.373	38.953	1.00	45.55	BBBB
	ATOM	1893	CG	PRO	217	60.942	31.740	40.263	1.00	45.13	BBBB
	ATOM	1894	C	PRO	217	58.910	29.393	38.335	1.00	47.66	BBBB
10	ATOM	1895	O	PRO	217	58.407	29.573	37.230	1.00	50.76	BBBB
	ATOM	1896	N	ASP	218	59.325	28.200	38.742	1.00	48.45	BBBB
	ATOM	1897	H	ASP	218	59.857	28.156	39.563	1.00	0.00	BBBB
	ATOM	1898	CA	ASP	218	59.133	27.016	37.912	1.00	53.00	BBBB
	ATOM	1899	CB	ASP	218	60.313	26.054	38.073	1.00	59.27	BBBB
15	ATOM	1900	CG	ASP	218	61.401	26.286	37.038	1.00	62.24	BBBB
	ATOM	1901	OD1	ASP	218	62.264	27.163	37.278	1.00	61.84	BBBB
	ATOM	1902	OD2	ASP	218	61.384	25.592	35.990	1.00	64.66	BBBB
	ATOM	1903	C	ASP	218	57.847	26.266	38.214	1.00	54.01	BBBB
	ATOM	1904	O	ASP	218	57.470	25.352	37.476	1.00	55.95	BBBB
20	ATOM	1905	N	GLU	219	57.221	26.606	39.339	1.00	54.49	BBBB
	ATOM	1906	H	GLU	219	57.552	27.392	39.808	1.00	0.00	BBBB
	ATOM	1907	CA	GLU	219	55.990	25.951	39.789	1.00	53.25	BBBB
	ATOM	1908	CB	GLU	219	55.744	26.201	41.285	1.00	52.75	BBBB
	ATOM	1909	CG	GLU	219	56.022	25.007	42.175	1.00	53.61	BBBB
25	ATOM	1910	CD	GLU	219	55.203	23.766	41.812	1.00	58.48	BBBB
	ATOM	1911	OE1	GLU	219	54.269	23.854	40.975	1.00	58.85	BBBB
	ATOM	1912	OE2	GLU	219	55.486	22.689	42.389	1.00	59.45	BBBB
	ATOM	1913	C	GLU	219	54.766	26.393	39.001	1.00	51.04	BBBB
	ATOM	1914	O	GLU	219	54.415	27.573	38.987	1.00	49.15	BBBB
30	ATOM	1915	N	LEU	220	54.077	25.419	38.421	1.00	50.75	BBBB
	ATOM	1916	H	LEU	220	54.442	24.515	38.500	1.00	0.00	BBBB
	ATOM	1917	CA	LEU	220	52.915	25.686	37.578	1.00	51.68	BBBB
	ATOM	1918	CB	LEU	220	52.817	24.622	36.484	1.00	54.60	BBBB
	ATOM	1919	CG	LEU	220	53.302	24.997	35.084	1.00	58.03	BBBB
35	ATOM	1920	CD1	LEU	220	52.102	25.048	34.146	1.00	59.62	BBBB
	ATOM	1921	CD2	LEU	220	54.038	26.341	35.107	1.00	60.10	BBBB
	ATOM	1922	C	LEU	220	51.600	25.726	38.357	1.00	49.77	BBBB
	ATOM	1923	O	LEU	220	50.638	26.363	37.929	1.00	48.89	BBBB
	ATOM	1924	N	ARG	221	51.605	25.116	39.540	1.00	47.79	BBBB
40	ATOM	1925	H	ARG	221	52.470	25.007	39.968	1.00	0.00	BBBB
	ATOM	1926	CA	ARG	221	50.377	24.679	40.217	1.00	45.16	BBBB
	ATOM	1927	CB	ARG	221	50.680	23.414	41.049	1.00	48.94	BBBB
	ATOM	1928	CG	ARG	221	51.461	22.326	40.282	1.00	51.97	BBBB

-62-

	ATOM	1929	CD	ARG	221	52.261	21.403	41.202	1.00	59.14	BBBB
	ATOM	1930	NE	ARG	221	51.422	20.383	41.840	1.00	71.38	BBBB
	ATOM	1931	HE	ARG	221	50.867	20.658	42.597	1.00	20.00	BBBB
	ATOM	1932	CZ	ARG	221	51.331	19.109	41.447	1.00	75.94	BBBB
5	ATOM	1933	NH1	ARG	221	50.486	18.279	42.061	1.00	75.00	BBBB
	ATOM	1934	HH11	ARG	221	49.905	18.611	42.804	1.00	0.00	BBBB
	ATOM	1935	HH12	ARG	221	50.417	17.331	41.752	1.00	0.00	BBBB
	ATOM	1936	NH2	ARG	221	52.093	18.651	40.453	1.00	77.87	BBBB
	ATOM	1937	HH21	ARG	221	52.745	19.258	39.998	1.00	0.00	BBBB
10	ATOM	1938	HH22	ARG	221	52.024	17.696	40.164	1.00	0.00	BBBB
	ATOM	1939	C	ARG	221	49.715	25.774	41.085	1.00	38.76	BBBB
	ATOM	1940	O	ARG	221	49.451	25.580	42.271	1.00	33.96	BBBB
	ATOM	1941	N	PHE	222	49.467	26.925	40.469	1.00	32.85	BBBB
	ATOM	1942	H	PHE	222	49.676	27.003	39.511	1.00	0.00	BBBB
15	ATOM	1943	CA	PHE	222	48.830	28.062	41.123	1.00	31.95	BBBB
	ATOM	1944	CB	PHE	222	49.698	29.321	40.980	1.00	35.29	BBBB
	ATOM	1945	CG	PHE	222	50.951	29.306	41.830	1.00	40.24	BBBB
	ATOM	1946	CD1	PHE	222	52.100	28.634	41.394	1.00	39.81	BBBB
	ATOM	1947	CD2	PHE	222	50.958	29.904	43.095	1.00	38.34	BBBB
20	ATOM	1948	CE1	PHE	222	53.234	28.540	42.212	1.00	42.53	BBBB
	ATOM	1949	CE2	PHE	222	52.087	29.818	43.927	1.00	40.72	BBBB
	ATOM	1950	CZ	PHE	222	53.229	29.131	43.485	1.00	41.46	BBBB
	ATOM	1951	C	PHE	222	47.485	28.312	40.440	1.00	31.88	BBBB
	ATOM	1952	O	PHE	222	47.438	28.497	39.233	1.00	30.41	BBBB
25	ATOM	1953	N	ASN	223	46.393	28.244	41.195	1.00	25.46	BBBB
	ATOM	1954	H	ASN	223	46.518	28.097	42.159	1.00	0.00	BBBB
	ATOM	1955	CA	ASN	223	45.057	28.452	40.632	1.00	22.95	BBBB
	ATOM	1956	CB	ASN	223	44.389	27.109	40.377	1.00	22.96	BBBB
	ATOM	1957	CG	ASN	223	45.190	26.234	39.440	1.00	30.10	BBBB
30	ATOM	1958	OD1	ASN	223	44.896	26.142	38.249	1.00	39.00	BBBB
	ATOM	1959	ND2	ASN	223	46.227	25.602	39.965	1.00	34.21	BBBB
	ATOM	1960	HD21	ASN	223	46.685	24.977	39.365	1.00	0.00	BBBB
	ATOM	1961	HD22	ASN	223	46.478	25.799	40.881	1.00	0.00	BBBB
	ATOM	1962	C	ASN	223	44.211	29.248	41.608	1.00	20.90	BBBB
35	ATOM	1963	O	ASN	223	44.150	28.908	42.784	1.00	24.24	BBBB
	ATOM	1964	N	ALA	224	43.598	30.324	41.148	1.00	19.58	BBBB
	ATOM	1965	H	ALA	224	43.709	30.554	40.197	1.00	0.00	BBBB
	ATOM	1966	CA	ALA	224	42.785	31.162	42.030	1.00	20.81	BBBB
	ATOM	1967	CB	ALA	224	43.349	32.588	42.086	1.00	17.03	BBBB
40	ATOM	1968	C	ALA	224	41.292	31.199	41.651	1.00	22.36	BBBB
	ATOM	1969	O	ALA	224	40.917	30.985	40.490	1.00	23.63	BBBB
	ATOM	1970	N	ILE	225	40.443	31.332	42.667	1.00	19.57	BBBB
	ATOM	1971	H	ILE	225	40.814	31.262	43.573	1.00	0.00	BBBB

	ATOM	1972	CA	ILE	225	39.022	31.595	42.456	1.00	18.02	BBBB
	ATOM	1973	CB	ILE	225	38.139	30.383	42.880	1.00	17.65	BBBB
	ATOM	1974	CG2	ILE	225	38.420	29.200	41.962	1.00	18.13	BBBB
	ATOM	1975	CG1	ILE	225	38.371	30.016	44.361	1.00	16.24	BBBB
5	ATOM	1976	CD	ILE	225	37.619	28.785	44.847	1.00	14.44	BBBB
	ATOM	1977	C	ILE	225	38.605	32.846	43.220	1.00	19.24	BBBB
	ATOM	1978	O	ILE	225	39.239	33.210	44.219	1.00	20.04	BBBB
	ATOM	1979	N	ALA	226	37.665	33.593	42.648	1.00	16.66	BBBB
	ATOM	1980	H	ALA	226	37.258	33.255	41.826	1.00	0.00	BBBB
10	ATOM	1981	CA	ALA	226	37.224	34.869	43.209	1.00	15.95	BBBB
	ATOM	1982	CB	ALA	226	37.347	35.958	42.154	1.00	12.73	BBBB
	ATOM	1983	C	ALA	226	35.775	34.757	43.679	1.00	18.07	BBBB
	ATOM	1984	O	ALA	226	34.971	34.086	43.019	1.00	18.08	BBBB
	ATOM	1985	N	LEU	227	35.492	35.237	44.894	1.00	18.46	BBBB
15	ATOM	1986	H	LEU	227	36.235	35.501	45.449	1.00	0.00	BBBB
	ATOM	1987	CA	LEU	227	34.105	35.292	45.382	1.00	18.63	BBBB
	ATOM	1988	CB	LEU	227	34.034	35.223	46.910	1.00	17.78	BBBB
	ATOM	1989	CG	LEU	227	32.630	35.026	47.507	1.00	15.56	BBBB
	ATOM	1990	CD1	LEU	227	31.934	33.818	46.849	1.00	11.24	BBBB
20	ATOM	1991	CD2	LEU	227	32.728	34.824	49.026	1.00	16.41	BBBB
	ATOM	1992	C	LEU	227	33.421	36.564	44.889	1.00	18.62	BBBB
	ATOM	1993	O	LEU	227	33.644	37.662	45.423	1.00	22.19	BBBB
	ATOM	1994	N	SER	228	32.617	36.409	43.841	1.00	21.18	BBBB
	ATOM	1995	H	SER	228	32.389	35.506	43.551	1.00	0.00	BBBB
25	ATOM	1996	CA	SER	228	32.101	37.547	43.082	1.00	23.05	BBBB
	ATOM	1997	CB	SER	228	32.340	37.337	41.583	1.00	21.38	BBBB
	ATOM	1998	OG	SER	228	33.717	37.354	41.256	1.00	27.97	BBBB
	ATOM	1999	HG	SER	228	33.938	38.255	40.993	1.00	0.00	BBBB
	ATOM	2000	C	SER	228	30.611	37.740	43.319	1.00	22.96	BBBB
30	ATOM	2001	O	SER	228	29.879	36.774	43.537	1.00	22.70	BBBB
	ATOM	2002	N	ALA	229	30.175	38.994	43.240	1.00	25.88	BBBB
	ATOM	2003	H	ALA	229	30.865	39.687	43.183	1.00	0.00	BBBB
	ATOM	2004	CA	ALA	229	28.755	39.339	43.272	1.00	27.79	BBBB
	ATOM	2005	CB	ALA	229	28.576	40.816	43.037	1.00	26.67	BBBB
35	ATOM	2006	C	ALA	229	27.947	38.557	42.253	1.00	30.41	BBBB
	ATOM	2007	O	ALA	229	28.343	38.421	41.091	1.00	28.94	BBBB
	ATOM	2008	N	ALA	230	26.875	37.943	42.727	1.00	34.26	BBBB
	ATOM	2009	H	ALA	230	26.619	38.098	43.649	1.00	0.00	BBBB
	ATOM	2010	CA	ALA	230	25.932	37.264	41.850	1.00	39.79	BBBB
40	ATOM	2011	CB	ALA	230	26.227	35.769	41.806	1.00	36.23	BBBB
	ATOM	2012	C	ALA	230	24.515	37.521	42.353	1.00	43.03	BBBB
	ATOM	2013	OT1	ALA	230	24.317	38.529	43.082	1.00	45.31	BBBB
	ATOM	2014	OT2	ALA	230	23.610	36.739	41.986	1.00	51.60	BBBB

-67-

[illegible]

[illegible]

[illegible]

-78-

	ATOM	2309	OH2	WAT	W	99	51.721	42.553	47.389	1.00	41.76
		CCCC									
	ATOM	2310	H1	WAT	W	99	51.081	42.890	48.009	1.00	0.00
		CCCC									
5	ATOM	2311	H2	WAT	W	99	51.195	42.024	46.779	1.00	0.00
		CCCC									
	ATOM	2312	OH2	WAT	W	100	20.643	35.624	58.943	1.00	43.37
		CCCC									
10	ATOM	2313	H1	WAT	W	100	20.409	35.144	58.139	1.00	0.00
		CCCC									
	ATOM	2314	H2	WAT	W	100	20.545	36.550	58.745	1.00	0.00
		CCCC									
	ATOM	2315	OH2	WAT	W	101	20.439	26.085	55.577	1.00	39.03
		CCCC									
15	ATOM	2316	H1	WAT	W	101	19.883	26.619	55.020	1.00	0.00
		CCCC									
	ATOM	2317	H2	WAT	W	101	20.888	25.519	54.938	1.00	0.00
		CCCC									
	ATOM	2318	OH2	WAT	W	102	59.643	24.389	43.849	1.00	39.53
20		CCCC									
	ATOM	2319	H1	WAT	W	102	58.961	24.708	44.432	1.00	0.00
		CCCC									
	ATOM	2320	H2	WAT	W	102	59.793	25.086	43.222	1.00	0.00
		CCCC									
25	ATOM	2321	OH2	WAT	W	103	60.566	27.542	41.229	1.00	46.40
		CCCC									
	ATOM	2322	H1	WAT	W	103	59.682	27.689	41.545	1.00	0.00
		CCCC									
	ATOM	2323	H2	WAT	W	103	60.987	27.015	41.915	1.00	0.00
30		CCCC									
	ATOM	2324	OH2	WAT	W	104	15.551	30.295	55.867	1.00	40.24
		CCCC									
	ATOM	2325	H1	WAT	W	104	14.606	30.439	55.676	1.00	0.00
		CCCC									
35	ATOM	2326	H2	WAT	W	104	15.858	29.940	55.028	1.00	0.00
		CCCC									
		END									

40 The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by

the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Structure Determination

Crystals of native and selenomethione-substituted UCH-L3 were grown in space group $P2_12_12_1$ ($a=48.6$ Å, $b=60.8$ Å, $c=81.4$ Å). There is one molecule in the asymmetric unit and the solvent content is 48%. The structure of selenomethione-substituted UCH-L3 was determined at 2.35 Å resolution by the method of multiwavelength anomalous dispersion (MAD) (FIG. 2). The native structure was subsequently refined against 1.8 Å data to an Rvalue of 23.0% (free Rvalue = 28.6%) with good stereochemistry (RMSD bonds = 0.010 Å). The current refined UCH-L3 model contains 205 of the 230 residues. Three regions of UCH-L3 lack defined electron density and have been omitted from the model (residues 1-4, 147-166 and 218). The side chains of Arg-145 and Glu-203 also lack defined density and have been included in the model with occupancy of zero.

Structure of UCH-L3

UCH-L3 has overall dimensions of 43 Å × 32 Å × 37 Å. The structure is organized around a central six-stranded antiparallel β -sheet and two long α -helices. His-169 and Asp-184, which have both been implicated in catalysis, are located at the amino and carboxyl-terminal ends of strands 3 and strand 4 respectively. The right lobe includes a long buried α -helix (helix 4) which contains the active site nucleophile Cys-95, and a cluster of smaller helices. Helix 4 makes predominantly hydrophobic interactions with the β -sheet, several helices, and an extended segment. The active site of UCH-L3 is located between the molecule's two lobes, within a long cleft that appears to be closed in this unliganded structure. As discussed below, the catalytic nucleophile Cys-95, the general base His-169, and Asp-184, form a catalytic triad

that, along with other structural features, resembles the well known family of papain-like cysteine proteases (see FIG. 4).

5 A predicted secondary structure assignment was recently proposed for UCH-L3 and other UCH isozymes (Larsen *et al.*, 1996) using the neural network program of the PredictProtein server (Rost and Sander, 1993). This analysis predicted 34% α -helical content and 17% β -sheet for UCH-L3, which is similar to the observation of 37% α -helix and 20% β -sheet in the crystal structure. The PredictProtein server correctly predicted 5 out of 7 helices, and 3 out of 6 strands. However, a number of
10 important secondary structural elements in the crystal structure are misidentified by the prediction, including helix 4, which contains the active site nucleophile, Cys-95, and strand 4, which terminates one residue before Asp-184, the third member of the catalytic triad.

15 **Comparison with Other Structures**

Although several well characterized classes of enzymes are known to have active site triads that apparently function to orient and activate either cysteine or serine nucleophiles, comparisons show that the papain family of cysteine proteases (Rawlings and Barrett, 1994), has great similarity with UCH-L3. The present
20 inventors compared 21 papain-like structures that have been deposited in the Brookhaven database to UCH-L3 (FIG. 4 and FIG. 5). Of the papain-like structures, 3 are free enzyme, 4 have the active Cys bound either to oxygen atoms, 2-mercaptoethanol or metal ion, and 14 are inhibitor complexes; 13 are of papain, 4 cathepsin B, 3 actinidin, and 1 glycyl endopeptidase. Of the papain-like enzymes,
25 cathepsin B has the structure with greatest overall similarity to UCH-L3 as indicated by a search performed with the Dali algorithm (Holm and Sander, 1993).

Overlap of the UCH-L3 active site triad (Cys-95, His-169, Asp-184) with the active site Cys, His, and Asn of the papain-like enzymes yields RMSD values on the
30 three C $^{\alpha}$ atoms of between 0.07 Å and 0.32 Å for 21 papain-like structures in the

Brookhaven protein data base (FIG. 4). In addition, UCH-L3 Gln-89 is structurally equivalent to Gln-19 of papain, which participates in the formation of a catalytically important structure known as the oxyanion hole (Drenth *et al.*, 1976; Ménard *et al.*, 1991; Schröder *et al.*, 1993). Overlap of all four of these UCH-L3 active site residues on the papain-like enzymes yields RMSD values that range from 0.59 Å to 0.79 Å for C^α atoms, and from 0.84 Å to 1.2 Å for all atoms. Interestingly, the structural similarity extends to three buried water molecules of UCH-L3 that are located between the two lobes of the protein below the active site Cys and His. Two of these water molecules are also found in the papain-like enzymes, with the third site occupied by a serine side chain. It is possible that these conserved water molecules serve architectural roles to allow juxtaposition of the two lobes of the enzyme. It is also possible that they function in catalysis, either by facilitating conformational change (Rashin *et al.*, 1986) or substrate binding (Meyer *et al.*, 1988).

Structural similarity at the active sites suggests that the catalytic mechanism of UCHs will resemble that of the papain-like enzymes (Storer and Ménard, 1994). Thus, it is likely that UCH-L3 Cys-95 and His-169 form a thiolate/imidazolium ion pair, Asp-184 functions to orient the enzyme active site and perhaps to stabilize the protonated form of His-169, and Gln-89 contributes to the oxyanion hole. These roles in catalysis are consistent with mutagenesis data for the Cys, His, and Asp residues of UCH-L1 (Larsen *et al.*, 1996). In the unliganded structure, it appears unlikely that the Cys-95 side chain is deprotonated because the carbonyl oxygen atom of Ser-92 is positioned to form a linear 3.2 Å hydrogen bond with the Cys-95 thiol. It is likely that the thiolate ion will form after displacement of Ser-92, which, as discussed below, is expected to undergo conformational change upon substrate binding.

Starting from overlap on the active-site tetrad C^α atoms, optimal C^α superpositions of UCH-L3 with the papain-like enzymes were obtained using the program LSQMAN (Kleywegt and Jones, 1994). The best overlays were obtained with cathepsin B (Turk *et al.*, 1995) which shows 53 equivalent C^α atoms with a RMSD of 1.6 Å. The second best agreement is found with papain (Kamphuis *et al.*,

1984), which shows 39 equivalent C^α atoms and an RMSD of 1.2 Å. Superposition of UCH-L3 with papain on the 53 C^α atoms of the optimal UCH-L3/cathepsin B overlap resulted in an RMSD of 2.45 Å.

5 Segments of UCH-L3 that have structural equivalents in papain-like enzymes include most of the central antiparallel β-sheet, helix 4 (which contains the active site Cys), and an extended β-like segment adjacent to helix 4 (FIG. 5). The major difference between these structures is that the active site helix precedes the β-sheet in papain, while the active site helix is formed from the sequence following the second
10 β-strand of the sheet in UCH-L3. This may have important functional consequences because it allows the positioning of a disordered loop of 20 residues over the active site of UCH-L3. As discussed below, this loop may play a role in substrate selection by the UCH enzymes.

15 A likely mode of substrate binding to UCH-L3 is suggested by analogy with complexes of papain-like enzymes, in which bound inhibitors occupy either the S or S' sites (FIG. 6). (Substrate residues amino- and carboxyl-terminal to the scissile bond are designated P and P' respectively, and the corresponding binding sites on the enzyme designated S and S') (Schechter and Berger, 1967). The corresponding
20 putative active-site cleft of UCH-L3 is closed by two short segments of the enzyme, which as described below, suggests a location to allow substrate binding. This proposed location for the UCH active site cleft is supported by the clustering of invariant surface-exposed residues in the region of the S site inhibitors of papain-like enzymes (FIG. 6C). This pattern of conserved residues is consistent with the very
25 high specificity of UCH enzymes for ubiquitin, which is expected to bind to the proposed S sites, and the lack of selection for residues following ubiquitin, which are expected to bind in the proposed S' sites.

30 Further insight on substrate binding is provided by the observation that UCH-L3 binds to ubiquitin with a micromolar dissociation constant and that this interaction has a significant electrostatic component (Larsen *et al.*, 1996). It is likely that the

positively charged basic face of ubiquitin (Wilkinson, 1988) will bind to UCH enzymes. Consistent with this idea, UCH-L3 has a molecular surface of almost entirely negative electrostatic potential (Nicholls *et al.*, 1991), including three invariant carboxylates (Glu-10, Glu-14, and Asp-33) at the putative S sites. As shown in FIG. 7, the present invention shows crudely docked ubiquitin against the proposed S sites of UCH-L3 so that electrostatic interactions appear favorable and the flexible C-terminal residues of ubiquitin are positioned analogously to the S site inhibitor of papain-like enzymes, with the ubiquitin C-terminus adjacent to the active site nucleophile, Cys-95. Hydrophobic surfaces on ubiquitin and UCH-L3 are also likely to contribute to the binding interaction.

Substrate Induced Conformational Changes

Comparison with ligand-bound complexes of papain-like enzymes suggests that the specificity of UCH enzymes for ubiquitin adducts may result, in part, from maintenance of an inactive enzyme conformation in the absence of a bound ubiquitin moiety. In the absence of a binding partner, the UCH-L3 active-site cleft appears to be closed by two loops (FIG. 8). The first of these loops includes Leu-9 and Glu-10, which are in van der Waals contact with groups on the opposite side of the cleft, and are in positions incompatible with the placement of papain-like enzyme inhibitors after least squares overlap on active site residues. It also seems likely that residues 11 and 12 will have to move in order to accommodate substrate. Interestingly, Glu-10 is one of the few surface exposed UCH residues that is invariant, and it is possible that binding of positively charged groups on ubiquitin to Glu-10 initiates opening of the UCH active site cleft.

The second loop that appears to block the active site, residues 90-94, spans the catalytic residues Gln-89 and Cys-95, and adopts a conformation that differs from the equivalent region of papain-like structures by displacements of more than 4 Å for the C^α atoms of residues 92 and 93. Consequently, the carbonyl oxygen of UCH-L3 Ser-92 is buried into the oxyanion hole in a position analogous to the oxygen atom of

inhibitors seen in the cysteine protease inhibitor/complex structures. The Ser-92 hydroxyl forms hydrogen bonding interactions with both the thiol and main chain amide of Cys-95. Because the adjacent residue, Asn-93, is both highly exposed and invariant, it is likely that this side chain may participate in substrate binding, thereby providing a mechanism to open the active site. Conformational change in both of the loops that appear to block the active site may be coupled since van der Waals contacts are observed from residue 9 to 93 and from 6 to 93 and 94.

Access to the active site appears to be further restricted by a 20 residue disordered loop consisting of residues 147 to 166 which spans the active site cleft. This loop may exist in several different conformations, and as discussed below, it is likely that it functions in the definition of substrate specificity. The observation of van der Waals contact between residues 7 and 146, and a hydrogen bonding interaction between residues 5 and 146 in the UCH-L3 crystal structure suggests the possibility of a coordinated conformational change upon substrate binding that includes the disordered loop.

Masking of the UCH active site in the absence of bound substrate may function to limit non-specific cleavages by these cytoplasmic proteases. An analogous conformational change probably does not occur for the papain-like enzymes. Inspection of the liganded and unliganded structures in the Brookhaven database shows no significant conformational changes in the enzyme S sites upon binding inhibitor. The papain-like enzymes, which are generally secreted or lysosomal, employ an alternative strategy to limit inappropriate reactions. Inhibitory N-terminal propeptide extensions are cleaved only after import into the lysosome (Carmona *et al.*, 1996; Coulombe *et al.*, 1996; Cygler *et al.*, 1996; Karrer *et al.*, 1993; Turk *et al.*, 1996).

Substrate Specificity

Although UCH-L3 has high specificity for ubiquitin N-terminal to the scissile bond, it is permissive for the residues following ubiquitin provided the adduct is small and unstructured. One possible rationale for the lack of activity against larger folded C-terminal ubiquitin fusions is that only highly extended substrates can be accommodated in a deep narrow groove of UCH S' sites. The UCH-L3 crystal structure does not appear to possess such a groove, however, and thus the ordered protein visible in the crystal structure does not obviously explain the preference of UCH enzymes for small unfolded substrates. Although it is possible that a deep S' site substrate cleft could be formed by conformation change upon binding to a substrate, the very low discrimination shown across a broad range of sequences that are cleaved from the ubiquitin C-terminus argues against this possibility.

Specific UCH Active Site Modifications

More subtle modifications and changes may be made in the structure of the encoded UCH-L3 polypeptides of the present invention and still obtain a molecule that encodes a protein or peptide with characteristics of the natural UCH-L3 polypeptides, including the variants described above. The following is a discussion based upon changing the amino acids of a protein to create an equivalent, or even an improved, second-generation molecule. The amino acid changes may be achieved by changing the codons of the DNA sequence, according to the following codon table, Table A:

Table A

Amino Acid Names and Abbreviations			Codons			
Alanine	Ala	A	GCA	GCC	GCG	GCU
Cysteine	Cys	C	UGC	UGU		
Aspartic acid	Asp	D	GAC	GAU		
Glutamic acid	Glu	E	GAA	GAG		

-86-

Table A (continued)

Phenylalanine	Phe	F	UUC	UUU					
Glycine	Gly	G	GGA	GGC	GGG	GGU			
Histidine	His	H	CAC	CAU					
Isoleucine	Ile	I	AUA	AUC	AUU				
Lysine	Lys	K	AAA	AAG					
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU	
Methionine	Met	M	AUG						
Asparagine	Asn	N	AAC	AAU					
Proline	Pro	P	CCA	CCC	CCG	CCU			
Glutamine	Gln	Q	CAA	CAG					
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU	
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU	
Threonine	Thr	T	ACA	ACC	ACG	ACU			
Valine	Val	V	GUA	GUC	GUG	GUU			
Tryptophan	Trp	W	UGG						
Tyrosine	Tyr	Y	UAC	UAU					

It is known that certain amino acids may be substituted for other amino acids in a protein structure in order to modify or improve its antigenicity or activity (*e.g.*,
5 Kyte and Doolittle, 1982; Hopp, U.S. Patent 4,554,101). For example, through the substitution of alternative amino acids, small conformational changes may be conferred upon a polypeptide which result in increased activity or stability. Alternatively, amino acid substitutions in certain polypeptides may be utilized to provide residues which may then be linked to other molecules to provide peptide-
10 molecule conjugates which retain enough antigenicity of the starting peptide to be useful for other purposes. For example, a selected UCH-L3 peptide bound to a solid support might be constructed which would have particular advantages in diagnostic embodiments.

The importance of the hydropathic index of amino acids in conferring interactive biological function on a protein has been discussed generally by Kyte and Doolittle (1982), wherein it is found that certain amino acids may be substituted for other amino acids having a similar hydropathic index or core and still retain a similar biological activity. As displayed in Table B below, amino acids are assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics. It is believed that the relative hydropathic character of the amino acid determines the secondary structure of the resultant protein, which in turn defines the interaction of the protein with substrate molecules. Preferred substitutions which result in an antigenically equivalent peptide or protein will generally involve amino acids having index scores within ± 2 units of one another, and more preferably within ± 1 unit, and even more preferably, within ± 0.5 units.

Table B

Amino Acid	Hydropathic Index
Isoleucine	4.5
Valine	4.2
Leucine	3.8
Phenylalanine	2.8
Cysteine/cystine	2.5
Methionine	1.9
Alanine	1.8
Glycine	-0.4
Threonine	-0.7
Tryptophan	-0.9
Serine	-0.8
Tyrosine	-1.3
Proline	-1.6
Histidine	-3.2
Glutamic Acid	-3.5
Glutamine	-3.5

Table B (continued)

Aspartic Acid	-3.5
Asparagine	-3.5
Lysine	-3.9
Arginine	-4.5

Thus, for example, isoleucine, which has a hydrophobic index of +4.5, will preferably be exchanged with an amino acid such as valine (+ 4.2) or leucine (+ 3.8).

5 Alternatively, at the other end of the scale, lysine (- 3.9) will preferably be substituted for arginine (-4.5), and so on.

Substitution of like amino acids may also be made on the basis of hydrophilicity, particularly where the biological functional equivalent protein or peptide thereby created is intended for use in immunological embodiments. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, *i.e.* with an important biological property of the protein.

15

As detailed in U.S. Patent 4,554,101, each amino acid has also been assigned a hydrophilicity value. These values are detailed below in Table C.

Table C

Amino Acid	Hydrophilic Index
arginine	+3.0
lysine	+3.0
aspartate	+3.0 \pm 1
glutamate	+3.0 \pm 1
serine	+0.3
asparagine	+0.2

Table C (continued)

glutamine	+0.2
glycine	0
threonine	-0.4
alanine	-0.5
histidine	-0.5
proline	-0.5 \pm 1
cysteine	-1.0
methionine	-1.3
valine	-1.5
leucine	-1.8
isoleucine	-1.8
tyrosine	-2.3
phenylalanine	-2.5

5 It is understood that one amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

10 Accordingly, these amino acid substitutions are generally based on the relative similarity of R-group substituents, for example, in terms of size, electrophilic character, charge, and the like. In general, preferred substitutions which take various of the foregoing characteristics into consideration will be known to those of skill in the art and include, for example, the following combinations: arginine and lysine;
15 glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine (See Table D, below). The present invention thus contemplates functional or biological equivalents of an UCH-L3 or variant UCH-L3 polypeptide as set forth above.

10

Table D

Original Residue	Exemplary Substitutions
Ala	Gly; Ser
Arg	Lys
Asn	Gln; His
Asp	Glu
Cys	Ser
Gln	Asn
Glu	Asp
Gly	Ala
His	Asn; Gln
Ile	Leu; Val
Leu	Ile; Val
Lys	Arg
Met	Met; Leu; Tyr
Ser	Thr
Thr	Ser
Trp	Tyr
Tyr	Trp; Phe
Val	Ile; Leu

Biological or functional equivalents of a polypeptide can also be prepared using site-specific mutagenesis. Site-specific mutagenesis is a technique useful in the preparation of second generation polypeptides, or biologically functional equivalent polypeptides or peptides, derived from the sequences thereof, through specific mutagenesis of the underlying DNA. As noted above, such changes can be desirable where amino acid substitutions are desirable. The technique further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.

In general, the technique of site-specific mutagenesis is well known in the art, as exemplified by Adelman, *et al.* (1983). As will be appreciated, the technique typically employs a phage vector which can exist in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage (Messing, *et al.*, 1981). These phage are commercially available and their use is generally known to those of skill in the art.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector which includes within its sequence a DNA sequence which encodes all or a portion of the UCH-L3 or variant UCH-L3 enzyme polypeptide sequence selected. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example, by the method of Crea *et al.* (1978). This primer is then annealed to the singled-stranded vector, and extended by the use of enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex

is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells such as *E. coli* cells and clones are selected which include recombinant vectors bearing the mutation. Commercially available kits come with all the reagents necessary, except the oligonucleotide primers.

In addition, peptides derived from these polypeptides, including peptides of at least about 6 consecutive amino acids from these sequences, are contemplated. Alternatively, such peptides may comprise about 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60 consecutive residues. For example, a peptide that comprises 6 consecutive amino acid residues may comprise residues 1 to 6, 2 to 7, 3 to 8 and so on of the UCH-L3 protein. Such peptides may be represented by the formula

15

$x \text{ to } (x + n) = 5' \text{ to } 3'$ the positions of the first and last consecutive residues

where x is equal to any number from 1 to the full length of the UCH-L3 protein and n is equal to the length of the peptide minus 1. Where the peptide is 10 residues long ($n = 10-1$), the formula represents every 10-mer possible for each antigen. For example, where x is equal to 1 the peptide would comprise residues 1 to $(1 + [10-1])$, or 1 to 10. Where x is equal to 2, the peptide would comprise residues 2 to $(2 + [10-2])$, or 2 to 11, and so on.

25

Syntheses of peptides are readily achieved using conventional synthetic techniques such as the solid phase method (*e.g.*, through the use of a commercially available peptide synthesizer such as an Applied Biosystems Model 430A Peptide Synthesizer). Peptides synthesized in this manner may then be aliquoted in predetermined amounts and stored in conventional manners, such as in aqueous solutions or, even more preferably, in a powder or lyophilized state pending use.

30

In general, due to the relative stability of peptides, they may be readily stored in aqueous solutions for fairly long periods of time if desired, *e.g.*, up to six months or more, in virtually any aqueous solution without appreciable degradation or loss of antigenic activity. However, where extended aqueous storage is contemplated it will generally be desirable to include agents including buffers such as Tris or phosphate buffers to maintain a pH of 7.0 to 7.5. Moreover, it may be desirable to include agents which will inhibit microbial growth, such as sodium azide or Merthiolate. For extended storage in an aqueous state it will be desirable to store the solutions at 4°C, or more preferably, frozen. Of course, where the peptide(s) are stored in a lyophilized or powdered state, they may be stored virtually indefinitely, *e.g.*, in metered aliquots that may be rehydrated with a predetermined amount of water (preferably distilled, deionized) or buffer prior to use.

Of particular interest are peptides that represent antigenic epitopes that lie within the UCH-L3 polypeptides of the present invention. An "epitope" is a region of a molecule that stimulates a response from a T-cell or B-cell, and hence, elicits an immune response from these cells. An epitopic core sequence, as used herein, is a relatively short stretch of amino acids that is structurally "complementary" to, and therefore will bind to, binding sites on antibodies or T-cell receptors. It will be understood that, in the context of the present disclosure, the term "complementary" refers to amino acids or peptides that exhibit an attractive force towards each other. Thus, certain epitopic core sequences of the present invention may be operationally defined in terms of their ability to compete with or perhaps displace the binding of the corresponding UCH-L3 antigen to the corresponding UCH-L3 -directed antisera.

The identification of epitopic core sequences is known to those of skill in the art. For example U.S. Patent 4,554,101 teaches identification and preparation of epitopes from amino acid sequences on the basis of hydrophilicity, and by Chou-Fasman analyses. Numerous computer programs are available for use in predicting antigenic portions of proteins, examples of which include those programs based upon Jameson-Wolf analyses (Jameson and Wolf, 1988; Wolf *et al.*, 1988), the program

PepPlot® (Brutlag *et al.*, 1990; Weinberger *et al.*, 1985), and other new programs for protein tertiary structure prediction (Fetrow and Bryant, 1993) that can be used in conjunction with computerized peptide sequence analysis programs.

5 In general, the size of the polypeptide antigen is not believed to be particularly crucial, so long as it is at least large enough to carry the identified core sequence or sequences. The smallest useful core sequence expected by the present disclosure would be on the order of about 6 amino acids in length. Thus, this size will generally correspond to the smallest peptide antigens prepared in accordance with the invention.
10 However, the size of the antigen may be larger where desired, so long as it contains a basic epitopic core sequence.

Small Molecule Inhibitors of UCH-L3 Variant Proteins

15 The present invention provides methods for screening and identifying small molecule inhibitors of UCH-L3 proteins and identifies such inhibitors. The rationale behind the design of the small molecule UCH-L3 protein inhibitors is that the structural differences between UCH-L3 proteins, caused by the deviations in the interatomic distances of the amino acid residues in the active site of the protein, will be exploited to design chemical ligands that bind to the active site of the different
20 variant proteins to yield complexes with sufficient thermodynamic stability to effectively inhibit the functional activity of the protein. The inhibited UCH-L3 protein is thus unable to protect the tumor cell against the toxic action of the anticancer agent used to treat it. To obtain appropriate ligands that bind to the active sites of different UCH-L3 variant proteins, the inventors utilize the technique of
25 forcefield docking of chemical fragments from both commercially available chemical fragment libraries, as well as in-house generated libraries, into the active electrophile-binding (H-) site in the derived crystal structure of each variant protein. The docked fragments will be energy-minimized and the binding energies computed and used to select candidate ligands.

30

Generation of UCH-L3 Inhibitors

Generation of inhibitors is accomplished by a rational drug development strategy involving force field docking and energy-minimization of chemical fragments and compounds into the active site of the variant UCH-L3 proteins. The compounds and chemical fragments can be drawn from chemical fragment libraries, such as that available in the Leapfrog database. Additional chemical libraries will be generated as necessary. The active site and other structural components of the variant UCH-L3 proteins will be derived from the published crystal structure of the UCH-L3 encoded protein.

One potential substitution that confers a functional change to the UCH-L3 protein is to replace cysteine 95 with a serine that, in context with other such changes, results in a protein that is more chemically stable and resistant to oxidation and heat. Other proposed changes in this context include substituting aspartic acid 184 for asparagine. Moreover, it is recognized that leucine may be substituted for methionine, or a serine or alanine may be substituted for cystine to result in increased stability. Increased protein stability also results from the addition of disulfide bonds and the creation of more hydrophobic interactions within the protein structure.

Based on the resultant DDH values obtained after energy minimization of chemical fragments/compounds, candidate inhibitors are selected and/or newly constructed from chemical fragments for synthesis and further analyses for their inhibitory or other action on the variant UCH-L3 proteins. Selection criteria for inhibitors for synthesis and further analysis includes lipophilicity, chemical stability and availability or ease of synthesis.

Candidate inhibitors of the present invention may include such molecules as substituted, heterocyclic aromatic compounds, sugar-linked aromatic compounds and other aromatic compounds.

The substituted groups may vary between the different compounds and result in significant changes in binding energies of the compounds in the active site pocket of the UCH-L3 protein. For example, R₁ substitutions of either NH₂ or OH, cause changes in binding energies of almost 10 kcals/mol. Other important substitutions are the alkyl or aminoalkyl substitutions of R₃, and the alkyl, phenyl or 2-pyridyl substitutions of R₄, some of which result in changes in binding energies of greater than 10 kcals/mol.

However it is conceivable that any of the R groups of the substituted isoxazoles may be a phenyl group, a benzyl group, an aryl group, an alkyl group, an aryl group linked to another aryl group through an ester linkage, an aryl group linked to an alkyl group with an ester linkage, an aryl group linked to another aryl group through an ether linkage and aryl group linked to an alkyl group with a thioester linkage, an alkyl group linked to another alkyl group through an ester linkage, an alkyl group linked to another alkyl group through an ether linkage, an alkyl to alkyl linked through an amino group, an aryl to alkyl linked through an amino group, an alkyl group through a disulphide group, an aryl linked to an alkyl group through a disulphide group, an aryl linked to another aryl group through a disulphide group, an alkyl linked to another alkyl group through a thioester linkage, an aryl linked to an alkyl group through a polyester linkage, an aryl group linked to another aryl through a polyester linkage, an alkyl group linked to another alkyl group through a polyamine linkage, an aryl linked to an alkyl group through a polyamine linkage, an aryl group linked to another aryl through a polyamine linkage, an alkyl group linked to another alkyl group through a polythioester linkage, an aryl linked to an alkyl group through a polythioester linkage, an aryl group linked to another aryl through a polythioester linkage.

An individual skilled in the art of organic synthesis in light of the present disclosure is able to prepare or identify a large variety of substituted isoxazoles which would be expected to have UCH-L3 inhibitory effects in the light of the present disclosure.

Screening for Modulators of UCH-L3.

Within certain embodiments of the invention, methods are provided for screening for modulators of UCH-L3 protein activity. Such methods may use labeled
5 UCH-L3 proteins or analogs, anti-UCH-L3 proteins or anti-UCH-L3 antibodies and the like as reagents to screen small molecule and peptide libraries to identify modulators of UCH-L3 protein activity. Within one example, a modulator screening assay is performed in which cells expressing UCH-L3 proteins are exposed to a test substance under suitable conditions and for a time sufficient to permit the agent to
10 effect activity of UCH-L3 proteins.

Assay for Ubiquitin Carboxy Terminal Hydrolase Activity

To perform the assay, purified UCH-L3 or variant UCH-L3 peptide is diluted into 10 mM dithiothreitol (DTT) and allowed to preincubate on ice for 1 h. The
15 standard assay contains 12 μ M UbOEt (ubiquitin carboxy-terminal ethyl ester), 100 mM potassium phosphate, pH 7.2 (37°C), 10 mM dithiothreitol, 0.2 mM EDTA, and enzyme diluted to a final concentration of 0.4 mIU/ml. The reaction is incubated at 37°C and aliquots containing 1-2 g total ester plus hydrolysis product are withdrawn at ten minute intervals and immediately injected onto an HPLC column
20 (C-8, 5 micron, 4 mm \times 250 mm; Altech Associates, Deerfield, IL), flow rate of 1 ml/min in a solvent comprising 25 mM sodium Perchlorate and 0.07% (v/v) perchloric acid in 49% HPLC grade acetonitrile. The absorbance at 205 nm is monitored and the resulting peaks are quantitated by manual integration of the areas.

25 Measurement of Deconjugating Activity

¹²⁵I-ubiquitin was synthesized by the chloramine-T method (Ciechanover *et al.* 1978, Biochem. Biophys. Res. Comm. 81, 1100-1104). ¹²⁵I-ubiquitin was conjugated to the proteins of reticulocyte fractions by incubating the following in a final volume of 0.8 ml: 2 mg/ml of proteins, 3 μ g/ml ¹²⁵I-ubiquitin (1.2×10^6

cpm/ μ g), 50 mM Tris HCl, pH 7.6, 1 mM magnesium chloride, 0.4 mM ATP, 0.4 mM DTT, 2 mM phosphocreatine, 3 units creatine phosphokinase, and 0.1 mM hemin. After incubating 2 h at 37°C, iodoacetamide was added to a final concentration of 10 mM, and was allowed to react for 30 min. at 37°C. Dithiothreitol was then added
5 to a concentration of 50 mM to quench the alkylating agent, and the mixture was chromatographed on a Sephadex G-50 column (1.5 cm \times 60 cm) equilibrated with 50 mM ammonium acetate. The fractions containing 125 I-ubiquitin were located by gamma counting, and the counts in the exclusion volume are pooled. The percentage of ubiquitin incorporated into high molecular weight complexes is about 10%, and
10 this fraction is utilized in deconjugation assays.

To measure deconjugation, the 125 I-ubiquitin conjugates are incubated with 0.01U of the UCH fraction in 50 mM Tris HCl pH 8.0, 0.1 mM EDTA, and 10 mM DTT. After 30 min. or 2 h, the reaction is terminated by the addition of two parts
15 reaction mixture to one part 9% SDS, 15% glycerol, 0.2 M Tris HCl, pH 6.8, and 3 mM EDTA. The samples are then subjected to SDS-PAGE according to standard techniques. The resulting gels dried and sliced into strips. The molecular weight distribution of 125 I-ubiquitin is determined by gamma counting of the gel slices. Rates of deconjugation is calculated by the fraction of counts appearing in the sub-
20 10 kD region relative to the entire lane.

Generally the test substance is added in the form of a purified agent, however it is also contemplated that test substances useful within the invention may include substances present throughout the handling of test sample components, for example
25 host cell factors that are present in a cell lysate used for generating the test sample. Such endogenous factors may be segregated between the test and control samples for example by using different cell types for preparing lysates, where the cell type used for preparing the test sample expresses a putative test substance that is not expressed by the cell type used in preparing the control sample.

30

The active compounds may include fragments or parts of naturally-occurring compounds or may be only found as active combinations of known compounds which are otherwise inactive. However, prior to testing of such compounds in humans or animal models, it may be necessary to test a variety of candidates to determine which have potential.

Accordingly, in screening assays to identify agents which alter the activity of UCH-L3 proteins in for example cancer cells, it is proposed that compounds isolated from natural sources, such as animals, bacteria, fungi, plant sources, including leaves and bark, and marine samples may be assayed as candidates for the presence of potentially useful pharmaceutical agents. It will be understood that the pharmaceutical agents to be screened could also be derived or synthesized from chemical compositions or man-made compounds.

In these embodiments, the present invention is directed to a method for determining the ability of a candidate substance to decrease the UCH-L3 activity of cancer cells, the method including generally the steps of:

- (a) obtaining a cell with UCH-L3 activity;
- (b) admixing a candidate substance with the cell; and
- (c) determining the ability of the candidate substance to inhibit the UCH-L3 activity of the cell.

To identify a candidate substance as being capable of decreasing UCH-L3 activity, one would measure or determine the basal UCH-L3 status of for example a cancer cell prior to any additions or manipulation. One would then add the candidate substance to the cell and re-determine the UCH-L3 activity in the presence of the candidate substance. A candidate substance which decreases the UCH-L3 activity relative to the composition in its absence is indicative of a candidate substance being an inhibitor of UCH-L3.

The candidate screening assay is quite simple to set up and perform, and is related in many ways to the assay discussed above for determining UCH-L3 content.

5 "Effective amounts", in certain circumstances, are those amounts effective at reproducibly decrease UCH-L3 activity in an assay in comparison to their normal levels. Compounds that achieve significant appropriate changes in activity will be used. If desired, a battery of compounds may be screened *in vitro* to identify other agents for use in the present invention.

10 A significant decreases in UCH-L3 activity, are represented by a decrease in UCH-L3 protein activity levels of at least about 30%-40%, and most preferably, by decreases of at least about 50%, with higher values of course being possible. Assays that measure UCH-L3 activity in cells are well known in the art and may be conducted *in vitro* or *in vivo*, and have been described elsewhere in the specification.

15 Quantitative *in vitro* testing of the UCH-L3 inhibitors is not a requirement of the invention as it is generally envisioned that the agents will often be selected on the basis of their known properties or by structural and/or functional comparison to those agents already demonstrated to be effective. Therefore, the effective amounts will
20 often be those amounts proposed to be safe for administration to animals in another context.

EXAMPLE 1: SMALL MOLECULE INHIBITORS OF **UCH-L3 AND UCH-L3 VARIANTS**

25

1. Materials and Methods

Generation of UCH-L3 inhibitors. Generation of inhibitors is accomplished by a rational drug development strategy involving force field docking and energy-minimization of chemical fragments and compounds into the active site of the variant
30 UCH-L3 proteins. The compounds and chemical fragments can be drawn from chemical fragment libraries, such as that available in the Leapfrog database.

Additional chemical libraries will be generated as necessary. The active site and other structural components of the variant UCH-L3 proteins will be derived from the published crystal structure of the UCH-L3 encoded protein. Selection criteria for inhibitors for synthesis and further analysis includes lipophilicity, chemical stability and availability or ease of synthesis.

Synthesis of UCH-L3 Inhibitors. If the identified and/or newly constructed potential inhibitors are not commercially available, then they will be synthesized using standard organic synthetic methodology, including heterocyclic ring construction and functionalization, and electrophilic and nucleophilic substitution reactions. Reaction mixtures will be separated by thin layer, flash silica gel column and high performance liquid chromatography (TLC, CC and HPLC). The compounds will be purified using standard techniques modified as necessary. Characterization of synthetic products will be done by melting point determination, Fourier transform infrared (FT-IR), ultraviolet (UV) and high resolution nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry. Compounds for biological testing will be purified by preparative HPLC. The purity of compounds will be determined by elemental analysis and HPLC.

Source of variant UCH-L3 proteins. To examine the ability of the inhibitors selected from the rational design described above to inhibit the variant UCH-L3 proteins, the present invention will utilize recombinant UCH-L3 proteins expressed in *E. coli* transfected with expression vectors containing the corresponding cDNAs. These vectors have been described elsewhere in this application. The UCH-L3 proteins will be purified by GSH-affinity chromatography on S-hexyl glutathione linked to epoxy-activated sepharose 6B. and then used for enzyme kinetic analysis.

It is also recognized that one may employ a ubiquitin affinity column to purify the UCH-L3 proteins and their variants. In this method, UCH-L3 and or variant UCH-L3 is contacted with activated CH-Sepharose 4B to which ubiquitin is bound. The enzyme forms a thiol ester linkage to the bound ubiquitin in the presence of ATP

and is eluted with AMP plus inorganic pyrophosphate. The amount of functional enzyme is determined from the counts of (³H)ATP made acid insoluble by formation of 1 enzyme equivalent of (³H)AMP-ubiquitin. Treatment of the activating enzyme with iodoacetamide renders it unable to form E_S-ubiquitin but has no effect on formation of E-AMP-ubiquitin (Ross and Warms, *Biochemistry*, 22:4234-4237 (1983)).

Analysis of inhibitors for UCH-L3 inhibitory activity. These studies will be performed using standard enzyme kinetic methodologies. The purified variant UCH-L3 proteins will be mixed with increasing inhibitor concentrations and at different time points, residual deubiquitinating activity will be determined as set forth above.

Synthesis of Isoxazoles. Using the techniques described above, potential UCH-L3 inhibitors such as isoxazoles have been identified. In the synthetic strategy for obtaining isoxazole deubiquitinating inhibitors, the ring system can be achieved by the usual approach of cyclization between hydroxylamine and three-carbon atom component such as 1,3-diketone or an α,β -unsaturated ketone or by a 1,3-dipolar cycloaddition reaction involving nitride oxides with alkenes or an alkyne (Glichrist, 1992).

The first class of compounds are substituted isoxazoles, with the general structure shown in structures 1-3. The substituted groups in the different compounds are represented by R₁, R₂, R₃, and R₄. The substituted groups vary between the different compounds and result in significant changes in binding energies of the compounds in the active site pocket of the UCH-L3 protein. For example, R₁ substitutions of either NH₂ or OH, cause changes in binding energies of almost 10 kcal/mol. Other important substitutions are the alkyl or aminoalkyl substitutions of R₃, and the alkyl, phenyl or 2-pyridyl substitutions of R₄, some of which result in changes in binding energies of greater than 10 kcal/mol.

Another group of potential variant UCH-L3 protein inhibitors identified by the strategy described in this invention are the heterocyclic aromatic compounds. The

binding energies range from -34 to -94 kcal/mol, depending upon the type of compound or substitution.

Antibodies

5 Antibodies to UCH-L3 or UCH-L3 variant peptides or polypeptides may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Patent 4,196,265. Typically, this technique involves immunizing a suitable animal with a selected immunogen composition, *e.g.*, purified or partially purified protein, synthetic protein or fragments thereof, as discussed in the section on
10 polypeptides. Animals to be immunized are mammals such as cats, dogs and horses, although there is no limitation other than that the subject be capable of mounting an immune response of some kind. The immunizing composition is administered in a manner effective to stimulate antibody producing cells. Rodents such as mice and rats are preferred animals, however, the use of rabbit, sheep or frog cells is possible. The
15 use of rats may provide certain advantages, but mice are preferred, with the BALB/c mouse being most preferred as the most routinely used animal and one that generally gives a higher percentage of stable fusions.

For generation of monoclonal antibodies (MAbs), following immunization,
20 somatic cells with the potential for producing antibodies, specifically β lymphocytes (β cells), are selected for use in the MAb generating protocol. These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred, the former because they are a rich source of antibody-producing cells that are in the dividing plasmablast
25 stage, and the latter because peripheral blood is easily accessible. Often, a panel of animals will have been immunized and the spleen of the animal with the highest antibody titer removed. Spleen lymphocytes are obtained by homogenizing the spleen with a syringe. Typically, a spleen from an immunized mouse contains approximately 5×10^7 to 2×10^8 lymphocytes.

The antibody-producing B cells from the immunized animal are then fused with cells of an immortal myeloma cell line, generally one of the same species as the animal that was immunized. Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency and enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of only the desired fused cells, called "hybridomas."

Any one of a number of myeloma cells may be used and these are known to those of skill in the art. For example, where the immunized animal is a mouse, one may use P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 41, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX0 Bul; for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all useful in connection with human cell fusions.

One preferred murine myeloma cell line is the NS-1 myeloma cell line (also termed P3-NS-1-Ag4-1), which is readily available from the NIGMS Human Genetic Mutant Cell Repository by requesting cell line repository number GM3573. Another mouse myeloma cell line that may be used is the 8-azaguanine-resistant mouse murine myeloma SP2/0 non-producer cell line.

Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 proportion, though the proportion may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes. Fusion methods using Sendai virus have been described by Kohler and Milstein (1975; 1976), and those using polyethylene glycol (PEG), such as 37% (v/v) PEG, by Gefter *et al.* (1977). The use of electrically induced fusion methods is also appropriate.

Fusion procedures usually produce viable hybrids at low frequencies, from about 1×10^{-6} to 1×10^{-8} . This does not pose a problem, however, as the viable, fused hybrids are differentiated from the parental, unfused cells (particularly the unfused myeloma cells that would normally continue to divide indefinitely) by culture in a selective medium. The selective medium generally is one that contains an agent that blocks the *de novo* synthesis of nucleotides in the tissue culture media. Exemplary and preferred agents are aminopterin, methotrexate and azaserine. Aminopterin and methotrexate block *de novo* synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis. Where aminopterin or methotrexate is used, the media is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium). Where azaserine is used, the media is supplemented with hypoxanthine.

The preferred selection medium is HAT. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium. The myeloma cells are defective in key enzymes of the salvage pathway, *e.g.*, hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive. The B cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B cells.

This culturing provides a population of hybridomas from which specific hybridomas are selected. Typically, selection of hybridomas is performed by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity. The assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot immunobinding assays, and the like.

The selected hybridomas are then serially diluted and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to

provide MAbs. The cell lines may be exploited for MAb production in two basic ways. A sample of the hybridoma can be injected, usually in the peritoneal cavity, into a histocompatible animal of the type that was used to provide the somatic and myeloma cells for the original fusion. The injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can then be tapped to provide MAbs in high concentration. The individual cell lines could also be cultured *in vitro*, where the MAbs are naturally secreted into the culture medium from which they can be readily obtained in high concentrations. MAbs produced by either means may be further purified, if desired, using filtration, centrifugation and various chromatographic methods such as HPLC or affinity chromatography.

Monoclonal antibodies of the present invention also include anti-idiotypic antibodies produced by methods well-known in the art. Monoclonal antibodies according to the present invention also may be monoclonal heteroconjugates, *i.e.*, hybrids of two or more antibody molecules. In another embodiment, monoclonal antibodies according to the invention are chimeric monoclonal antibodies. In one approach, the chimeric monoclonal antibody is engineered by cloning recombinant DNA containing the promoter, leader, and variable-region sequences from a mouse antibody producing cell and the constant-region exons from a human antibody gene. The antibody encoded by such a recombinant gene is a mouse-human chimera. Its antibody specificity is determined by the variable region derived from mouse sequences. Its isotype, which is determined by the constant region, is derived from human DNA.

In another embodiment, monoclonal antibodies according to the present invention is a "humanized" monoclonal antibody, produced by techniques well-known in the art. That is, mouse complementary determining regions ("CDRs") are transferred from heavy and light V-chains of the mouse Ig into a human V-domain, followed by the replacement of some human residues in the framework regions of their murine counterparts. "Humanized" monoclonal antibodies in accordance with

this invention are especially suitable for use in *in vivo* diagnostic and therapeutic methods for treating *Moroxella* infections.

As stated above, the monoclonal antibodies and fragments thereof according to
5 this invention can be multiplied according to *in vitro* and *in vivo* methods well-known in the art. Multiplication *in vitro* is carried out in suitable culture media such as Dulbecco's modified Eagle medium or RPMI 1640 medium, optionally replenished by a mammalian serum such as fetal calf serum or trace elements and growth-sustaining supplements, *e.g.*, feeder cells, such as normal mouse peritoneal exudate cells, spleen
10 cells, bone marrow macrophages or the like. *In vitro* production provides relatively pure antibody preparations and allows scale-up to give large amounts of the desired antibodies. Techniques for large scale hybridoma cultivation under tissue culture conditions are known in the art and include homogenous suspension culture, *e.g.*, in an airlift reactor or in a continuous stirrer reactor or immobilized or entrapped cell
15 culture.

Large amounts of the monoclonal antibody of the present invention also may be obtained by multiplying hybridoma cells *in vivo*. Cell clones are injected into mammals which are histocompatible with the parent cells, *e.g.*, syngeneic mice, to
20 cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially oils such as Pristane (tetramethylpentadecane) prior to injection.

In accordance with the present invention, fragments of the monoclonal
25 antibody of the invention can be obtained from monoclonal antibodies produced as described above, by methods which include digestion with enzymes such as pepsin or papain and/or cleavage of disulfide bonds by chemical reduction. Alternatively, monoclonal antibody fragments encompassed by the present invention can be synthesized using an automated peptide synthesizer, or they may be produced
30 manually using techniques well known in the art.

The monoclonal conjugates of the present invention are prepared by methods known in the art, *e.g.*, by reacting a monoclonal antibody prepared as described above with, for instance, an enzyme in the presence of a coupling agent such as glutaraldehyde or periodate. Conjugates with fluorescein markers are prepared in the presence of these coupling agents, or by reaction with an isothiocyanate. Conjugates with metal chelates are similarly produced. Other moieties to which antibodies may be conjugated include radionuclides such as ^3H , ^{125}I , ^{131}I , ^{32}P , ^{35}S , ^{14}C , ^{51}Cr , ^{36}Cl , ^{57}Co , ^{58}Co , ^{59}Fe , ^{75}Se , ^{152}Eu , and $^{99\text{m}}\text{Tc}$, are other useful labels which can be conjugated to antibodies. Radioactively labeled monoclonal antibodies of the present invention are produced according to well-known methods in the art. For instance, monoclonal antibodies can be iodinated by contact with sodium or potassium iodide and a chemical oxidizing agent such as sodium hypochlorite, or an enzymatic oxidizing agent, such as lactoperoxidase. Monoclonal antibodies according to the invention may be labeled with technetium- $^{99\text{m}}$ by ligand exchange process, for example, by reducing pertechnate with stannous solution, chelating the reduced technetium onto a Sephadex column and applying the antibody to this column or by direct labeling techniques, *e.g.*, by incubating pertechnate, a reducing agent such as SnCl_2 , a buffer solution such as sodium-potassium phthalate solution, and the antibody.

The present invention contemplates that the exclusion of large ubiquitin fusions from the UCH-L3 active site results from the 20 residue loop between Thr-147 and Val-166 that is disordered in the instant crystals. This loop is topologically distinct from the papain-like enzymes. The ends of the loop are anchored 20 Å apart on opposite sides of the active site Cys-95 and three different classes of conformations can be envisioned for the loop with respect to the proposed UCH-substrate interaction geometry (FIG. 9).

The loop may be sandwiched between the body of UCH-L3 and the ubiquitin moiety of a substrate (red conformation in FIG. 9). This arrangement seems unlikely, however, in light of the probable ubiquitin binding surface on UCH-L3 (see above). Furthermore, the loop sequence is not well conserved, and thus seems poorly suited to

mediate interactions with ubiquitin, for which all UCH enzymes that have been characterized exhibit high specificity.

5 A second possible conformation places the loop over the active site, with residues C-terminal to the scissile bond passing through the loop (blue in FIG. 9). When modeled in a maximally open conformation the loop has an internal diameter of approximately 15 Å, which is suitable for passage of an unfolded extended polypeptide chain, although it is expected to limit passage of even a small folded structure such as an α -helix. A problem with this model is that the *D. melanogaster* UCH is able to cleave ubiquitin from conjugates with the large substrate I κ B α (Roff
10 *et al.*, 1996), and that the *S. cerevisiae* UCH cleaves conjugates from cytochrome c (Cohen).

15 Alternatively, the disordered loop may fold completely away from the proposed ubiquitin-binding surface (magenta in FIG. 9). This conformation would be analogous to the occluding loop of cathepsin B, which is also located along the S' sites and defines the exopeptidase specificity of cathepsin B by making specific interactions with the substrate carboxyl terminus two residues beyond the scissile bond (Turk *et al.*, 1995). An important topological distinction is that, unlike the
20 disordered loop of UCH-L3, the cathepsin B occluding loop does not straddle the active cleft site (in FIG. 5A the occluding loop partially obscures the active site Gln, Cys, and His of cathepsin B).

25 The present invention contemplates changing the topology of the UCH-L3 protein to make it more papain-like in structure, such that the resulting protein is capable of cleaving peptides as well as larger proteins from ubiquitin. In constructing such a molecule, the disordered loop that straddles the active site is reduced or eliminated, thus opening the active site.

30 It is possible that upon binding of ubiquitin adducts, the disordered loop will remain mobile, fluctuating between the extreme magenta and blue conformations of

FIG. 9. Thus, the loop will impede active site access for a wide range of larger substrates, which may eventually attain a productive complex by using either the blue or magenta conformations. It is also possible that the disordered loop plays a more active role in the selection of substrates *in vivo*, perhaps even becoming ordered and contributing directly to binding of some physiological substrates. This model suggests the intriguing possibility that the disordered loops of the different UCH enzymes, which are of similar length but relatively dissimilar sequence identities, function as modular units to confer different substrate specificity on the various UCH isozymes.

Regulating protein degradation by regulating protein deubiquitination can be stimulating or inhibiting degradation. Where protein degradation is to be stimulated a protein whose degradation is ubiquitin-dependent is exposed to a UCH-L3 or mutant UCH-L3 enzyme of the present invention.

Where protein degradation is to be inhibited, a protein whose degradation is ubiquitin-dependent is exposed to a mutant deubiquitinating enzyme of the present invention, which mutant does not catalyze the deubiquitination of proteins.

Exposing can be accomplished *in vitro* or *in vivo*. *In vitro* deubiquitinating processes have application in the industrial bulk production of proteins such as enzymes. A deubiquitinating enzyme of the present invention can be used in such processes to remove ubiquitin from the produced protein or to direct the removal of selected terminal amino acid residues. The use of deubiquitinating enzymes for generating desired amino-terminal residues of proteins is described in United States Patent No. 5,093,242, the disclosure of which is incorporated herein by reference.

Where exposing is accomplished *in vivo*, cells lacking an endogenous deubiquitinating system or cells having a mutation or deficiency in a deubiquitinating enzyme are transfected with a polynucleotide comprising a DNA sequence that encodes a deubiquitinating enzyme. Alternatively, a cell can be transfected with an

expression vector comprising a DNA sequence that encodes a mutant UCH-L3 such that the natural protein degradation pathway for a protein is inhibited.

Processes for destabilizing proteins *in vivo*, producing proteins using ubiquitin fusion and the *in vitro* cleavage of ubiquitin fusion proteins are well known in the art. Descriptions of such processes can be found in United States Patent Nos. 5,122,463, 5,132,213 and 5,196,321, the disclosures of which are incorporated herein by reference. In addition, the nucleotide and amino acid residue sequences of ubiquitin-specific proteases can be found in United States Patent No. 5,212,058, the disclosure of which is incorporated herein by reference.

EXAMPLE 2: SPECIFICITY AND *IN VIVO* ROLES OF UCH ISOZYMES

To further define the specificity and the *in vivo* roles of UCH isozymes, the present inventors tested natural and semi-synthetic ubiquitin derivatives as substrates, with specific emphasis on their potential role in ubiquitin proprotein and polyubiquitin processing. The results suggest that human UCH isozymes L1 and L3 are apparently involved in processing of proubiquitin gene products and small molecular weight ubiquitin adducts, but not larger derivatives of ubiquitin.

Procedures

Materials

Ubiquitin C-terminal hydrolases were prepared as described previously (Larsen *et al.*, 1996). All chemicals were reagent grade or better. Restriction endonucleases and DNA modification enzymes were from New England Biolabs, Beverly, MA. Recombinant human ubiquitin was expressed in *E. coli* and purified as described below.

Subcloning of proprotein genes

The human UbCEP52 and UbCEP80 and the *S. cerevisiae ubi4* proubiquitin genes were excised from pSP72 cloning vector (Monia *et al.*, 1989) by digestion with *EcoRV* and *KpnI*. The cassette was ligated to a 5' *NdeI* site (Klenow polymerase blunted) and the 3' *KpnI* site of the prokaryotic expression vector pRSET B (Invitrogen) with T4 DNA ligase. After transformation of the ligation mixture to Top 10 F' competent *E. coli* (Invitrogen), clones were grown for DNA miniprep and assayed by restriction digestion with *ScaI* and *XhoI* (UbCEP52) or *ScaI* and *BamHI* (UbCEP80). Correct recombinant plasmids were amplified and stored at -20°C in TE buffer (Sambrook *et al.*, 1989). The yeast proubiquitin gene was similarly inserted into the Klenow-blunted pRSET using *EcoRV* and *HindIII*, and colonies were screened with by *XhoI* restriction digests of the isolated plasmids. These ubiquitin proprotein expression plasmids were named pRSUb52, pRSUb80, or pRSyUb5, respectively.

Purification of ubiquitin proproteins

The *E. coli* host strain BL21(DE3) (Invitrogen) was transformed with the appropriate expression vectors described above. For Ub-CEP proteins, the strain BL21(DE3)pLysE was used. Individual colonies were inoculated into 200 ml LB media (Sambrook *et al.*, 1989) supplemented with ampicillin (50 µg/ml) and grown overnight at 37°C. This culture was used to inoculate 2 or 12 liters of LB media. When the optical density (600 nm) of the cultures reached 0.45 (UbCEP) or 0.6 (yUb5), IPTG was added to 0.3 mM, and the cultures were grown for an additional 3 h. The cells were pelleted at 4000 RPM in an RC-3 rotor. Lysozyme was added to 0.1 mg/ml, and the bacteria were incubated for thirty minutes at 37°C, sonicated, and recentrifuged as above. UbCEP52 was purified from the supernatant as described previously (Monia *et al.*, 1989), with additional purification over a 300 ml sephadex G-75SF gel filtration column and MonoS FPLC (Pharmacia)

Recombinant yeast proubiquitin was expressed in *E. coli* and purified by a modification of Jonnalagadda *et al.* (1987). The bacteria were harvested by centrifugation, suspended in 50 mM Tris-Cl, pH 7.8, 1 mM EDTA, and sonicated (Heat Systems). After centrifugation for thirty minutes at $15,000 \times g$, the supernatant was raised to 65°C for five minutes, and centrifuged again as above. The resulting heat stable supernatant was made 85% saturated in ammonium sulfate, stirred gently overnight at 4°C, and was centrifuged for thirty minutes at $10,000 \times g$ in a GSA rotor. The pellet was resolubilized in a minimal volume of water, and after lowering its pH to 4.6 with 1 M acetic acid, was applied to an FPLC Mono S 5/5 column (Pharmacia) in 50 mM NaOAc pH 4.5. Ubiquitin oligomers were eluted in a linear gradient of 0 to 550 mM NaCl. Oligomers which cross reacted with anti-ubiquitin polyclonal antibodies (Accurate Scientific) eluted at 150, 200, 290, 350, and 400 mM NaCl ($n=1$ to 5 ubiquitins respectively). The pooled fractions were dialyzed against 10 mM Tris-Cl, pH 7.6, concentrated by ultrafiltration. The preparation was homogeneous as judged by coomassie-stained SDS-PAGE.

Purification of truncated ubiquitin gene products

To study P' specificity, the truncated ubiquitin gene products, Ub-CEP52¹⁻¹⁰, Ub-CEP80¹⁻¹⁰, and Ub-Ub¹⁻¹⁰ were prepared. Vectors encoding ubiquitin fused to the first ten residues of CEP52 (Ub-IIEPSLRQLA) (SEQ ID NO:1), CEP80 (Ub-GKKRKKKVYT) (SEQ ID NO:2), or Ub (Ub-MQIFVKTLTG) (SEQ ID NO:3). Bacteria harboring the expression plasmids were grown to an A_{600} of 0.6, and induced for protein production with 0.5 mM IPTG. Supernatants were made as above, but with 10 mM DTT in the buffer. The supernatants containing Ub-CEP52¹⁻¹⁰ or the Ub-CEP80¹⁻¹⁰ were heat treated at 86°C for five minutes, cooled to 4°C, and centrifuged at $3,500 \times g$ for 15 min. In most cases, the supernatant was chromatographed on a 1 liter column of G-100 superfine (Pharmacia). The supernatant containing Ub-Ub¹⁻¹⁰ was pretreated with 2.5% perchloric acid and centrifuged. The acid-soluble supernatant was subjected to gel filtration as above. In

all cases, the fusion proteins obtained were homogeneous as judged by Coomassie-stained SDS-PAGE.

Preparation of Ub-amino acid extension proteins

5 A vector library encoding a variety of single amino acids C-terminal to ubiquitin was constructed using the polymerase chain reaction. To create this amino acid library at position 77, the coding region of the pRSUb80 vector (see above) was amplified with a degenerate 3' primer which contained all possible codons followed by a stop codon and a *Hind*III site. The primer sequences were: 5'-ATCCATATGCAGATCTTCG-3' (SEQ ID NO:4), and 10 5'-CAAGCTTCTANNNACCACCACGAAGTC-3' (SEQ ID NO:5). The PCR™ products from this reaction were subcloned *en masse* into pCRII (Invitrogen, San Diego, CA), and 40 minipreps were prepared. Inserts were present in 25 of the 40 minipreps and these inserts were sequenced (Sanger *et al.*, 1977). Clones were 15 identified which encoded D, H, K, P, S, or T at the C-terminus. These were subcloned into pRSET using their *Nde*I and *Hind*III sites. Proteins were expressed and purified by heat denaturation and gel filtration, as described above. One additional clone was recovered due to a deletion in the PCR™ product. This frameshift resulted in a vector encoding N α -ubiquitinyl-PRSLDSC, which was also expressed and purified.

20 *Co-translational processing*

 The kanamycin resistance gene was incorporated into plasmids encoding UCH-L1 or UCH-L3 by insertion of a DNA cassette from pUC4K (Pharmacia). pRSUCH plasmids were digested with *Eco*RI and calf intestinal phosphatase. The 25 kan^r gene cassette was excised from pUC4K with *Eco*RI. After gel purification of the insert and vector fragments, they were ligated and plated onto LB-kanamycin agar plates. The correct transformants were identified by the presence of a unique *Sca*I site in the kan^r cassette, and the amp^r gene was subsequently disabled by excision of an *Ava*II fragment in its center, followed by religation.

To co-express enzymes and putative substrates in the same cell, BL21(DE3) cells harboring either the pRSyUb5, the pRSUb52, or the pRSUb80 plasmid (amp^r) were transformed with a pRSUCH plasmid (kan^r) and plated on LB agar containing both kanamycin and ampicillin to select for co-transformants. Induction with IPTG resulted in co-expression of the selected UCH isozyme along with a putative substrate. Processing was assessed by adding SDS-PAGE sample buffer directly to cell pellets and analyzed by Western blotting using antibodies specific for each substrate.

Other substrates

A plasmid encoding a Ub-R- β -galactosidase fusion protein was obtained from Dr. Alex Varshavsky (pKKUbR β Gal). Synthesis of Ub-R- β -gal was induced as described previously, and the fusion protein was purified as described for UCH, except that the anion exchange resin was eluted with 50 mM Tris-HCl, pH 7.5 and containing 150 mM NaCl. This resulted in significantly purified protein preparation (>80% homogeneous) which was used in gel and HPLC assays of fusion protein processing.

K48-linked diubiquitin (N ϵ -Ubiquitinyl-K⁴⁸Ub) was synthesized *in vitro* by incubation of human recombinant or bovine ubiquitin (Sigma, St. Louis, MO) with the activating and conjugating enzymes of the ubiquitin system (Chen and Pickart, 1990). Incubations contained 50 mM Tris-Cl pH 8.0, 2 mM ATP, 5 mM MgCl₂, 5 mM phosphocreatine, 0.3 units/ml phosphocreatine kinase, 0.3 U/ml inorganic pyrophosphatase, 10 μ g/ml ovalbumin, 30 μ M E2-25k (plasmid obtained from Cecile Pickart), 0.1 μ M E1 from rabbit liver (A. L. Haas), and 5 to 10 mg/ml ubiquitin. Reaction mixtures were incubated at 37°C for 40 min. The E1 and E2 enzymes were removed by passing the reaction mixture over a Mono Q anion exchange column (Pharmacia) at pH 7.6. Polyubiquitin chains were purified by chromatography on Mono S FPLC (Pharmacia) as described above for proubiquitin.

As used herein, the term "polyubiquitin chains" or "polymeric ubiquitin derivatives" are named as follows. The polyprotein ubiquitin gene product (UBI4p in yeast) is referred to as proubiquitin. The products of the UBI1, 2 and 3 genes in yeast are referred to as ubiquitin C-terminal extension proteins (UbCEP). The length of the CEP can be added as a suffix; *i.e.* UbCEP52 or UbCEP76 in yeast. When the C-terminal carboxyl group of ubiquitin is involved in an amide bond, it is referred to as the ubiquitinyl group (Ub). The amino component of this amide bond can be contributed by either the amino terminus of a peptide (N α -ubiquitinyl-peptide) or the ϵ -amino group of lysine (N ϵ -ubiquitinyl-lysine). Where known, the number of the specific lysine in a peptide can be specified as a superscript prefix. Thus, a K48 linked ubiquitin dimer is referred to as N ϵ -ubiquitinyl-^{K48}Ub. A larger polymer of ϵ -linked ubiquitin is referred to as polyubiquitin, with the identity of the specific lysine involved specified as a superscript prefix (*i.e.* ^{K48}polyubiquitin, ^{K63}polyubiquitin, *etc.*).

Also, as used herein, the nomenclature referring to amino acids of the substrate, from the N-terminus, amino acids of the substrate are abbreviated asP3-P2-P1-P1'-P2'-P3'.... The scissile bond is that between the P1 and the P1' residue. The corresponding sites on the enzyme are labeled ...S3-S2-S1-S1'-S2'-S3' *etc.* Other abbreviations are: UBP, ubiquitin-specific processing protease; UCH, ubiquitin C-terminal hydrolase; and SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.

An ϵ -linked ubiquitin dimer missing the C-terminal glycylglycine (N ϵ -ubiquitinyl-^{K48}Ub¹⁻⁷⁴) was synthesized as described above for N ϵ -ubiquitinyl-^{K48}Ub, except that 6 mg/ml of des-glygly-ubiquitin was reacted with 2 mg/ml of native ubiquitin. The reaction was incubated at 37°C overnight. Progress of the synthesis was assayed with HPLC, and terminated by the method outlined above. Under these conditions, polyubiquitin chains are <97% terminated with des-glygly-Ub. The reaction products were separated on Mono S FPLC (Pharmacia).

Ne-Ubiquitinyl-L-lysine and Ne-ubiquitinyl-^{K48}Ub-L-lysine derivatives were synthesized as above except that the reactions included 200 mM to 500 mM concentration of the particular lysine derivative: either N α -acetyl-L-lysine (500 mM),
5 Ne-acetyl-L-lysine (500 mM), L-lysine (200 mM), or N α -acetyl-L-lysine-N-methyl amide (200 mM). These reactions were allowed to incubate overnight at 37°C to assure maximal lysine conjugation. C-8 Reverse phase HPLC was used to monitor these reactions, and the reactions were terminated as described above.

10 *Hydrolysis studies*

Hydrolysis rates were measured by incubating the above substrates with homogeneous UCH-L1 or L3. Conditions for assay were essentially as described previously (Wilkinson *et al.*, 1986). Incubation of UCH was performed at 37°C in
15 50 mM Tris-Cl, pH 7.6, with 5 mM DTT and 50 μ g/ml ovalbumin, for varying amounts of time. Substrate concentrations were 15 μ M, approximately 20-fold higher than the K_m for ubiquitin ethyl ester. Values are reported as the mean and the standard error of the mean for between 6 and 30 determinations. In cases where no catalysis was observed, the substrate was raised to its highest possible concentration.

20 **Results**

P1' specificity

Removal of a single amino acid or small peptide from the C-terminus of ubiquitin must occur during processing of ubiquitin precursors and metabolites (see Table 4). As ubiquitin ethyl ester (Wilkinson *et al.*, 1986) and Ub-DTT (Rose and
25 Warms, 1983) are both rapidly hydrolyzed by UCH isozymes, it was of interest to determine if these enzymes exerted any specificity for residues at the P1' position of ubiquitin fusion proteins². Such specificity might manifest itself in differential rates of cleavage of α -linked amino acid extensions. FIG. 1 shows the hydrolysis rates obtained with UCH-L1 and -L3 isozymes for Ub-pro, Ub-lys, Ub-his, and Ub-asp,

relative to ubiquitin ethyl ester, the inventors' generic reference substrate. The data show that neither UCH isozyme exhibited a strong preference for the P1' residue (1) immediately following ubiquitin, except when it was proline. Ub-amino acid extensions were hydrolyzed by both UCH isozymes at rates only 1 to 2 orders of magnitude more slowly than UbOEt, whereas Ub-Pro was hydrolyzed at about 3 or 5 orders of magnitude more slowly than UbOEt (Table 3). These rates were determined at 15 μ M substrates and probably represent V_{max} values. Thus, these UCH isozymes are not selective with respect to the charge or size of residues at the P1' position when the ubiquitin extension is a single non-proline amino acid residue.

Table 3: Rates of hydrolysis of ubiquitin derivatives by UCH-L1 and UCH-L3

Substrate		UCH-L1 Activity (μ moles/min/mg)		UCH-L3 Activity (μ moles/min/mg)	
		¹ Mean	¹ SEM	¹ Mean	¹ SEM
1.	Ub-[OEt]	30	6.0	110	22
2.	N α -Ub-[L-histidine]	6.0	0.9	26	2.6
3.	N α -Ub-[L-lysine]	7.2	0.7	20	4.0
4.	N ϵ -Ub-[L-lysine]	3.7	1.4	23	4.0
5.	N ϵ -Ub-[N α -acetyl-L-lysine]	6.3	1.3	13	2.6
6.	N α -(Ub- ^{K48} Ub)-[L-lysine]	4.7	0.3	9.9	2.2
7.	N ϵ -(Ub- ^{K48} Ub)-[N α -acetyl-L-lysine]	5.0	1.0	10	2.0
8.	N α -Ub-[L-aspartate]	9.9×10^{-1}	9.0×10^{-1}	15	2.4
9.	N α -Ub-[MQIFVRPR]	1.5×10^{-1}	6.3×10^{-2}	79	8.8
10.	N α -Ub-[MQIFVKTLTG]	6.0×10^{-3}	1.9×10^{-3}	8.8	1.7
11.	N α -Ub-[IIEPSLRQLA]	1.4×10^{-4}	6.6×10^{-5}	8.5	0.9
12.	N α -Ub-[CEP52]	2.1×10^{-4}	4.8×10^{-4}	8.4	5.9
13.	N α -Ub-[L-proline]	3.9×10^{-4}	2.5×10^{-3}	1.3×10^{-1}	8.8×10^{-2}
14.	N α -Ub-[UB]	$<1 \times 10^{-5}$	-	$<1 \times 10^{-5}$	-
15.	N α -Ub-[PRSLDSC]	$<1 \times 10^{-5}$	-	$<1 \times 10^{-5}$	-

Rates of hydrolysis of the indicated substrates are shown. The leaving group is bracketed. The detection limit in this assay is about 1×10^{-5} μ moles/min/mg. ¹The mean and the standard error of the mean were derived from between 6 and 30 replicate measurements.

5

Table 4: Illustrative C-terminal Extensions of the Proubiquitin Gene Product in Various Organisms

Extension	Organism (# Ub repeats)
-AF	<i>Acetabularia cliftonii</i> (9)
-C	<i>Bos taurus</i> (4), <i>Homo sapiens</i> (3)

-120-

Extension	Organism (# Ub repeats)
-DI	<i>Caenorhabditis elegans</i> (11)
-DF	<i>Petroselinum crispum</i> (6)
-F	<i>Geodia cydonium</i> (6), <i>Nicotiniana glauca</i> (6), <i>Pisum sativum</i> (5), <i>Arabidopsis thaliana</i> (5), <i>Glycine max</i> (4), <i>Antirrhinum majus</i> (>3), <i>Sus scrofa</i> (>3), <i>Candida albicans</i> (3), <i>Euplotes eurystomus</i> (3),
-IQA	<i>Drosophila melanogaster</i> (3)
-K	<i>Hordeum vulgare</i> (>2)
-L	<i>Dictyostelium discoideum</i> (5 and 3), <i>Trypanosoma brucei</i> <i>brucei</i> (1)
-M	<i>Aglaothamnion neglectum</i> (6)

Table 4 (continued)

-N	<i>Dictyostelium discoideum</i> (7 and 5), <i>Gallus gallus</i> (3). <i>Phytophthora infestans</i> (3)
-Q	<i>Strongylocentrotus purpuratus</i> (10), <i>Zea mays</i> (7), <i>Oryza sativa</i> (6), <i>Tetrahymena pyriformis</i> (5), <i>Avena fatua</i> (4), <i>Neurospora crassa</i> (4)
-TQTSGKTFMTELTL	<i>Artemius nauplius</i> (>2)
-VYASPIF	<i>Cavia porcellus</i> (4)
-V	<i>Homo sapiens</i> (9)
-Y	<i>Cricetulus griseus</i> (5), <i>Gallus gallus</i> (4), <i>Mus musculus</i> (4)

The proubiquitin genes of most organisms encode head-to-tail repeats of the ubiquitin coding sequence with an additional amino acid or peptide at the C-terminus. A wide variety of residues must be cleaved from the polyubiquitin gene containing a variable number of ubiquitin repeats. Hence, the activity responsible for this cleavage are expected to show little P1' specificity. Note the absence of proline at the junction.

Comparison of peptidase and isopeptidase activities

Because ubiquitin is also conjugated to proteins through an isopeptide bond (*i.e.* through the ϵ -amino group of lysine), it was of interest to examine whether UCH isozymes could cleave Ub- ϵ -amino lysine derivatives. It has been shown that UCH-L3 can hydrolyze both types of bonds (Pickart and Rose, 1985), although absolute rates were not determined. As a model isopeptidase substrate, the inventors synthesized N ϵ -ubiquitinyl lysine by incubation of ubiquitin and lysine with the E1 activating enzyme, the E2-25K conjugating enzyme and ATP. In this synthesis, the excess lysine nucleophile captures the thiolesterified ubiquitin from the transient E2-Ub intermediate, forming exclusively the N ϵ -ubiquitinyl lysine product and halting further synthesis of polyubiquitin by E2-25k. Both UCH isozymes rapidly hydrolyzed N ϵ -linked lysine (FIG. 10). Additionally, the rates were essentially identical to those obtained with N α -linked lysine (Table 2).

Table 2. Refinement Statistics

Resolution Range (Å)	6.0 - 1.8
High resolution shell (Å)	(1.88-1.80)
Rvalue (%) ^a	23.0 (36.9)
Rfree (%) ^b	28.6 (36.4)
rmsd(bonds) (Å) ^c	0.010
rmsd(angles) (°) ^c	1.867
#Residues included (total)	205 (230)
#Atoms with occupancy - 0.0 ^d	10
#Water molecules	121
 (Å ²) Protein/Water	27.9 / 36.6
# ϕ/ψ angles (%): Most Favored ^d	92.8
Additional	6.7
Generous	0.6
Forbidden	0

^a Rvalue = $100 * \Sigma(|F_p(\text{obs})| - |F_p(\text{calc})|) / \Sigma|F_p(\text{obs})|$

^b Rfree = Rvalue for a randomly selected subset (5%) of the data that were not used for minimization of the crystallographic residual (Brünger, 1992a).

^c Stereochemistry was analyzed with PROCHECK (Laskowski *et al.*, 1993).

^d Non-hydrogen atoms only. Atoms of the Arg-145 and Glu-203 side chains were assigned an occupancy of zero because they lack defined electron density.

A more relevant ϵ -linked substrate might be an N ϵ -ubiquitinated peptide similar to the degradation remnants expected to be generated by the action of the proteasome on ubiquitinated proteins. To more closely mimic a peptide bond at the α amino group of an N ϵ -linked lysine, the inventors synthesized and tested N ϵ -ubiquitinyl-(N- α -acetyl)lysine as a substrate. The addition of an acetyl functionality to the α -amino group did not affect the hydrolysis rate of N ϵ -ubiquitinyl-lysine

(FIG. 10). Both isozymes cleaved acetylated and unacetylated substrates at a rate roughly 8 to 10 fold slower than the rate of cleavage of ubiquitin ethyl ester. Subsequent studies showed that there was also no effect of amidating the carboxyl group of lysine with N-methyl amine.

5

Polyubiquitin processing

Because Nε-ubiquitinyl-lysine was a good UCH substrate, the inventors sought to determine if an Nε-diubiquitinyl lysine derivatives were good UCH substrate. If these enzymes function in the removal of a K48-linked remnant peptide from polyubiquitin, they should process lysine derivatives at the C-terminus of polyubiquitin chains. As a model substrate, the inventors synthesized Nε-(Ub-^{K48}Ub)-lysine and Nε-(Ub-^{K48}Ub)-(N-α-acetyl)lysine. The lysine is removed from these polyubiquitin derivatives at rates identical to the simpler Nε-Ub-lysine derivatives, regardless of the presence of a second ubiquitin (FIG. 1). Neither UCH is able to hydrolyze the K48 isopeptide bond. Neither Ub-^{K48}Ub, nor Ub-^{K48}Ub(des-glygly) is cleaved, even at a four-fold molar excess of enzyme for two hours at 37°C. This hydrolysis rate is therefore more than eight orders of magnitude slower than the ubiquitin esterase rate of either enzyme. This suggests that the ubiquitin binding site on UCH isozymes recognizes a face of ubiquitin distant from the K48 linkage site, and suggests that UCH could function in generating a free C-terminus on polyubiquitin chains by the removal of small peptides and/or cellular nucleophiles.

15

20

Fusion peptide processing

It has been postulated that Ubiquitin C-terminal hydrolases could participate in the processing of ubiquitin gene products. It is unlikely that a protein as small as UCH could exhibit specificity for ubiquitin and also a significant portion of the C-terminal extension. Thus, if UCH activity were responsible for processing ubiquitin gene products, then these enzymes would be expected to exhibit specificity for the peptide sequences at the junction between ubiquitin and the C-terminal extension. Model substrates synthesized to test this hypothesis consisted of ubiquitin

25

30

followed by the first ten amino acids of the C-terminal extensions; *i.e.*, Ub-CEP52¹⁻¹⁰ (substrate 11, FIG. 10) and Ub-Ub¹⁻¹⁰ (substrate 10, FIG. 10).

FIG. 10 shows that isozyme L3 exhibited little selectivity for any of the peptide extensions, cleaving them nearly as rapidly as it cleaves single amino acid extensions. This is also consistent with data which suggests that UCH-L3 has no difficulty cleaving a wide variety of peptide substrates from ubiquitin if the peptides are less than about twenty residues. Interestingly, UCH-L1 exhibited considerably more specificity, showing rates of hydrolysis of these substrates that are over two orders of magnitude slower than the rates of L3-catalyzed hydrolysis (Table 3). Still, UCH-L1 exhibits notable selectivity; the Ub-Ub¹⁻¹⁰ substrate is hydrolyzed over forty fold faster than the Ub-CEP¹⁻¹⁰ substrates by this enzyme.

Aside from the natural peptide sequences at the C-terminus of ubiquitin, one other substrate was created. Ub-PRSLDSC, a ubiquitin-peptide fusion with proline at the P' cleavage junction was created by a PCRTM error that resulted in the read-through of the reading frame into the vector multicloning site. Neither enzyme was able to cleave this fusion peptide at a measurable rate, in spite of the fact that UCH-L3 is able to cleave Ub-pro. The hydrolysis rate of these peptide fusions was more than seven orders of magnitude slower than that for UbOEt.

Ubiquitin proprotein processing

Because model substrates containing the first ten residues of ubiquitin proproteins were hydrolyzed by UCH isozymes, the inventors determined the rate of cleavage of full-length ubiquitin gene products by these enzymes. Purified α -linked Ub oligomers were very slow substrates for UCH-L1, and were not cleaved at all by UCH-L3 (FIG. 10). Micromolar UCH-L1 was able to cleave N α -diubiquitin at 37°C *in vitro* with a half-life of thirty minutes. This corresponds to a rate of at least 6 orders of magnitude slower than for UbOEt. UCH-L1 is reported to exist at 1-2 % of total soluble brain protein (Day, 1990).

The zinC-finger fusion proteins UbCEP52 and UbCEP80 are the two other natural ubiquitin proprotein substrates studied. High amounts (100 mU) of either recombinant UCH added to bacterial expression lysates for two hours failed to hydrolyze UbCEP52 or UbCEP80 to their monomeric components, based on immunoblotting of the expression lysates. Because UbCEP52 was more highly expressed than UbCEP80, and because the antibodies to CEP52 had a higher titer and were more specific than the anti-CEP80 antibodies, the UCH-catalyzed hydrolysis of the UbCEP52 protein was further characterized.

Surprisingly, purified UbCEP52 was hydrolyzed by both enzymes, though the L3 isozyme catalyzed the reaction much more rapidly (FIG. 10 and FIG. 11). The rate of processing of UbCEP52 by UCH-L3 approaches the rate of hydrolysis of the Ub-amino acid extensions, about 200 min^{-1} . To confirm the specificity of this reaction, SDS-PAGE and immunoblotting were used to identify the products (FIG. 11). The appearance of ubiquitin and CEP52 detected by SDS-PAGE is consistent with the rates measured by HPLC. UCH-L1 also hydrolyzed the substrate to a measurable degree, but the rate was $2.1 \times 10^{-4} \text{ } \mu\text{moles/min/mg}$, or about 10^{-5} the rate of ester hydrolysis.

The above results suggest that the bacterial lysates contain something which interferes with UbCEP52 hydrolysis, but not with UbOEt hydrolysis. UbCEP52 possesses a C₂H₂ zinC-finger binding motif, so it was determined whether binding of zinc could inhibit the UCH-L3 hydrolysis of UbCEP52. Zn(OAc)₂ (10 mM) did not inhibit UbCEP52 hydrolysis by either enzyme. Whether the zinC-finger motif binds metal *in vivo* remains to be elucidated, however, addition of excess metal ion does not inhibit the processing of the proprotein by UCH.

The presence of a zinc finger motif in a ribosomal protein is presumptive evidence of nucleic acid binding. To test if binding of nucleic acid inhibited processing, assays were performed in the presence of nucleic acids. *In vitro* addition

of 50 µg/ml of either plasmid DNA, or a double stranded 26-base pair DNA cassette inhibited the hydrolysis of UbCEP52 by 50%, whereas a single stranded 42-base pair oligodeoxynucleotide at the same concentration was only minimally effective (FIG. 12). Whole yeast RNA was even better at inhibiting processing, showing 60 to 80% inhibition. Phenol/chloroform extraction of this RNA did not improve the processing, suggesting that the inhibition was not due to other contaminating proteins in the RNA preparation. Also, preincubation of the RNA with RNaseA restored the UbCEP hydrolysis rate back to control rates. These results imply that the nascent proprotein can only be cleaved by UCH before nucleic acids are bound to the fusion peptide, and that assembly into the ribosomal subunit would probably prevent processing.

UCH isozymes can co-translationally process ubiquitin proproteins.

Ubiquitin proproteins are very rapidly processed *in vivo* (Finley *et al.*, 1989; Baker *et al.*, 1992). The UCH isozymes appear to be very efficient at processing peptides from the C-terminus of ubiquitin, but not if the C-terminal extension has a chance to fold into a tight, globular domain (see above). Further, only UCH-L1 is able to rapidly process the proubiquitin precursor, and this isozyme is present at low levels in most tissues. These observations suggest that processing of some ubiquitin gene products may occur before folding or subunit assembly is completed. To test the idea that UCH isozymes can process UbCEPs co-translationally, the inventors co-transformed cells with vectors expressing UCH and Ub proproteins in various combinations. UCH-L1 was found to hydrolyze polyubiquitin (60%) and UbCEP80 (50%), but not the UbCEP52 (>5%) (FIG. 13). This data is consistent with the above data from peptide hydrolysis, in that UCH-L1 prefers to hydrolyze ubiquitin-like peptides and also hydrolyzes the complete proubiquitin, albeit slowly. In contrast, UCH-L3 was found to hydrolyze both Ub-CEP fusions, but not proubiquitin (FIG. 13).

The present invention describes attributes relating to the substrate specificity of two closely related UCH isozymes, UCH-L1 and -L3. The hydrolysis rates reported herein were determined at 15 μ M substrates, approximately the same concentration as that of total ubiquitin in the cell. The K_m for hydrolysis of ubiquitin ethyl ester is approximately 1 μ M and is identical to the ubiquitin binding constant (Larsen *et al.*, 1996). Thus, in the absence of unfavorable interactions between the enzyme and the leaving groups, the measured rates would reflect V_{max} values. With some of the poorer substrates however, the slower observed rates of hydrolysis may be due to higher K_m values for these substrates. Irrespective of the reasons for the slower rates of hydrolysis, it is clear that these differences are manifest at concentrations that are many times that observed in a cell and that the rates reported may overestimate the relative rates of hydrolysis that would pertain *in vivo*.

Ubiquitin binding to the S site(s)

The available evidence suggests that the S sites form an extensive binding site for intact ubiquitin. The only demonstrated activity of UCH isozymes is for cleavage of amide and ester bonds at the C-terminus of ubiquitin. There is little or no affinity for small peptides at the C-terminus of ubiquitin (such as glycylglycine) but ubiquitin is bound with a micromolar binding constant (Larsen *et al.*, 1996). Ubiquitin aldehyde is a tightly-bound inhibitor of these enzymes. Further, NMR measurements have confirmed an extensive area of contact between ubiquitin and UCH-L3; encompassing over 20% of the surface residues on ubiquitin (Wand and Wilkinson) including the C-terminus. This contact surface cannot include the N-terminus of ubiquitin, as a hexahistidine tag at the N-terminus has little or no effect on the rates of hydrolysis. In agreement with this result, it has been shown that these enzymes bind to immobilized (his)₆ ubiquitin (Beers and Callis, 1993). The surface of ubiquitin containing K48 is also not in the S1 recognition site on ubiquitin, as N ϵ -Ub-^{K48}Ub derivatives are good substrates for cleavage of the leaving group from the free C-terminus (FIG. 10 and Table 3). N ϵ -Ub-^{K48}Ub does not appear to be a substrate, probably because the leaving group ubiquitin is tightly folded against the C-terminal

face of the distal ubiquitin. Finally, the interactions between ubiquitin and UCH-L3 are predominantly ionic, as evidenced by the previously observed inhibition of binding and activity by salt (Larsen *et al.*, 1996).

5 S1' Specificity

Many different amino acids and peptides are found as natural extensions of ubiquitin genes in eukaryotes (Table 4). Putative processing enzymes would have to either have broad specificity at the P1' site or exhibit significant sequence variability from species to species in order to accommodate their respective species-specific
10 leaving groups. In fact, UCH sequences are very similar across species, with rat, human and bovine UCH-L1 being over 98% identical. The inventors' results show that UCH isozymes exhibit very little specificity for the P1' residue of ubiquitin substrates (FIG. 10) with essentially identical rates with acidic, basic or neutral
15 leaving groups. If UCH isozymes were responsible for processing the amino acid extensions of ubiquitin gene products, they would exert little selective pressure on the nature of that leaving group. This may be why there seems to be little selective pressure to maintain the identity of this extension amino acid (see Table 4).

20 As both α -, and ϵ -linked derivatives have to be processed from the C-terminus of ubiquitin, the selectivity for cleavage of these two types of amide bonds was examined. These enzymes exhibited little or no discrimination based on the identity of the amide bond to lysine (α vs. ϵ), the charge at the other amine (free amine vs. N-acetyl), or the charge at the carboxyl group (carboxyl vs. N-methyl amide). Further,
25 the same derivatives can be efficiently processed from the C-terminus of the polyubiquitin chain. Thus, at least with small leaving groups, these enzymes could be involved in processing both the amino acid and small peptide extensions of various gene products, as well as the N ϵ -(poly)ubiquitinyl lysine expected to be generated by the action of the proteasome on polyubiquitinated protein substrates.

30

The S site(s) Will Not Bind Larger Protein Domains

FIG. 10 demonstrates that UCH-L3 is generally able to hydrolyze a variety of small peptide fusions at the C-terminus of ubiquitin. To examine if there was any selectivity based upon P' sequences, the inventors have also measured the rates of processing of the ubiquitin gene products and short model substrates consisting of ubiquitin fused to the first ten amino acids of the C-terminal domains.

UCH isozymes exhibit significant selectivity in the processing of the ubiquitin gene products. UCH-L3 is able to efficiently process the Ub-CEP52 gene product, but not the Ub-CEP80 or proubiquitin gene products. Isozyme L1 is only able to slowly process the proubiquitin gene product *in vitro* and *in vivo*. It has been reported that the yeast homolog, YUH1, also exhibits a similar selectivity in that small fusion proteins can be efficiently processed, but not larger fusions (Miller *et al.*, 1989). The drosophila homolog has been reported to be able to process α -ubiquitinyl-I κ B α (314 amino acids), but not larger fusions (Roff *et al.*, 1996).

Interestingly, nucleic acid binding to Ub-CEP52 likely prevented its processing by UCH-L3 (FIG. 12). The addition of nucleic acid to UbOEt had no effect on its hydrolysis, suggesting that the nucleic acid was directly binding to Ub-CEP52 and causing a conformational change which prevented processing. The binding of nucleic acid by Ub-CEP52 is not unexpected; the CEP domain contains a zinc-finger motif, the protein is a ribosomal subunit, and mutants in this gene are defective in rRNA processing.

The above results suggest that the selectivity of the S' sites may be based on factors other than size. One factor could be the accessibility of the peptide bond at the C-terminus of ubiquitin. It might be expected that ubiquitin fusion proteins with significant mobility and flexibility at the junction could be good substrates while those that are more constrained (proline) and/or sterically restricted (large) would be poor substrates. This is consistent with the ligand-induced inhibition described above

(*i.e.* binding of nucleic acid may cause a less mobile conformation around the Ub-CEP52 junction) as well as the restricted nature of the substrate binding cleft observed in the UCH-L3 crystal structure (Johnston *et al.*, 1997).

5 **Substrate Specificity Based on the P' Peptide Sequence**

An alternative explanation for the observed selectivity in processing of ubiquitin gene products is that the enzymes may exhibit significant selectivity based on the amino acid sequences binding to the S' sites. To examine the contribution of the P' residues to the observed selectivity, the inventors have used model substrates
10 consisting of ubiquitin fused to small peptides, including the first ten amino acids of each ubiquitin gene product. FIG. 10 demonstrates that UCH-L3 is not very selective for the P' residues, processing every small peptide tested except those containing proline at the scissile bond. This specificity is similar to that reported for the yeast UCH; *i.e.* ubiquitin extended by E, C, D, G, T, or M (but not P) was hydrolyzed
15 efficiently (Miller *et al.*, 1989). This may be because the secondary amine of the proline has a somewhat higher pK_a than the primary amino group in the peptide bond of most amino acids, or it may reflect a steric constraint imposed at the scissile bond. UCH-L3 is unable to process at proline in the Ub-PRSLDSC peptide fusion. It is likely that the presence of proline at the P1' position "kinks" the peptide such that it
20 can not be accommodated in the active site cleft. The presence of a proline at position P4' (Ub-CEP52¹⁻¹⁰, substrate 11) or P7' (Ub-Ub¹⁻⁵-RPR, substrate 9) has little effect on the rate of peptide processing by UCH-L3, suggesting that the cleft may be considerably less restricted at that distance from the active site nucleophile. The Ub-Ub¹⁻¹⁰ construct is processed very effectively by UCH-L3, but the Ub-Ub fusion
25 protein is not cleaved at all, reinforcing the conclusion that a tightly folded domain at the C-terminus of ubiquitin is not generally a substrate for these enzymes.

In contrast to the permissiveness of UCH-L3 processing, the processing by UCH-L1 is more selective, with ubiquitin related peptide fusions being reasonable
30 substrates and Ub-CEP52¹⁻¹⁰ being a poor substrate. While it is not clear whether this

selectivity is due to subsite specificity at P1'-P3', or the presence of proline in sites P4'-P7', it is clear that this is a much more selective enzyme. This specificity may be related to interactions with an occluding loop which is postulated to form part of the S' sites on the UCH family of enzymes.

5

Co-translational Processing

These results demonstrate that there is considerable selectivity in the processing of ubiquitin gene products by these UCH isozymes. UCH-L3 appears to prefer processing of Ub-CEP gene products, while UCH-L1 is very selective for the proubiquitin gene product. There is, however, some question as to the physiological significance of these processing events, especially those catalyzed by UCH-L1 which occur at an extremely slow rate. This led the inventors to ask if these enzymes might be involved in co-translational processing. Normal processing is known to be extremely efficient, with no evidence for accumulation of intermediates in the process. Further, if these enzymes are involved in processing, they must act before significant assembly into ribosomal subunits, and/or folding of stable domains C-terminal to ubiquitin. When enzyme and substrate were co-expressed in *E. coli*, the efficiency of processing was high and the selectivity was similar to that observed above. UCH-L1 was able to process over 80% of the proubiquitin gene product, and little of the Ub-CEP gene products, while UCH-L3 was most efficient in processing the Ub-CEP fusion proteins (> 50% processed). Thus, it appears that processing is much more efficient if the enzyme is present during the synthesis of the substrate. Confirmation of this phenomenon was attempted by demonstrating the association of UCH-L3 with polyribosomes synthesizing the substrates. When an *in vitro* transcription/translation system is supplemented with DNA encoding the substrate, endogenous UCH activity is found exclusively in the soluble fractions. Even upon addition of exogenous UCH isozymes, little or no UCH activity can be found stably associated with the ribosomes. It may be that the association is only fleeting and unstable, or it may be that processing occurs after release of the substrate polypeptide from the ribosome but before folding of the complete protein.

30

Molecular Basis of Specificity

As shown above, the x-ray crystal structure of UCH-L3 has a core catalytic structure that strongly resembles cathepsin B, a papain-like protease. The active site groove is occluded by two loops, and it is postulated that a substrate-induced conformational change is required to clear the cleft and allow access to the active-site cysteine. Thus, only ubiquitin derivatives are substrates because only they can form the extensive interactions with the S' site required to trigger the necessary conformational change generating the active conformation of the enzyme.

Specificity for P' residues must be determined by the residues lining the corresponding S' sites on the UCH enzymes. The sequence of these proteins varies widely in several areas, including a region just N-terminal to the active site histidine. This sequence is disordered in the UCH-L3 structure, but may be positioned to form a significant contact region with the P' residues of substrates (Johnston *et al.*, 1997). Thus, it is likely that this hypervariable region is important in determining substrate selectivity and the somewhat shorter loop near the active site cysteine in UCH-L1 restricts the possible substrates by conferring a narrower or more restricted active site cleft. These predictions could be tested by obtaining the structure of UCH-L1 and/or using site directed mutagenesis and domain swapping approaches.

Potential Physiological Roles for UCH Isozymes

The possible physiological roles for UCH isozymes are limited by the temporal and spatial patterns of expression of the enzymes and putative substrates, as well as by restrictions imposed by the substrate specificity examined here. With respect to the former, there is a marked tissue specificity to the expression of UCH isozymes, with UCH-L1 being expressed at very high levels in neural and diffuse neuroendocrine tissues, and UCH-L3 being expressed primarily in hematopoietic tissues (Wilkinson *et al.*, 1992). There is little evidence of temporal regulation, as these enzymes seem to be present in all stages of the cell cycle and both early and late

in development. A third isozyme, UCH-L2 has been reported to be widely distributed, albeit at lower levels than either of the two isozymes studied here (Wilkinson *et al.*, 1992).

5 The distribution of putative substrates is more difficult to assess, although the results discussed above suggest that substrates will include the ubiquitin proproteins and small molecule adducts of ubiquitin. The latter are expected to be widely distributed, as there is extensive activation and conjugation of ubiquitin in all tissues examined. All of the intermediates in the enzymatic activation of the C-terminus of
10 ubiquitin are thiol esters and they are effectively trapped by reaction with small molecular weight thiols and amines. There is a much more specific expression of ubiquitin pro-proteins. Rapidly growing cells have been shown to express high levels of ubiquitin-ribosomal fusion proteins, while more differentiated cells (such as neurons), express ubiquitin primarily from the proubiquitin locus.

15 These considerations suggest that UCH-L1, the neuronal specific isozyme, may be more efficient at cleaving the proubiquitin precursor, while the hematopoietic specific UCH-L3 might prefer ubiquitin ribosomal fusion proteins as substrates. These predictions are borne out using ubiquitin fusion peptides as substrates. UCH-
20 L1 is found at high levels only in neurons and diffuse neuroendocrine tissues, and it cleaves the proubiquitin model substrate (Ub-Ub¹⁻¹⁰, substrate 10) much faster than it cleaves the ubiquitin ribosomal fusion protein model substrate Ub-CEP52¹⁻¹⁰ (substrate 11). UCH-L3 on the other hand can cleave all the model substrates at a significant rate. The specificity of co-translational cleavage of the full length gene
25 products reflects the results with small peptide fusions, implying that a portion of the UCH specificity derives from interactions with P' residues. Large, tightly folded leaving groups are not substrates for this class of enzyme, although there are differences in the selectivity demonstrated by each enzyme.

30 These results support the idea that UCH enzymes are responsible for co-translational processing of the polymeric ubiquitin gene products and/or salvage of

ubiquitin from small molecular weight adducts. Only ubiquitin derivatives will be substrates, probably because of the obligatory substrate-induced conformational change required to generate the active enzyme. Isozymic differences may be due to sequence differences in the hypervariable loop region and presumably reflect the metabolic flux of the tissues wherein these isozymes are expressed, although confirmation of this role awaits identification of mutations in these loci or development of transgenic animal models.

EXAMPLE 3 - SUBSTRATE BINDING AND CATALYSIS BY UBIQUITIN C-TERMINAL HYDROLASES

There are several polymeric ubiquitin structures which contribute to the biology of ubiquitin. Ubiquitin is post-translationally conjugated to a variety of proteins present in the cell. Proteins can be multiubiquitinated by the addition of ubiquitin to several surface lysines or polyubiquitinated by the addition of ubiquitin to one surface lysine followed by the addition of another ubiquitin to K48 of the first ubiquitin. Long polymeric chains can thus be assembled by the conjugation of ubiquitin to the distal end of this chain. These polyubiquitinated proteins are then degraded by the 26S proteasome to yield free amino acids and the polyubiquitin chain (Eytan *et al.*, 1989; Hough *et al.*, 1987). The ubiquitin isopeptide bond linking these subunits must be hydrolyzed by the action of specific proteases. This hydrolysis is necessary to salvage ubiquitin for conjugation as well as to prevent the accumulation of free polyubiquitin chains which are known to bind to the 26S proteasome and inhibit proteolysis (Deveraux *et al.*, 1994). The inventors have recently shown that this reaction is catalyzed by a 93 kDa protein termed isopeptidase T (Wilkinson *et al.*, 1995).

In addition to isopeptide-linked polymeric ubiquitin, the cell must also proteolytically process polymeric ubiquitin linked by peptide bonds. Ubiquitin is always translated from mRNA as a fusion protein, either with additional copies of ubiquitin itself or with one of two different zinc fingers (Ozkaynak *et al.*, 1987). The proubiquitin gene product consists of multiple copies of ubiquitin, is induced by

stress, and must be processed to monomeric ubiquitin by the action of a processing protease (Finley *et al.*, 1987. Similarly, two ubiquitin-zinc finger fusion proteins are synthesized in rapidly growing cells. They must be accurately processed to free ubiquitin and the zinc finger CEP52 and CEP80, which are ribosomal proteins (Finley *et al.* 1989).

The proteolytic processing of both α - and ϵ -amide linked ubiquitin occurs at the carboxyl group of glycine 76, suggesting that such processing proteases might have specificity for binding the ubiquitin monomer. Several proteases with these properties have been described, including those known as ubiquitin C-terminal hydrolases (Pickart and Rose, 1985), ubiquitin specific proteases (Tobias and Varshavsky, 1991; Baker *et al.*, 1992), or isopeptidases (Matsui *et al.*, 1982). These proteases can be grouped into two families. The ubiquitin-specific protease family (UBP) consists of several distantly-related proteases of 50-300 kDa which show several homologies around an active site thiol and a putative active site histidine. (Abbreviations used: CD, circular dichroism; DTT, DL-dithiothreitol; EDTA, ethylenediaminetetraacetic acid; IPTG, isopropyl β -D-thiogalactopyranoside; MES, 2-[N-morpholino]ethanesulfonic acid; PAGE, polyacrylamide gel electrophoresis; PCRTM, polymerase chain reaction; PMSF, phenylmethylsulfonyl fluoride; SDS, sodium dodecyl sulfate; Tris, tris(hydroxymethyl)aminomethane; Ub, ubiquitin; UbOEt, ubiquitin ethyl ester (Wilkinson *et al.*, 1986); UBP, ubiquitin specific proteases (Baker *et al.*, 1992); UCH, ubiquitin carboxyl-terminal hydrolase (Wilkinson *et al.*, 1989). This family is also known as UCH family 2 and includes at least 11 members in yeast with other known homologues in mammals and *Drosophila* (Papa and Hochstrasser, 1993; Wilkinson *et al.*, 1995). They are thought to be involved with processing various ubiquitin-protein fusions expressed in eukaryotic cells and/or the polyubiquitin degradation signal (Tobias and Varshavsky, 1991; Baker *et al.*, 1992, Wilkinson *et al.*, 1995). The ubiquitin carboxyl-terminal hydrolase (UCH) family is a group of small, closely-related thiol proteases consisting of three mammalian isozymes (Wilkinson *et al.*, 1989) and with close homologues in *Saccharomyces cerevisiae* (Liu *et al.*, 1989) and *Drosophila melanogaster* (Zhang *et*

al., 1993). They exhibit no apparent homology to the UBP family, and this dissimilarity implies two functionally convergent ancestral genes. The presence of multiple, tissue specific UCH isozymes (Wilkinson *et al.*, 1992) suggests that the metabolism of ubiquitin may also be tissue specific. These enzymes prefer small leaving groups and/or extended peptide chains at the C-terminus of ubiquitin. It is postulated that they are involved in the co-translational processing of the proubiquitin and ubiquitin-zinc finger fusion proteins which are the ubiquitin gene products. It is not clear how any of these processing proteases distinguish among the several types of polymeric ubiquitin or achieve hydrolytic specificity. Since many, if not all of them, bind ubiquitin, their hydrolytic specificities and *in vivo* rates may depend on the specific recognition of leaving group peptides, side chains, or proteins in the non-ubiquitin portion of the substrate the P' site according to the nomenclature of Schechter and Berger (1967).

The UCH class of proteases is unique in several ways. Firstly, they appear to represent a new family of thiol proteases, as there is no apparent sequence homology to any other proteases. As such, the structure and function of these proteins is of general interest. Secondly, they are extremely specific, cleaving only after the C-terminal glycine of ubiquitin. Recombinant UCH's can be expressed in high amounts in *Escherichia coli*, do not form inclusion bodies, and are nontoxic to the host. This is consistent with the enzymes having a very narrow spectrum of proteolytic specificity. In contrast with members of the papain super-family, which exhibit broad P site specificity (Fox *et al.*, 1995), UCH's show strict and narrow P site specificities for the RGG C-terminus of Ub. Finally, these enzymes are mechanistically unique in that binding of ubiquitin results in a finite equilibrium of thiol ester between the C-terminus and the active site thiol of the protease. Thus, the enzyme- substrate complex (ubiquitin + UCH-L3) can be reduced by borohydride to give the thiohemiacetal of the protease and ubiquitin aldehyde (Pickart and Rose, 1986). The energy required to form even a small amount of intermediate thiol ester must result from extensive binding interactions between ubiquitin and the protease. For these reasons, a more detailed structural analysis of the UCH family is of interest.

The inventors previously reported four UCH activities from bovine thymus with specificity for cleavage of the C-terminal ethyl ester of ubiquitin (Mayer and Wilkinson, 1989). Three of these enzymes are approximately 25 kDa in size, while the fourth activity is of higher molecular weight and is less well understood. These ~25 kDa activities are named UCH-L1, UCH-L3 and UCH-L3 on the basis of their order of elution from a DE-52 anion exchange matrix, and the inventors have found UCH-L1 to be identical to the protein PGP 9.5 (Wilkinson *et al.*, 1989). This hydrolase is most highly expressed in neuronal and neurosecretory tissues. Additionally, it is selectively accumulated (along with ubiquitin conjugates) in the plaques of Alzheimer's disease as well as in lesions of other neurodegenerative diseases (Lowe *et al.*, 1990). In the present work, UCH-L1 was cloned and mutagenized, and three important residues were identified, including the active site cysteine and histidine. Various spectral characterizations demonstrate that UCH contains α/β folding motifs and that the UCH mutants studied demonstrate normal parameters of thermal denaturation. Thus, these residues appear to be unimportant for protein folding or stability. As UCH-L1 is insoluble above 1.5 mg/mL, the physical characteristics of a more tractable isozyme, UCH-L3, were studied. The inventors find that ubiquitin binding to this isozyme is stoichiometric and inhibited by salt. These data provide the first detailed analysis of the binding of ubiquitin with one of its adjunct enzymes, and so provides additional insights into the nature of the ubiquitin UCH protein-protein binding interactions.

PROCEDURES

UCH Cloning and Subcloning. The cDNA encoding UCH-L3 from the plasmid pBHA (Wilkinson *et al.*, 1989) was subcloned into the T7 expression vector pRSET (Invitrogen, San Diego, CA). Plasmids pBHA and pRSET were digested with *NdeI* and *EcoRI* (New England Biolabs, Beverly, MA). The 780 bp UCH-3 insert and the 2810 bp vector were gel-purified and ligated, and the resultant plasmid was used to transform Top 10 F' *E. coli* (Invitrogen). Colony minipreps were screened, and

several which were linearized by *Nde*I to give a 3.5 kb linear fragment were selected. An insert from a positive clone was sequenced to verify the integrity of the plasmid ("pRS-UCHL3") and was used to transform the *E. coli* expression host BL21(DE3) (Novagen). On IPTG induction, cells with this plasmid overexpressed a 25 kDa protein which cross-reacted with anti-human UCH-L3 polyclonal antibodies. Cytosol from the sonicated cells showed significant enzymatic activity in cleaving ubiquitin ethyl ester (Wilkinson *et al.*, 1986). Human UCH-L1 was cloned *via* reverse transcriptase-mediated polymerase chain reaction (RT-PCR™, Perkin-Elmer Cetus) from a human fetal brain poly-A RNA library (obtained from Dr. Stephen T. Warren) using primers to the known human PGP9.5 sequence (Day *et al.*, 1990). It was subcloned by the dideoxy method (Sanger *et al.*, 1977), subcloned into pRSET to give pRSL1, and transformed into BL21 *E. coli* as described above. Sequencing revealed two apparent PCR™ errors affecting the codons for residues 73 and 200. Since the change at codon 200 was silent, it was not corrected. The codon at position 73 was repaired as follows. A rat PGP9.5 (UCH-L1) fragment (Kajimoto *et al.*, 1992) was amplified by PCR™ to generate a new silent 5' *Bss*HII site. The resulting *Bss*HII/*Dra*III cassette codes for identical residues in the rat and the human sequences and so was inserted into pRSL1 in place of the human gene fragment. The construct was sequenced and shown to have the correct predicted amino acid sequence.

UCH Purification. The inventors cloned, expressed, and purified recombinant UCH-L1 and UCH-L3 to study their physical and enzymatic properties. With the exceptions noted, the purification of all UCH isozymes and mutants was similar. A single colony of BL21(DE3) carrying the pRSET-UCH L3 plasmid was inoculated into 2 L of LB media (Sambrook *et al.*, 1986) and grown at 37°C to an absorbance of 0.8 at 600 nm. IPTG (Sigma, St. Louis, MO) was added at 0.4 mM, and the cells were incubated for an additional 1.5 h before the bacteria were centrifuged at 4000g and the pellets were collected. After induction, UCH levels reached an average of 15% of the soluble *E. coli* protein. The cell paste (16 g) was resuspended in 100 mL of lysis buffer (50 mM Tris-HCl, pH 7.5, 10 mM DTT, 50 µM PMSF, 1 mM EDTA, 10 mM MgCl₂). Lysozyme was added to 10 000 units/mL for 30 min, and the

suspension was sonicated (Heat Systems, Inc.). The debris was removed by centrifugation at 10 000g for 40 min. The supernatant was concentrated to 50 mL by ultrafiltration (Amicon, YM-10) and applied to a 200 mL Fast Flow Q-Sepharose column equilibrated with buffer A (50 mM Tris•HCl, pH 7.6; 0.5 mM EDTA; 5 mM DTT). The column was eluted with a 300 mL linear gradient to 0.5 M NaCl in buffer A. Fractions with ubiquitin esterase activity eluted at 265 mM NaCl and contained the 25 kDa protein as determined on SDS-PAGE. Enzymatically active fractions from ion exchange were pooled and concentrated to 30 mL and applied to a 1 L Sephadex G-100 Superfine gel filtration column (Pharmacia) in buffer A. Active fractions were pooled again and shown to be >98% pure by Coomassie-stained SDS-PAGE. These detailed enzymes have been used for kinetic studies and for the CD and UV spectroscopy, but for Raman spectra the enzymes were further purified on Mono Q FPLC anion exchange, using the same buffers and gradient as in the ion exchange step described above. The homogeneous fractions were pooled and concentrated by ultrafiltration. Purifications of UCH-L1 were similar to that for UCH-L3, except that the anion exchange salt gradients were 1-300 mM NaCl, with UCH-L1 eluting at 110 mM. Homogeneous UCH-L1 is obtained in two steps, due to slightly higher expression levels and weaker binding to Q-Sepharose. The inventors find the specific activities of homogeneous recombinant UCH-L1 and UCH-L3 are 30 and 110 $\mu\text{mol}/\text{min}/\text{mg}$, respectively, using ubiquitin ethyl ester as the substrate. By comparison, UCH-L1 from bovine brain has a specific activity of 25/ $\mu\text{mol}/\text{min}/\text{mg}$, and UCH-L3 purified from calf thymus exhibits a specific activity of approximately half the recombinant value. These enzymes are therefore fully active and has been shown to bind one mole of substrate per mole of enzyme (see below), suggesting that they are fully functional as purified.

Mutagenesis. Mutagenesis of UCH-L1 was performed using a combination of M13-based (Kunkel, 1985), cassette subcloning, and PCR™ methods. In M13 mutagenesis, UCH-L1 was excised from pRSET with *Xba*I and *Hin*DIII (New England Biolabs, Beverly, MA) and inserted into M13mp18 at the same sites. Annealing, T7 polymerase extension (T7 Sequenase, USB), and ligation of primers

(containing a new, silent *HpaI* site 5' to the mutation) with purified uracil-containing single-stranded M13 DNA generated the UCH-L1 H161D and H161Y mutants. These mutants were identified by screening plaque minipreps (Sambrook *et al.*, 1986) for susceptibility to *HpaI* digestion. The new *HpaI* site was then used to create the mutations H161Q, H161N, and H161K: degenerate cassettes produced by PCR™ were inserted by their *HpaI* and *KpnI* sites into pRSL1 and sequenced. Lastly, C90S and D176N mutant PCR™ cassettes were made and inserted into the *BssHII* and *DraIII* (C90S) or *BssHII* and *BsmI* sites (D176N). In all cases, the cassettes were always smaller than 400 base pairs and were sequenced after insertion into the expression vector to verify the absence of Taq polymerase-induced mutations. All isozymes and mutants were expressed in BL21(DE3) cells, and the supernatants from lysozyme lysis were assayed. In most cases, the mutants were purified as above and their catalytic velocities and Michaelis constants were determined (Wilkinson *et al.*, 1986).

UV-Vis, CD, and Raman Spectroscopy.

UV-visible spectra from 190 to 800 nm were acquired on a CARY 219 dual-beam spectrophotometer. CD spectra were obtained on an Aviv Associates 62DS, using 10 or 1 mm path length quartz cuvettes (Hellma, Forest Hills, NY) at $25.0 \pm 0.1^\circ\text{C}$. Each spectrum was the average of five scan repetitions. CD spectra of the native protein were collected at 0.95 mg of protein/mL (40 μM) with 1 or 10 mm path length cells. To monitor ubiquitin binding by CD spectroscopy, ubiquitin and UCH-L3 (1 mL, 4 μM) were placed in separate compartments of a dual-compartment 9 mm cell, and the spectrum was recorded. The contents of the compartments were then mixed, and the spectrum was again recorded. The former spectrum was subtracted from the latter to give the difference binding spectrum. A similar procedure was used for determining the effects of ubiquitin binding on the UV absorbance spectra, but with UCH-L3 and ubiquitin at 20 μM .

Circular dichroic spectroscopy was used to monitor the thermal denaturation of UCH at protein concentrations of 0.1 g/L (4 μM) in 1 mm path length cells, or at 0.1 g/L in 10 mm path length cells. The latter conditions were used for the H161K and

H161Y mutants, which aggregated at higher concentrations. The temperature was controlled with a Hewlett Packard 89100A temperature controller equipped with an immersible temperature probe. The temperature scan rate was varied over a 4-fold range to confirm that measurements were made at equilibrium. Scans in both directions (heating and cooling) confirmed that the transitions measured were reversible. The fraction of native protein present at each temperature was calculated assuming a two-state transition between the initial and final spectra obtained, *i.e.*, at any temperature the fraction of native species = (final ellipticity - observed ellipticity)/(final ellipticity - initial ellipticity). Thermodynamic parameters were calculated from plots of $\ln K_{eq}$ vs $1/T$ or by curve fitting in Sigma Plot 4.16 for Macintosh. Equilibrium constants were used to calculate thermodynamic state functions according to $K_{eq} = \min + ((\max - \min)/(1 + 1/\exp(s - h/x)))$ where $x = T$, $s = \partial H/8.314 \text{ J/K mol}$ and $h = \partial H/8.314 \text{ J/mol}$.

Nonresonance Raman spectra were recorded using the 488 nm emission line of an argon laser (Spectra Physics model 165). Light scattered from the sample at 90° to the incident laser beam was dispersed by a holographic diffraction grating in a 0.6 m triple monochromator (Triplemate, Spex Industries, Metuchen, NJ) and detected by an intensified photo-diode array detector (Princeton Instruments, Trenton, NJ). Power at the sample was less than 100 mW. The known Raman lines of toluene calibrated the system for each measurement, making the measured frequencies accurate to $\pm 1 \text{ cm}^{-1}$.

Equilibrium Gel Filtration. Equilibrium gel filtration measurements were performed as described (Hummel and Dreyer, 1962) with the following modifications. Tandem Superose 6 and 12 columns ($0.5 \times 30 \text{ cm}$, Pharmacia) were equilibrated with running buffer (30 mM Tris•HCl, pH 7.5; 5 mM DTT) containing $50 \mu\text{g}$ of ubiquitin/mL. After equilibration with three column volumes, the ubiquitin concentration in the effluent was identical to that in the applied buffer. Purified UCH-L3 ($100 \mu\text{L}$, $5.8 \mu\text{M}$) was supplemented with ubiquitin to a final concentration of $50 \mu\text{g/mL}$ ($5.8 \mu\text{M}$) and applied to this column. The concentration of ligand (ubiquitin) in the effluent was determined in triplicate by HPLC using a Waters WISP

710 B autoinjector and a Gilson HPLC equipped with a Spectra Physics SP4290 integrator (Wilkinson *et al.*, 1986). To determine the effect of salt on ubiquitin binding, the studies were repeated in the presence of 0.5 M NaCl.

5 RESULTS AND DISCUSSION

UCH Isozyme Family. Ubiquitin C-terminal hydrolases comprise a small, newly defined, and novel family of thiol proteases. Among these, UCH-L3 is the best-characterized member. Human (Wilkinson *et al.*, 1989) *Drosophila* (Zhang *et al.*, 1993), and yeast (Liu *et al.*, 1989) homologues have been described. These
10 known UCH sequences are aligned in FIG. 14, where only residues found in at least three sequences are highlighted. All of these enzymes have slightly acidic isoelectric points ($pI \sim 5.0$) and molecular weights between 24 and 27 kDa. The numbering system used here corresponds to the human UCH-L1 residues. A number of areas in
15 the sequence show a high degree of identity, most notably at positions 88-102 (the amino acid numbering system refers to the UCH-L1 sequence) (containing a conserved cysteine), 109-118, and 161-178 (containing a conserved histidine and an ELDGR sequence. Many of the positions in the aligned sequences are identical in all four sequences (44/249) or are similar in all four (52/249).

20 This degree of similarity in primary sequence and physical properties is usually taken as evidence of similar secondary and tertiary structure. In support of this assumption, all four UCH sequences give essentially identical plots of Kyte-Doolittle hydropathy. This suggests that the structural properties of these isozymes may be similar. The high homology also implies that the differential enzymatic
25 specificity of each is a consequence of a few sequence differences at the substrate recognition site. A basal collection of UCH residues is probably necessary for proper folding and ubiquitin binding. These binding residues are expected to be on the surface of the protein and in regions that show significant sequence homology in the alignments shown in FIG. 14. Additionally, catalytic residues are expected to be near
30 the surface but are generally at the bottom of a cleft or invagination of the protein

surface. To examine these relationships and make predictions about which residues to mutate, the secondary structure for this protein family has been predicted by submitting the aligned sequences shown in FIG. 14 to the PredictProtein server (PredictProtein@EMBL-Heidelberg,DE). This method of prediction uses a neural net and preserves the information content of the aligned sequences, as well as that of surrounding residues rather than using only a single consensus residue at each position (Rost and Sander, 1993). These predictions (with an 82% level of confidence) are given in the last row of FIG. 14 and are consistent with analyses by the Raman and circular dichroic spectroscopies discussed below.

Interestingly, the putative active site cysteine at position 90 in UCH-L1 (see below) is flanked by two putative hydrophobic β -sheet regions. These two regions of β -sheet may span from the surface of the molecule to a more protected site deeper in the molecule and position the active site thiol in the expected catalytic cleft. The cysteine is juxtaposed between the very small residues, alanine and glycine. They may allow the approach of a scissile peptide bond to form the tetrahedral intermediate. If the inventors presume the mechanism of this protease to be papain-like, then there must also be a conserved histidine which can act as a catalytic base, polarizing the sulfhydryl and enhancing its nucleophilicity. Two positions in the UCH family have conserved histidines, these being positions 97 and 161 in UCH-L I. H97 is unlikely to be involved since it is only seven residues removed from the active site and at the opposite end of the predicted β -sheet. In contrast to papain and the serine proteases, thiol proteases of the interleukin-converting enzyme (ICE) family do not position a third residue to hydrogen bond to the catalytic histidine (Walker *et al.*, 1994). Thus, it is not known if a "catalytic triad" is involved in catalysis by the UCH gene family.

UCH Expression and Purification. Recombinant proteins were expressed in *E. coli* using a modified pRSET vector (Invitrogen). The modification removed the coding region for the oligohistidine leader sequence present in the parent vector. Expression in this system is driven by a T7 RNA polymerase promoter, with induction of the polymerase by IPFG. Upon induction, the UCH isozymes and

mutants were expressed at 15%-30% of the soluble protein. The enzymes were expressed, purified (see Experimental Procedures), and assayed for kinetic parameters.

To identify the active site residues involved in UCH catalysis, the inventors have mutagenized the wild type UCH-L1 cDNA. The vector encoding this UCH isozyme is more tractable for mutagenesis (compared to UCH-L3) because of its greater number of useful restriction sites. Several mutants were made whose properties are summarized in Table 5. In every case, UCH-L1 mutant proteins were produced in amounts equal to the wild type enzyme, based on SDS-PAGE analysis of expression lysates. The inventors assayed each expression lysate for activity, and active mutants were purified as described.

TABLE 5:
Mutagenesis and Kinetics of UCH-L1 Mutants^a

Mutant	Codon Change	Relative Rate	
		(Velocity/wt Velocity)	K_m (μ M)
wild type		1.00	1.20
C90S	TGT \rightarrow TCT	$<1 \times 10^{-7}$	nd
H97Q	CAC \rightarrow CAA	0.85	0.65
H97N	CAC \rightarrow AAC	0.87	0.60
H161D	CAT \rightarrow GAC	8.5×10^{-5}	1.50
H161K	CAT \rightarrow AAA	$<1 \times 10^{-7}$	nd
H161N	CAT \rightarrow AAC	$<1 \times 10^{-7}$	nd
H161Q	CAT \rightarrow CAA	$<1 \times 10^{-7}$	nd
H161Y	CAT \rightarrow TAC	$<1 \times 10^{-7}$	nd
D176N	GAT \rightarrow AAT	0.025	7.40
Q73R	CAA \rightarrow CGA	0.97	1.10

^aActive mutants were purified as described for the wild type enzyme (see Experimental Procedures). Hydrolysis rates are the average of two determinations at 15 μ M UbOEt, or were Michaelis constants determined according to Wilkinson *et al.* (1986). Wild type UCH-L1 velocity is

25 $\mu\text{mol}/\text{min}/\text{mg}$ vs ubiquitin ethyl ester (nd: not determined).

Identification of the Active Site Cysteine. The inventors examined the effect of changing the putative active site thiol (C90) to a serine. This cysteine residue is conserved among all UCH's and was suspected to be involved in catalysis, though direct proof of this residues role in catalysis has not yet been shown. The inventors generated a UCH-L1-C90S mutant (see Procedures). Assay of the bacterial lysate expressing UCH-L1-C90S showed no detectable activity. To quantitatively assess the upper limit of this activity, the C90S mutant was purified and assayed. Even at equimolar enzyme to substrate ratio (17 μM), the half-life of the substrate is over 4.5 h. Because serine is isoelectronic with cysteine, it is likely that this abrogation of activity is a direct effect and not the result of a structural change. In support of this, the C90S mutant exhibits a thermal denaturation profile with thermodynamic parameters nearly identical to the native enzyme (see below). Therefore, cysteine 90 is directly involved in catalysis, probably as the active site nucleophile.

Identification of an Active Site Histidine. The inventors next sought to identify the active site histidine. Two positions in the alignment have a conserved histidine, corresponding to H97 and H161 in UCH-L1. To determine if these were important to catalytic function, the inventors conservatively mutated H97 to a glutamine or asparagine. These carboxamide residues cannot provide a general base for catalytic function, but could provide hydrogen bonding similar to the N1 or N3 imidazole nitrogens and hence could provide a structural replacement. Purified UCH-L1 H97Q and H97N catalytic velocities are approximately 85% as rapid as the wild type enzyme (Table 5 and Experimental Procedures). This suggests that H97 is not involved in catalysis.

The inventors then mutated the other fully conserved histidine at position 161. In short, all H161 mutants were either catalytically inactive or very significantly impaired. H161Q, H161N, H161Y, and H161K possess no measurable esterase

activity down to the detection limit of the inventors' assay. These mutants are minimally seven orders of magnitude slower than the wild type hydrolase. Individual H161 mutations could be expected to supply an adequate structural replacement for positive electrostatic charge (lysine), hydrogen bonding by the imidazole π (asparagine) and τ (glutamine) nitrogens (Vaaler and Snell, 1989), or aromaticity and steric volume (tyrosine). Interestingly, UCH-L1 H161D shows detectable activity, about 4 orders of magnitude less than that of native enzyme. Determination of the K_m of this purified mutant showed that only the reaction rate was altered and that the K_m was unchanged (Table 5). In this context a carboxylate may function as a general base or a hydrogen bond acceptor. Either interaction would abstract proton density from the nearby cysteine thiol and enhance its nucleophilicity. Since neither H161N nor H161Q can support this level of catalysis, but could hydrogen bond, the inventors favor a direct role for D161 as a general base. This would be the first example of a functional cys—asp dyad in a protease, though the velocity of catalysis is small. UCH-L1 H161D shows CD spectra typical of native UCH-L1 (described below), suggesting that this residue is not important for the gross enzyme structure. The inventors' data therefore indicate that histidine 161 is intimately involved in catalysis, probably as an active site general base.

Mutation of the ELDGR Box. Because the binding of ubiquitin to UCH is primarily electrostatic (shown below), and since acid residues may be involved in catalysis, the inventors mutated a universally conserved aspartate in the most conserved area of the UCH sequence, the ELDGR box. D176 was changed to an asparagine, resulting in a sterically unaltered charge mutant in a highly conserved region. This mutant shows a significant, measurable activity of 2.5% wild type. To determine if the drop in catalytic rate was due to an effect on binding strength, the K_m was determined (Wilkinson *et al.*, 1986). Progress curve kinetics (Wilkinson *et al.*, 1986; Orsi and Tipton, 1979) show this mutant to have a $K_m = 7.4 \mu\text{M}$, approximately 6-fold weaker than that of the native enzyme. The inventors find that the calculated specificity constant V_m/K_m is 250-fold lower than the wild type L1. Catalytic efficiency is thus lowered dramatically, but is not obliterated, and this might be

expected for a residue not directly involved in catalysis. The ELDGR box may therefore be involved in the formation of a binding site or the orientation of the substrate.

5 *Mutation of Q73.* The amplification of the UCH-L1 coding sequence by RT-PCR™ resulted in two errors. One of these changes, a G to C transversion affecting V200, was silent and was not repaired. Another G to A transition generated the mutant Q73R. The inventors repaired the R73 mutation by replacing the defective region with a fragment from the rat UCH-L1 cDNA. Both rat and human proteins
10 have identical sequences in this region (Kajimoto *et al.*, 1992; Day *et al.*, 1990), and the swap thus repaired the original PCR™ mutation (Experimental Procedures). Residue 73 is 17 residues N-terminal to the active site cysteine. It is predicted to be at the surface of the enzyme, possibly as part of a turn at the opposite end of the β -sheet anchoring the active site cysteine. Since all known UCH sequences have a Q in this
15 region (equivalent to either position 73 or 74 in UCH-L1), it was of interest to examine the catalytic activity of this mutant. Table 1 shows that mutation of this position to the positively charged R residue had no effect on the activity of the enzyme or its affinity for substrate.

20 *Structural Effects of These Mutations.* To ensure that the lack of activity in these mutants was not due to gross structural misfolding of the enzymes, the inventors analyzed selected mutants by circular dichroism. UCH-L1 mutants Q73R, H161D, D176N, and C90S all show CD spectra typical of UCH-L1 (described below), suggesting that these residues are not important for the gross enzyme structure. All of
25 these mutants were expressed at levels similar to the wild type, again suggesting that folding and solubility were not problems with these specific mutations.

Binding of Ubiquitin to UCH-L3. To characterize the ubiquitin binding site and to identify any structural changes and/or perturbation of the environment of amino
30 acid side chains associated with the binding of ubiquitin to UCH, the inventors have studied the spectral properties of the more soluble isozyme, UCH-L3, upon binding of

ubiquitin. Circular dichroism has previously been used to monitor protein-protein interactions accompanied by conformational changes, as well as to examine the environment of aromatic residues (Beltramini *et al.*, 1992; Blazy *et al.*, 1992; Grobler *et al.*, 1994; Vuillemier *et al.*, 1993). The inventors purified UCH-L3 (Experimental Procedures) and used it to study substrate binding by various approaches. The inventors were unable to detect any changes of ellipticity in CD difference spectra upon binding of ubiquitin and UCH-L3. This suggests that the structure of the two proteins are not altered by binding, such that no gross "induced fit" conformational changes are detectable.

To examine if aromatic residues were perturbed by substrate binding, the UV spectra of Ub and UCH-L3 were recorded in dual-compartment cells. After the compartment contents were mixed to initiate binding, no significant spectral change was seen relative to the unmixed control. The data from UV and CD spectra cannot distinguish minor tertiary structure alterations in UCH, and the inventors cannot comment on this possibility solely on their basis. The data do suggest that the electronic environments of the aromatic side chains are not radically altered by ubiquitin binding. Above 340 nm, the lack of UV absorption is consistent with the absence of chromophoric prosthetic groups in the enzyme. The spectra of UCH-L3 yield a Beer-Lambert extinction coefficient of 21 000 L/tool cm at 280 nm. UCH-L1 exhibits similar spectral characteristics, with an extinction of 15 600 L/tool cm. These data are consistent with the expected extinction based on the aromatic content of the polypeptides.

Binding of ubiquitin to UCH-L3 was not detectable by any of the spectral methods used above. Nonetheless, kinetic evidence predicts a sub-micromolar binding constant (Wilkinson *et al.*, 1986). Additionally, it is known that the enzyme is specifically bound to and eluted from a ubiquitin affinity column (Duerksen-Hughes *et al.*, 1989; Pickart and Rose, 1985). The kinetically obtained K_m must not be interpreted as a substrate dissociation constant, and the ubiquitin affinity column cannot be used to quantify the binding strength. Thus a direct gel filtration

approach was used to monitor this binding. In these studies, the column buffer is equilibrated with ligand ubiquitin and the enzyme sample is supplemented with an equal concentration of ligand. If binding occurs, one expects to observe a peak of ligand at the elution position of the enzyme and a depressed level of ligand at the included volume of the column. FIG. 15A shows that purified UCH-L3 is 91% occupied by ubiquitin when chromatographed in the presence of 5 μ M ubiquitin-containing buffer. Integration of the peak area shows that 3.45 nmol of ubiquitin was bound to the 3.80 nmol of UCH-L3 applied. An apparent binding constant of 0.5 μ M can be calculated from these data. This is similar to the K_m for UbOEt (Wilkinson *et al.*, 1986) and implies that most of the binding energy is due to ubiquitin alone and not the ester functionality. These data demonstrate that UCH-L3 possesses only one binding site with a micromolar K_d and that the stoichiometry of binding is 1:1.

The above data demonstrate the binding of ubiquitin to UGH-L3 and suggest that there are few gross structural changes associated with this binding. Further, the environment of aromatic residues is not greatly perturbed. This suggests that polar interactions may be important for the binding. Indeed, the inventors have noted that increased ionic strength inhibits hydrolysis of ubiquitin ethyl ester. This inhibition is virtually complete at 10 μ M substrate and 0.40 M NaCl. To examine if the inhibition by ionic strength was due to decreased substrate binding, or to a change in the catalytic properties of the protein, the inventors have repeated these binding studies in the presence of inhibitory levels of salt. Ubiquitin binding is completely abrogated in the presence of 0.5 M NaCl (FIG. 15B). The structure of the enzyme is not grossly perturbed by the presence of salt, as the CD spectra of UCH-L3 in 0 and 0.5 M NaCl are virtually identical. These data suggest that the binding interactions of the enzyme and substrate are primarily electrostatic and not hydrophobic.

Spectroscopic: Analysis of UCH-L3. Circular dichroism spectroscopy was used to estimate the amount of secondary structure motifs in UCH isozymes and mutants (FIG. 16) and to evaluate the effects of mutation on the folded protein

structure. The CD spectra show an absolute minima at 222 nm, characteristic of the presence of α -helices. This is also confirmed by the relative minima at 208 nm and absolute maxima at 202 nm (Johnson, 1988). Calculating the mean residue ellipticity, at 208 and 222 nm, the inventors obtain values of 12 090 and 9160 deg cm²/dmol, respectively. Using the sum of structures constraint (Greenfield and Fasman, 1969) these values predict α -helix contents of 31.2% and 32.4%. Also shown in FIG. 16 is the near-UV dichroism due to the chiral environment of the aromatic residues (curve labeled $\times 100$). As is typical, this region shows much less ellipticity (~ 60 deg cm²/dmol), but since this region might serve as an environmentally sensitive reporter for the aromatic residues the inventors have shown it.

Finally, classical nonresonance laser Raman spectroscopy was also used as a structural probe. FIG. 16 shows the Raman spectra of UCH-L3 from 400 to 1750 cm⁻¹. The inventors used two methods to calculate the amounts of structural motifs which are based on the conformationally sensitive nature of the peptide carbonyl stretch absorbance. The spectral bandwidth, intensity, and position of this amide I Stokes emission were used to estimate quantities of four generic secondary structures: helix, β -sheet, turn, and random (Alix *et al.*, 1981). This method suggests 48% helical content, 25% β -sheet, 16% turn, and 11% "other". Another method (Lippert *et al.*, 1976) uses the spectral characteristics (1240, 1632, and 1660 cm⁻¹ transitions) of pure helix, β -sheet, and random forms of poly L-lysine to calculate the secondary structure content. The inventors' data predict 40% helix, 43% β -sheet, and 17% random coil when analyzed in this way, but this method cannot distinguish between β -turn and β -sheet motifs. These predictions therefore concur generally with predictions based on Alix *et al.* (1988) and also with the CD data presented above. Weighting the Raman, CD, and prediction algorithms equally, approximate averages of 38% helix, 22% β -sheet, 18% turn or loop, and 19% "nonordered" secondary structures are obtained. Minor discrepancies between the methods may arise as a consequence of the "sum of structure" constraints or from the nature of the model compounds used as the basis for the various computations described above.

The inventors' data show that UCH isozymes possess both helix and β -sheet motifs, similar to the papain family of thiol proteases. To date, the solution crystal structures of five thiol proteases have been solved. Three of these, papain, calotropin D1, and actinidin, are from plant sources; two others, liver cathepsin B and the interleukin 1- β -converting enzyme "ICE", are from mammalian sources [reviewed by Walker *et al.* (1994)]. These enzymes differ from the all- β -chymotrypsin class of serine proteases in both catalytic residues and overall structure. ICE and subtilisin both possess helical content, however, and exhibit an antiparallel β -sheet core domain. While UCH enzymes resemble the papain family members in size and secondary structure content, sequence comparison with the papain family suggests that the UCH family should be classified as a distinct gene family. The solution of a UCH crystal structure would provide a valuable addition to the small collection of α/β -proteases, and these studies are ongoing.

Thermal Denaturation. The above results demonstrate that the recombinant enzymes and mutants display normal spectroscopic properties at room temperature. This suggests that all mutants tested fold correctly and are soluble under these conditions. However, the temperature of the enzymatic assay and normal physiological environment of these enzymes is 37°C. To demonstrate that the loss of activity was due to a direct effect and not irreversible unfolding of the enzymes at assay temperature, the inventors have conducted thermal denaturation studies monitoring the 222 nm circular dichroism signal. Using this technique, the thermodynamics of protein denaturation have been studied for several enzymes Alexander *et al.*, 1992; reviewed by Privalov and Gill (1988). This method provides a powerful, general tool for assessing the structural stability of enzymes and mutants. FIG. 17 shows the temperature-dependent changes in the 222 nm CD signal of UCH-L1. As can be seen, there is a thermal transition at approximately 52°C resulting in a 45% diminishment in this conformationally sensitive signal. UCH-L3 is also subject to the same transition, though the loss of ellipticity is slightly less. Cooling the sample results in the restoration of the original spectra, and wavelength scans at 65°C are typical of proteins with high random coil content. Also, the

transition is fully reversible if the protein concentration is less than 100 $\mu\text{g/mL}$ (10 $\mu\text{g/mL}$ for H161K and H161Y) and if the protein is not allowed to remain denatured for more than 5 min before the temperature is lowered.

These data can be analyzed according to a two-state model, and the relevant thermodynamic parameters can be calculated. The inset to FIG. 17 shows the Arrhenius plot of the data. As obtained from the replot, this transition is characterized by values of $\Delta H = 1.56 \text{ kJ/mol}$ of residue, $\Delta S = 4.80 \text{ J/K mol}$ of residue, and $\Delta G = 28.6 \text{ kJ/mol}$ of UCH-L1 at 25°C. It is assumed that this transition is the reversible denaturation of UCH. The rather modest stability, of this protein is consistent with the reversible folding of a single domain protein. Many small globular proteins exhibit folded states stabilized by only 20-60 kJ/mol of Gibbs free energy (Privalov, 1979).

TABLE 6

Thermodynamics of Denaturation of UCH's"

Enzyme	Melting Point (T_m , $\pm 0.2^\circ\text{C}$)	Enthalpy, ΔH (kJ/mol of aa)	Entropy, ΔS (J/K mol of aa)	Gibbs Energy, ΔG (kJ/mol of UCH)
UCH-L3	50.9	1.15	3.52	21.7
UCH-L1	51.8	1.56	4.80	28.6
UCH-L1 C90S	51.5	1.55	4.78	27.7
UCH-L1 H161D	49.9	1.50	4.69	22.6
UCH-L1 H161K	52.7	1.07	3.30	19.1
UCH-L1 H161Y	52.7	1.10	3.40	19.2

^aMelting points are derived from the primary denaturation data. Thermodynamic values for denaturation are calculated as described in the text, where $\Delta H = \text{kJ/mol}$ of amino acid residue, $\Delta S = \text{J/K mol}$ of amino acid residue, and $\Delta G = \text{kJ/mol}$ of UCH at 25°. Conventions are according to Privalov (1979).

The inventors also performed this thermodynamic analysis for the UGH-L3 isozyme and the L1 isozyme mutants C90S, H161D, H161K, and H161Y. In general

the wild-type and mutant enzymes have virtually indistinguishable circular dichroism spectra and only slightly differing denaturation curves. All denature at 50-53°C, where the melting point is defined as that point in the thermal denaturation curve where $K_{eq} = 1$, *i.e.*, the midpoint. Thermodynamic values thus derived are shown in Table 6. By comparison, the neuron specific UCH-L1 appears slightly more stable than its hemopoietic homologue, UCH-L3. Wild type L1 and the isoelectronic mutant C90S both show virtually identical melting points and thermodynamic stabilities per residue (Privalov and Gill, 1988) with ΔG : 28.6 and 27.7 kJ/mol at 25°C, respectively. Mutations at the catalytic histidine were only slightly destabilizing. as determined by a melting point depression (H161D) or unfavorably altered thermodynamic state functions (H161K and H161Y). On the basis of these data, the inventors conclude that the inactivity of the C90 and H161 mutants is due to the loss of important catalytic residues and not due to misfolding or a decreased stability of the folded form.

5

10

15

Given the above observations, the present invention also contemplates constructing columns containing a matrix material that has immobilized enzyme bound to its surface. Such a column may be constructed such that it is much more likely than not that the immobilized enzyme, whether UCH-L1, UCH-L3, or variants thereof, shows greater catalytic activity as opposed to unbound enzyme. Also contemplated is protecting the face of the enzyme utilizing a cross-linked ubiquitin-protein or ubiquitin-peptide complex. The binding of such a complex to the enzyme is generally tight and specific, and if cross linked, the complex serves as a protector of the active site. To activate the enzyme, one may disassociate the ubiquitin with, for example, a high salt concentration. Such columns will find use in catalytically cleaving and then separating ubiquitin from the peptides and small proteins that are part of the fusion protein. Conversely, if one wanted to further purify the enzyme, one could employ a column having ubiquitin bound to its matrix, and more preferably, ubiquitin that has been cross linked.

The inventors have presented data to demonstrate that cysteine 90 and histidine 161 are the active site nucleophile and general base involved in UCH-L1 catalysis. These data assist in crystallographic model building, as the two residues must be juxtaposed in the tertiary structure and will define the active site. It can also be safely assumed that the other isozymes of the UCH family possess the same catalytic chemistry and residues, for reasons described above. The electronic nature of the binding suggests that one of two faces of ubiquitin is involved in an extensive interaction with this enzyme. One face has been defined as an "acidic face" with many such clustered on the surface of the α -helix from residues 20 to 34. Many of the basic residues are clustered on the opposite face of the molecule. It is not immediately obvious which face is contacting the surface of the enzyme, although there are several approaches which could be pursued to further define this. It is interesting to note that the majority of amino acid substitutions across species occur in the "acidic" face of ubiquitin (Wostmann *et al.*, 1992), and for this reason, the inventors assume that the "basic" face is involved in these binding interactions. Data from Burch and Haas (1994) suggest that R42 of ubiquitin is involved in recognition

by UCH-L3. Also, the aspartate in the conserved ELDGR box may be involved in the binding. The effect of the D176N mutation on the Michaelis constant for ubiquitin shows that this residue may participate in an ionic interaction with ubiquitin or provide minor "orienting" effects for the fine tuning of substrate positioning. Rose and Warms (1983) have also shown that the two C-terminal glycine residues are necessary for effective inhibition of UCH-L3 by ubiquitin. The inventors find that the attachment of a hexahistidine motif to the N-terminus of ubiquitin does not affect hydrolysis rates to any measurable extent.

In summary, the inventors' data suggest that UCH isozymes (a) utilize cysteine 90 as the nucleophile, (b) use histidine 161 as the general base catalyst, (c) bind ubiquitin electrostatically, (d) bind the intact ubiquitin C-terminus, (e) may possess a carboxylate P3 binding pocket for arginine, (f) do not bind the amino terminus of ubiquitin, (g) bind other basic residues in ubiquitin, and (h) utilize several of UCH's acidic residues in binding. These studies are useful in building models of the enzyme for crystallographic and structural studies, for defining the enzyme-substrate interaction, and in site-directed mutagenesis studies designed to alter recognition and specificity of these enzymes.

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

PAGE INTENTIONALLY LEFT BLANK

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

- Bacon and Anderson, "A fast algorithm for rendering space-filling molecule pictures," *J. Molec. Graphics*, 6:219-220, 1988.
- Baker, Tobias, Varshavsky, "Ubiquitin-specific proteases of *Saccharomyces cerevisiae*: cloning of UBP2 and UBP3, and functional analysis of the UBP gene family," *J. Biol. Chem.*, 267:23364-23375, 1992.
- Beers and Callis, *J. Biol. Chem.*, 268:21645-21649, 1993.
- Bradbury, "Reversible histone modifications and the chromosome cell cycle," *Bioessays*, 14:9-16, 1992.
- Brünger, "Free R value: a novel statistical quantity for assessing the accuracy of crystal structures," *Nature*, 355:472-475, 1992a.
- Brünger, "X-PLOR version 3.1, a system for X-ray crystallography and NMR," New Haven, CT: Yale University Press, 1992b.
- Carmona, Dufour, Plouffe, Takebe, Mason, Mort, Menard, "Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases," *Biochem.*, 35:8149-8157, 1996.
- CCP4, The CCP4 suite: programs for protein crystallography," *Acta Cryst.*, 50(D):760-763, 1994.
- Chau, Tobias, Bachmair, Marriott, Ecker, Gonda, Varshavsky, "A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein," *Science*, 243:1576-1583, 1989.
- Chen and Pickart, *J. Biol. Chem.*, 265:21835-21842, 1990.
- Chen, Parent, Maniatis, "Site-specific phosphorylation of I κ B α by a novel ubiquitination-dependent protein kinase activity," *Cell*, 84:853-862, 1996.

- Ciechanover and Schwartz, "The ubiquitin-mediated proteolytic pathway: mechanisms of recognition of the proteolytic substrate and involvement in the degradation of native cellular proteins," *FASEB J.*, 8:182-191, 1994.
- 5 Coulombe, Grochulski, Sivaraman, Ménard, Mort, Cygler, "Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment," *EMBO J.*, 15:5492-5503, 1996.
- Cowtan, 'dm': "An automated procedure for phase improvement by density modification," *Joint CCP4 and ESF-EACBM newsletter on protein crystallography*, 31:34-38, 1994.
- 10 Cygler, Sivaraman, Grochulski, Coulombe, Storer, Mort, "Structure of rat procathepsin B. Model for inhibition of cysteine protease activity by the proregion," *Structure*, 4:405-416, 1996.
- Drenth, Kalk, Swen, "Binding of chloromethyl ketone substrate analogues to crystalline papain," *Biochem.*, 15:3731-3738, 1976.
- 15 Finley, Bartel, Varshavsky, *Nature*, 338:394-401, 1989.
- Glichrist, *In: Heterocyclic Chemistry*, 2nd Ed., John Wiley & Sons, New York, Ch. 8, pp 314-316, 1992.
- Gregori, Poosch, Cousins, Chau, "A uniform isopeptide-linked multikubiquitin chain is sufficient to target substrate for degradation in ubiquitin-mediated proteolysis,"
- 20 *J. Biol. Chem.*, 265:8354-8357, 1990.
- Haas, Katzung, Reback, Guarino, "Functional characterization of the ubiquitin variant encoded by the baculovirus *Autographa californica*," *Biochem.*, 35:5385-5394, 1996.
- Henchoz, De Rubertis, Pauli, Spierer, "The dose of a putative ubiquitin-specific protease affects position-effect variegation in *Drosophila melanogaster*,"
- 25 *Mol. Cell. Biol.*, 16:5717-5725, 1996.
- Hershko and Ciechanover, "The Ubiquitin System for Protein Degradation," *Annu. Rev. Biochem.*, 61:761-807, 1992.
- Hicke and Riezman, "Ubiquitination of a yeast plasma membrane receptor signals its
- 30 ligand-stimulated endocytosis," *Cell*, 84:277-287, 1996.

- Holm and Sander, "Protein structure comparison by alignment of distance matrices," *J. Mol. Biol.*, 233:123-138, 1993.
- Huang, Baker, Fischer-Vize, "Control of cell fate by a deubiquitinating enzyme encoded by the *fat facets* gene," *Science*, 270:1828-1831, 1995.
- 5 Hutchinson and Thornton, "PROMOTIF - A program to identify and analyze structural motifs in proteins," *Prot. Sci.*, 5:212-220, 1996.
- Jentsch, "Ubiquitin-dependent protein degradation: a cellular perspective," *Trend. Cell Biol.*, 2:98-103, 1992.
- Johnston, Larsen, Cook, Wilkinson, Hill, *EMBO J.*, 16:3787-3796, 1997.
- 10 Jones, Zou, Cowan, Kjeldgaard, "Improved methods for building protein models in electron density maps and location of errors in these models," *Acta Cryst.*, 47(A):110-119, 1991.
- Jonnalagadda, Butt, Marsh, Sternberg, Mirabelli, Ecker, Crooke, *J. Biol. Chem.*, 262:17750-17756, 1987.
- 15 Kamphuis, Kalk, Swarte, Drenth, "Structure of papain refined at 1.65 Å resolution," *J. Mol. Biol.*, 179:233-256, 1984.
- Karrer, Peiffer, DiTomas, "Two distinct gene subfamilies within the family of cysteine protease genes," *Proc. Natl. Acad. Sci. USA*, 90:3063-3067, 1993.
- Kleywegt and Jones, "A super position," *Joint CCP4 and ESF-EACBM newsletter on*
- 20 *protein crystallography*, 31:9-14, 1994.
- Kraulis, "Molscript: a program to produce both detailed and schematic plots of protein structures," *J. Appl. Cryst.*, 24:946-950, 1991.
- Larsen, Price, Wilkinson, "Substrate binding and catalysis by ubiquitin C-terminal hydrolases: Identification of two active site residues," *Biochem.*,
- 25 35:6735-6744, 1996.
- Laskowski, MacArthur, Moss, Thornton, "PROCHECK: a program to check the stereochemical quality of protein structures," *J. Appl. Cryst.*, 26:283-291, 1993.
- Liu, Miller, Kohr Jr., Silber, "Purification of a ubiquitin protein peptidase from yeast
- 30 with effecient *in vitro* assays," *J. Biol. Chem.*, 264:20331-20338, 1989.
- Matthews, "Solvent content of protein crystals," *J. Mol. Biol.*, 33:491-497, 1968.

- Matunis, Coutavas, Blobel, "A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex," *J. Cell. Biol.*, 135:1457-1470, 1995.
- McRee, "A visual protein crystallographic software system for X11/XView," *J. Molec. Graph.*, 10:44-46, 1992.
- 5 Ménard, Carrière, Laflamme, Plouffe, Khouri, Vernet, Tessier, Thomas, Storer, "Contribution of the glutamine 19 side chain to transition-state stabilization in the oxyanion hole of papain," *Biochem.*, 30:8924-8928, 1991.
- Meyer, Cole, Radhakrishnan, Epp, "Structure of native porcine pancreatic elastase at 1.65 Å resolution," *Acta Crystallogr.*, 44(B):26-55, 1988.
- 10 Miller, Henzel, Ridgeway, Kuang, Chisholm, Liu, "Cloning and expression of a yeast ubiquitin-protein cleaving activity in *E. coli*," *Biotech.*, 7:698-704, 1989.
- Moazed and Johnson, "A deubiquinating enzyme interacts with SIR4 and regulates silencing in *S. cerevisiae*," *Cell*, 86:667-677, 1996.
- 15 Monia, Ecker, Jonnalagadda, Marsh, Gotlib, Butt, Crooke, *J. Biol. Chem.*, 264:4093-4103, 1989.
- Narasimhan, Potter, Haas, "Conjugation of the 15-kDa interferon-induced ubiquitin homolog is distinct from that of ubiquitin," *J. Biol. Chem.*, 271:324-330, 1996.
- Nicholls, Sharp, Honig, "Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons," *PROTEINS, Structure, Function and Genetics*, 11:281-296, 1991.
- 20 O'Hara, Hemmings, Buttle, Pearl, "Crystal structure of glycyl endopeptidase from carica papaya: A cysteine endopeptidase of unusual substrate specificity," *Biochem.*, 34:13190-13195, 1995.
- 25 Olvera and Wool, "The carboxyl extension of a ubiquitin-like protein in rat ribosomal protein S30," *J. Biol. Chem.*, 268:17967-17974, 1993.
- Otwinowski, "Maximum likelihood refinement of heavy atom parameters," In: *Isomorphous replacement and anomalous scattering*, (ed.) Evans, Leslie, (Daresbury Lab.: Warrington WA4 4AD, England), pp. 80-86, 1991.

- Otwinowski, "Oscillation data reduction program," *In: Data collection and processing*, (ed.) Sawyer, Isaacs, Bailey, (SERC Daresbury Laboratory: Warrington WA4 4AD, England), pp. 56-62, 1993.
- Özkaynak, Finley, Solomon, Varshavsky, "The yeast ubiquitin genes: a family of
5 natural gene fusions," *EMBO J.*, 6:1429-1439, 1987.
- Papa and Hochstrasser, "The yeast DOA4 gene encodes a deubiquinating enzyme related to product of the human *tre-2* oncogene," *Nature*, 366:313-319, 1993.
- Pickart and Rose, "Ubiquitin carboxyl-terminal hydrolase acts on ubiquitin carboxyl-terminal amides," *J. Biol. Chem.*, 260:7903-7910, 1985.
- 10 Pickart and Rose, "Mechanism of ubiquitin carboxyl-terminal hydrolase: borohydride and hydroxylamine inactivate in the presence of ubiquitin," *J. Biol. Chem.*, 261:10210-10217, 1986.
- Ramakrishnan and Biou, "Treatment of MAD as a special case of MIR," *Method. Enzymol.*, 1997 (IN PRESS).
- 15 Rashin, Iofin, Honig, "Internal cavities and buried waters in globular proteins," *Biochem.*, 25:3619-3625, 1986.
- Rawlings and Barrett, "Families of cysteine peptidases," *In: Method Enzymol.*, Barrett (Ed.), Academic Press, San Diego, 244:461-486, 1994.
- Roff, Thompson, Rodriguez, Jacque, Baleux, Arenzana-Seisdedos, Hay, "Role of
20 I κ B α ubiquitination in signal-induced activation of NG- κ B *in vivo*," *J. Biol. Chem.*, 271:7844-7850, 1996.
- Rose and Warms, *Biochemistry*, 22:4234-4237, 1983.
- Rost and Sander, "Improved prediction of protein secondary structure by use of sequence profiles and neural networks," *Proc. Natl. Acad. Sci. U.S.A.*,
25 90:7558-7562, 1993.
- Sambrook, Fritsch, Maniatis, *In: Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Press, Cold Springs Harbor, pp ?, 1989.
- Sanger, Nicklen, Coulson, *Proc. Natl. Acad. Sci. USA*, 74:5463-5467, 1977.
- Schechter and Berger, "On the size of the active site of proteases," *Biochem. Biophys. Res. Commun.*, 27:157-162, 1967.
30

- Schröder, Phillips, Garmen, Harlos, Crawford, "X-ray crystallographic structure of a papain-leupeptin complex," *FEBS Lett.*, 315:38-42, 1993.
- Storer and Ménard, "Catalytic mechanism in papain family of cysteine peptidases. In: *Method. Enzymol.*, Barrett (Ed.), Academic Press, San Diego, 244:486-500, 1994.
- Studier and Moffatt, "Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes," *J. Molec. Biol.*, 189:113-130, 1986.
- Tobias and Varshovsky, "Cloning and functional analysis of the ubiquitin-specific protease gene Ubpl of *Saccharomyces cerevisiae*," *J. Biol. Chem.*, 266:12021-12028, 1991.
- Turk, Podobnik, Kuhelj, Dolinar, Turk, "Crystal structures of human procathepsin B at 3.2 and 3.3 Å resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide," *FEBS Lett.*, 384:211-214, 1996.
- Turk, Podobnik, Popovic, Katunuma, Bod., Huber, Turk, "Crystal structure of cathepsin B inhibited with CA030 at 2.0 Å resolution: A basis for the design of specific epoxysuccinyl inhibitors," *Biochem.*, 34:4791-4797, 1995.
- Vijay-Kumar, Bugg, Cook, "Structure of ubiquitin refined at 1.8Å resolution," *J. Molec. Biol.*, 194:531-544, 1987.
- Wand and Wilkinson, **INCOMPLETE CITE**
- Weber, Gittis, Mullen, Abeygunawardana, Lattmann, Mildvan, "NMR docking of a substrate into the X-ray structure of staphylococcal nuclease," *Proteins: Structure, Function, and Genetics*, 13:275-287, 1992.
- Wilkinson, "Purification and structural properties of ubiquitin. In: *Ubiquitin*, Rechsteiner (Ed.), Plenum Press, New York, pp 5-38, 1988.
- Wilkinson, "Ubiquitin carboxyl-terminal hydrolase. In: *A Handbook of Proteolytic Enzymes*, Barrett and Rawlings (Ed.), Academic Press, San Diego, pp ?, 1997, (IN PRESS).
- Wilkinson, Cox, Mayer, Frey, "Synthesis and characterization of ubiquitin ethyl ester, a new substrate for ubiquitin carboxyl-terminal hydrolase," *Biochem.*, 25:6644-6649, 1986.

- Wilkinson, Deshpande, Larsen, "Comparisons of neuronal (PGP 9.5) and non-neuronal ubiquitin C-terminal hydrolases," *Biochem. Sec. Trans.*, 20:631-637, 1992.
- 5 Wilkinson, Lee, Deshpande, Duerksen-Hughes, Boss, Pohl, "The neuron-specific protein PGP9.5 is a ubiquitin carboxyl-terminal hydrolase," *Science*, 246:670-673, 1989.
- Wilkinson, Tashayev, O'Connor, Larsen, Kasperek, Pickart, "Metabolism of the polyubiquitin degradation signal: Structure, mechanism and role and isopeptidase T," *Biochem.*, 34:14535-14546, 1995.
- 10 Zhu, Carroll, Papa, Hochstrasser, D'Andrea, "DUB-1, a deubiquinating enzyme with growth-suppressing activity," *Proc. Natl. Acad. Sci. USA*, 93:3274-3279, 1996.

WHAT IS CLAIMED IS:

1. A method of preparing a molecule that binds to a UCH-L3 protein but does not substantially bind to a variant UCH-L3 protein, comprising determining a three-dimensional structure of a UCH-L3 or variant UCH-L3 protein and designing a molecule that binds to a UCH-L3 protein, but that does not bind substantially to a variant UCH-L3 protein.
2. The method of claim 1, further comprising testing the designed molecule for binding to said UCH-L3 protein.
3. A method for the identification of a candidate inhibitor substance that inhibits UCH-L3 activity comprising the steps of:
 - a) contacting a cell expressing a UCH-L3 protein with a candidate inhibitor substance; and
 - b) comparing the properties of said cell with the growth of said cell in the absence of said candidate inhibitor substance;wherein a change in the properties is indicative of said substance being an inhibitor of UCH-L3 activity.
4. The method of claim 3, wherein said UCH-L3 protein expressed is a variant UCH-L3 protein
5. The method of claim 3, wherein said candidate substance is a small molecule inhibitor.
6. The method of claim 5, wherein the small molecule inhibitor is a substituted isoxazole, heterocyclic aromatic compound; or a sugar-linked aromatic compound.

7. A method for the identification of a candidate inhibitor substance that inhibits UCH-L3 expression comprising the steps of:

- 5 a) contacting a cell expressing a UCH-L3 protein with a candidate inhibitor substance; and
- b) comparing the expression of UCH-L3 of said cell with the expression of UCH-L3 of said cell in the absence of said candidate inhibitor substance;

10 wherein a decrease in the expression of UCH-L3 is indicative of said substance being an inhibitor of UCH-L3 expression.

8. The method of claim 7, wherein said candidate substance is a small molecule inhibitor.

15

9. The method of claim 8, wherein the small molecule inhibitor is a substituted isoxazole, heterocyclic aromatic compound; or a sugar-linked aromatic compound.

20 10. A method of preparing a molecule that binds to a UCH-L3 protein, comprising determining a three-dimensional structure of a UCH-L3 protein and designing a molecule that binds to a UCH-L3 protein.

11. The method of claim 10, wherein the molecule increases the stability of the UCH-L3 protein.

25 12. The method of claim 10, wherein the molecule decreases the stability of the UCH-L3 protein.


13. A variant UCH-L3 molecule having the properties of increased stability.


30


-166-

14. A process of regulating protein deubiquitination comprising exposing said protein to a deubiquitinating enzyme or a mutant deubiquitinating enzyme, which mutant does not catalyze the deubiquitination of said protein.
- 5 15. A variant UCH-L3 molecule having the properties of papain-like activity and deubiquitinating activity.

UCL-L3	UCL-L1	UCL-L2	UCL-L4	UCL-L5	UCL-L6	UCL-L7	UCL-L8	UCL-L9	UCL-L10	UCL-L11	UCL-L12	UCL-L13	UCL-L14	UCL-L15	UCL-L16	UCL-L17	UCL-L18	UCL-L19	UCL-L20	UCL-L21	UCL-L22	UCL-L23	UCL-L24	UCL-L25	UCL-L26	UCL-L27	UCL-L28	UCL-L29	UCL-L30	UCL-L31	UCL-L32	UCL-L33	UCL-L34	UCL-L35	UCL-L36	UCL-L37	UCL-L38	UCL-L39	UCL-L40	UCL-L41	UCL-L42	UCL-L43	UCL-L44	UCL-L45	UCL-L46	UCL-L47	UCL-L48	UCL-L49	UCL-L50	UCL-L51	UCL-L52	UCL-L53	UCL-L54	UCL-L55	UCL-L56	UCL-L57	UCL-L58	UCL-L59	UCL-L60	UCL-L61	UCL-L62	UCL-L63	UCL-L64	UCL-L65	UCL-L66	UCL-L67	UCL-L68	UCL-L69	UCL-L70	UCL-L71	UCL-L72	UCL-L73	UCL-L74	UCL-L75	UCL-L76	UCL-L77	UCL-L78	UCL-L79	UCL-L80	UCL-L81	UCL-L82	UCL-L83	UCL-L84	UCL-L85	UCL-L86	UCL-L87	UCL-L88	UCL-L89	UCL-L90	UCL-L91	UCL-L92	UCL-L93	UCL-L94	UCL-L95	UCL-L96	UCL-L97	UCL-L98	UCL-L99	UCL-L100	UCL-L101	UCL-L102	UCL-L103	UCL-L104	UCL-L105	UCL-L106	UCL-L107	UCL-L108	UCL-L109	UCL-L110	UCL-L111	UCL-L112	UCL-L113	UCL-L114	UCL-L115	UCL-L116	UCL-L117	UCL-L118	UCL-L119	UCL-L120	UCL-L121	UCL-L122	UCL-L123	UCL-L124	UCL-L125	UCL-L126	UCL-L127	UCL-L128	UCL-L129	UCL-L130	UCL-L131	UCL-L132	UCL-L133	UCL-L134	UCL-L135	UCL-L136	UCL-L137	UCL-L138	UCL-L139	UCL-L140	UCL-L141	UCL-L142	UCL-L143	UCL-L144	UCL-L145	UCL-L146	UCL-L147	UCL-L148	UCL-L149	UCL-L150	UCL-L151	UCL-L152	UCL-L153	UCL-L154	UCL-L155	UCL-L156	UCL-L157	UCL-L158	UCL-L159	UCL-L160	UCL-L161	UCL-L162	UCL-L163	UCL-L164	UCL-L165	UCL-L166	UCL-L167	UCL-L168	UCL-L169	UCL-L170	UCL-L171	UCL-L172	UCL-L173	UCL-L174	UCL-L175	UCL-L176	UCL-L177	UCL-L178	UCL-L179	UCL-L180	UCL-L181	UCL-L182	UCL-L183	UCL-L184	UCL-L185	UCL-L186	UCL-L187	UCL-L188	UCL-L189	UCL-L190	UCL-L191	UCL-L192	UCL-L193	UCL-L194	UCL-L195	UCL-L196	UCL-L197	UCL-L198	UCL-L199	UCL-L200	UCL-L201	UCL-L202	UCL-L203	UCL-L204	UCL-L205	UCL-L206	UCL-L207	UCL-L208	UCL-L209	UCL-L210	UCL-L211	UCL-L212	UCL-L213	UCL-L214	UCL-L215	UCL-L216	UCL-L217	UCL-L218	UCL-L219	UCL-L220	UCL-L221	UCL-L222	UCL-L223	UCL-L224	UCL-L225	UCL-L226	UCL-L227	UCL-L228	UCL-L229	UCL-L230	UCL-L231	UCL-L232	UCL-L233	UCL-L234	UCL-L235	UCL-L236	UCL-L237	UCL-L238	UCL-L239	UCL-L240	UCL-L241	UCL-L242	UCL-L243	UCL-L244	UCL-L245	UCL-L246	UCL-L247	UCL-L248	UCL-L249	UCL-L250	UCL-L251	UCL-L252	UCL-L253	UCL-L254	UCL-L255	UCL-L256	UCL-L257	UCL-L258	UCL-L259	UCL-L260	UCL-L261	UCL-L262	UCL-L263	UCL-L264	UCL-L265	UCL-L266	UCL-L267	UCL-L268	UCL-L269	UCL-L270	UCL-L271	UCL-L272	UCL-L273	UCL-L274	UCL-L275	UCL-L276	UCL-L277	UCL-L278	UCL-L279	UCL-L280	UCL-L281	UCL-L282	UCL-L283	UCL-L284	UCL-L285	UCL-L286	UCL-L287	UCL-L288	UCL-L289	UCL-L290	UCL-L291	UCL-L292	UCL-L293	UCL-L294	UCL-L295	UCL-L296	UCL-L297	UCL-L298	UCL-L299	UCL-L300	UCL-L301	UCL-L302	UCL-L303	UCL-L304	UCL-L305	UCL-L306	UCL-L307	UCL-L308	UCL-L309	UCL-L310	UCL-L311	UCL-L312	UCL-L313	UCL-L314	UCL-L315	UCL-L316	UCL-L317	UCL-L318	UCL-L319	UCL-L320	UCL-L321	UCL-L322	UCL-L323	UCL-L324	UCL-L325	UCL-L326	UCL-L327	UCL-L328	UCL-L329	UCL-L330	UCL-L331	UCL-L332	UCL-L333	UCL-L334	UCL-L335	UCL-L336	UCL-L337	UCL-L338	UCL-L339	UCL-L340	UCL-L341	UCL-L342	UCL-L343	UCL-L344	UCL-L345	UCL-L346	UCL-L347	UCL-L348	UCL-L349	UCL
--------	--------	--------	--------	--------	--------	--------	--------	--------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	-----











A**UCH-L3****Fig. 5A****Cathepsin B**

Fig. 5B

B**UCH-L3****Cathepsin B**





---C1




Fig. 9






FIG. 10




FIG. 11




FIG. 12




FIG. 13



Ubiquitin C-Terminal Hydrolases




FIG. 15A





FIG. 15B

**FIG. 16**




FIG. 17

-1-

SEQUENCE LISTING

5 . <110> Hill, Christopher P.
 Wilkinson, Keith D.
 Johnston, Steven C.
 Larsen, Christopher N.
 Cook, William J.

10 <120> METHODS AND COMPOSITIONS FOR A DEUBIQUITINATING ENZYME
 AND VARIANTS THEREOF

 <130> UTAH:006

15 <140> Unknown
 <141> 1998-07-01

 <150> 60/051,437
 <151> 1997-07-01

20 <160> 5

 <170> PatentIn Ver. 2.0

25 <210> 1
 <211> 10
 <212> PRT
 <213> Escherichia coli

30 <220>
 <223> Attached to the amino terminus of Ubiquitin

 <400> 1
 Ile Ile Glu Pro Ser Leu Arg Gln Leu Ala
 1 5 10

35

 <210> 2
 <211> 10
 <212> PRT
 40 <213> Escherichia coli

 <220>
 <223> Attached to the amino terminus of Ubiquitin

45 <400> 2
 Gly Lys Lys Arg Lys Lys Lys Val Tyr Thr
 1 5 10

50 <210> 3
 <211> 10
 <212> PRT
 <213> Escherichia coli

55 <220>
 <223> Attached to the amino terminus of Ubiquitin

-2-

5. <400> 3
 Met Gln Ile Phe Val Lys Thr Leu Thr Gly
 1 5 10

10 <210> 4
 <211> 19
 <212> DNA
 <213> Escherichia coli

15 <400> 4
 atccatatgc agatcttcg 19

 <210> 5
 <211> 27
 <212> DNA
 <213> Escherichia coli

20 <400> 5
 caagcttcta nnnaccacca cgaagtc 27

SEQUENCE LISTING

<110> Hill, Christopher P.
Wilkinson, Keith D.
Johnston, Steven C.
Larsen, Christopher N.
Cook, William J.

<120> METHODS AND COMPOSITIONS FOR A DEUBIQUITINATING ENZYME
AND VARIANTS THEREOF

<130> UTAH:006

<140> Unknown

<141> 1998-07-01

<150> 60/051,437

<151> 1997-07-01

<160> 5

<170> PatentIn Ver. 2.0

<210> 1

<211> 10

<212> PRT

<213> Escherichia coli

<220>

<223> Attached to the amino terminus of Ubiquitin

<400> 1

Ile Ile Glu Pro Ser Leu Arg Gln Leu Ala

1 5 10

<210> 2

<211> 10

<212> PRT

<213> Escherichia coli

<220>

<223> Attached to the amino terminus of Ubiquitin

<400> 2

Gly Lys Lys Arg Lys Lys Lys Val Tyr Thr

1 5 10

<210> 3

<211> 10

<212> PRT

<213> Escherichia coli

<220>

<223> Attached to the amino terminus of Ubiquitin

<400> 3

Met Gln Ile Phe Val Lys Thr Leu Thr Gly
1 5 10

<210> 4

<211> 19

<212> DNA

<213> Escherichia coli

<400> 4

atccatatgc agatcttcg

19

<210> 5

<211> 27

<212> DNA

<213> Escherichia coli

<400> 5

caagcttcta nnnaccacca cgaagtc

27



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/00, 1/44, C12N 9/18, G01N 33/53	A3	(11) International Publication Number: WO 99/01567 (43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/US98/13776 (22) International Filing Date: 1 July 1998 (01.07.98) (30) Priority Data: 60/051,437 1 July 1997 (01.07.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/051,437 (CIP) Filed on 1 July 1997 (01.07.97) (71) Applicants (for all designated States except US): THE UNIVERSITY OF UTAH [US/US]; 229 Wintrow, Salt Lake City, UT 84132 (US). EMORY UNIVERSITY [-/US]; 1510 Clifton Road, Atlanta, GA 30322 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): HILL, Christopher, P. [-/US]; 465 3rd Avenue, Salt Lake City, UT 84103 (US). WILKINSON, Keith, D. [-/US]; 2633 Apache Lane, Lilburn, GA 30247 (US). JOHNSTON, Steven, C. [-/US]; 1554 East Bryan, Salt Lake City, UT 84105 (US). LARSEN, Christopher, N. [-/US]; 30 Blain Street, Allston, MA 02134		(US). COOK, William, J. [-/US]; 1322 Badham Drive, Birmingham, AL 35216 (US). (74) Agent: SERTICH, Gary, J.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US). (81) Designated States: CA, JP, KR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> (88) Date of publication of the international search report: 1 April 1999 (01.04.99)
(54) Title: METHODS AND COMPOSITIONS FOR A DEUBIQUITINATING ENZYME AND VARIANTS THEREOF (57) Abstract <p>The present invention relates to methods for the identification of candidate inhibitor substances that inhibit deubiquitinating activity based on the x-ray crystallographic structure of the active site of the enzyme. Changes in the properties of the enzyme are useful in identifying such substances. Also disclosed are variants of the enzyme that are useful in deubiquitinating proteins and small peptides.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/13776

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12Q 1/00, 1/44; C12N 9/18; G01N 33/53

US CL :435/4, 7.6, 19, 197

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/4, 7.6, 19, 197

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS and STN (Bioscience and Patents Indexes): ubiquitin C-terminal hydrolase, UCH, UCH-L3, ubiquitin, hydrolase

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,585,466 A (CARTER) 17 December 1996, col. 3, lines 11-57.	1, 2, 10-12
Y,E	US 5,834,228 A (BECKER ET AL.) 10 November 1998, col. 6, lines 14-46.	1, 2, 10-12
Y	LARSEN ET AL. Substrate Binding and Catalysis by Ubiquitin C-Terminal Hydrolases: Identificaiton of Two Active Site Residues. Biochemistry. May 1996. Vol. 35. pages 6735-6744.	1, 2, 10-13, 15

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 NOVEMBER 1998

Date of mailing of the international search report

13 JAN 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LISA J. HOBBS, PH.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/13776

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1, 2, 10-13 and 15
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest



The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1, 2, 10-12, drawn to methods of preparing a molecule which selectively binds.

Group II, claims 3-6, drawn to methods of identification of inhibitors of enzyme activity.

Group III, claims 7-9, drawn to methods of identification of inhibitors of gene expression.

Group IV, claims 13, 15, variant UCH-L3 enzymes.

Group V, claim 14, drawn to a process of regulating deubiquitination.

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the methods of Group I have the special technical feature of the binding molecule, which is not present in Groups II-V; the methods of Group II have the special technical feature of identifying enzyme inhibitors, which is not present in Groups I and II-V; the methods of Group III have the special technical feature of identifying gene expression inhibitors, which is not present in Groups I-II and IV-V; the product of Group IV has the special technical feature of the enzyme, which is not present in Groups I-III and V; the process of Group V has the special technical feature of regulating deubiquitination, which is not present in Groups I-IV.